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SUMMARY 
Thanks to the rapid progress on the research of genomics and genetics, our 
knowledge on the molecular basis of diseases has been significantly enhanced, 
which has greatly contributed to the discovery of disease markers for disease 
differentiation, and to the design of disease-targeting molecules like 
small-molecule agents or antibodies for disease treatment. The key disease 
markers determine the characteristics of disease, therefore could be further 
analyzed the possibility of these markers severing as targets for disease targeting 
molecule design. The main objective of this dissertation is to develop a disease 
marker discovery system from microarray data and a bioinformatics tool for 
disease-targeting molecule prediction. 
 
It is of crucial essence to find the marker genes responsible for disease initiation 
and progress. The marker genes may benefit early disease diagnosis and correct 
prediction of prognosis. The expression level of such markers presents potential 
therapeutic drug targets and may give suggestions to proper treatment regime. 
Microarray can measure the expression level of thousand of genes at one time, 
presenting the most important platform for disease diagnosis, disease prognosis 
and disease marker discovery. Current microarray data analysis tools provided 
good predictive performance. However, the markers produced by those tools have 
been found to be highly unstable with the variation of patient sample size and 
combination. The patient-dependent nature of the markers diminishes their 
application potential for diagnosis and prognosis. To solve this problem, we 
developed a novel gene selection method based on Support Vector Machines, 
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recursive feature elimination, multiple random sampling strategies and multi-step 
evaluation of gene-ranking consistency. The as-developed program can be utilized 
to derive disease markers which present both good prediction performance and 
high levels of consistency with different microarray dataset combinations. 
 
After program implementation, two different cases were tested: colon cancer 
marker discovery by using a well-studied 62-sample colon-cancer dataset and lung 
adenocarcinoma survival marker discovery by using an 86-sample lung 
adenocarcinoma dataset. In the first case, the derived 20 colon cancer marker 
signatures are found to be fairly stable with 80% of top-50 and 69%~93% of all 
markers shared by all 20 signatures. The shared 104 markers include 48 
cancer-related genes, 16 cancer-implicated genes and 52 previously-derived colon 
cancer markers. The derived signatures outperform all previously-derived 
signatures in predicting colon cancer outcomes from an independent dataset. The 
possibility of the markers as therapeutic target was exploited by a therapeutic 
target prediction system. Six known targets and 18 potential targets were 
identified by this system. In the second case, 21 lung adenocarcinoma survival 
markers were shared by 10 marker signatures. 5 known and 7 novel targets were 
predicted as therapeutic targets. These results suggested the effectiveness of our 
system on deriving stable disease markers and discovering therapeutic target. 
 
One major application of marker discovery is the finding of disease targeting 
molecules for disease prevention and treatment. For this purpose, therapeutic 
antibodies, a class of effective disease-targeting molecules, were employed to 
develop a therapeutic antibody prediction system based on antibody-antigen 
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sequence recognition information. Eventually, an antibody antigen information 
resource (AAIR) database, which provides information of sequence-specific 
antibody-antigen recognition and their immunological relevance, was developed. 
Three classes of information are included in the database. The first class is antigen 
information consisting of antigen name, sequence, function and source organism. 
The second class is antibody information containing antibody isotype, source 
organism, molecular and structural type of antibody. The third one is disease and 
therapeutic information composed of disease class, targeted disease, diagnosis and 
therapeutic indication. Currently, AAIR contains 2,777 antibody-antigen pairs 
covering 159 disease conditions, 2,035 antibody heavy chain sequences, 1,701 
antibody light chain sequences, 619 distinct antigen sequences (584 
proteins/peptides and 35 other molecules), 254 antigen epitope sequences, and 157 
binding affinity constants for antigen-antibody pairs from various viruses, bacteria, 
tumor types, and autoimmune responses.  
 
The potential application of the data in AAIR for the study of antibody-antigen 
recognition was demonstrated by applying machine learning models to predict 
antibody from antigen sequence. It can be concluded from the performance of 
machine learning models that the information in AAIR is capable of producing 
comparable and reasonable preliminary results to characterize pair-wise 
interaction between antibody and antigen, and would be useful for antibody and 
antigen design. 
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1 Introduction  
Functional genomics has been widely applied in determining disease 
mechanisms and identifying disease markers. The possibility of the marker as a 
good therapeutic target can be evaluated by how well therapeutic molecules, such 
as small molecules or antibodies, can target them. However, the disease marker 
selection, which is critical for disease diagnosis, prognosis, treatment and 
disease-targeting molecule design, can be a difficult task since human genome 
contains approximately 25,000 genes (1), which are expressed at different time 
and are cooperated as an integrated team. The discovery of the disease markers 
can facilitate disease target identification and disease targeting molecule design. 
The first section (Section 1.1) of this chapter gives an overview of disease markers 
and therapeutic molecules. The following two sections of this chapter introduce 
the current progress in disease marker discovery (Section 1.2) and therapeutic 
molecules prediction (Section 1.3). The motivation of this work and outline of the 
structure of this document are presented in Section 1.4.  
 
1.1 Overview of disease markers and therapeutic molecules 
Knowing the origin of a disease is the first step in understanding the entire 
abnormal course of the disease and helping the treatment of the disease. 
Sometimes it is very easy to determine the cause of certain diseases, such as 
infectious diseases which are generally caused by virus, bacteria or parasites. 
However, the sources of some diseases may not be easily identified, especially 
some genetic diseases resulting from an accumulation of inherited and 
Chapter 1 Introduction 
2 
environmentally-induced changes or mutations in the genome, such as cancer 
(2-6), diabetes (7, 8), cardiovascular disorders (9, 10) and obesity (11). For 
accurate disease diagnosis and proper treatment selection, it is very important to 
identify the gene markers responsible for disease initiation. Moreover, the 
discovery of the markers responsible for disease progress is critical because such 
markers can be used to identify disease stages, subtypes and prognosis effect in an 
accurate manner. As such, proper treatment regime can be applied and the 
survivability of the patients can be ultimately extended (12).  
 
The completion of human genome sequencing (1, 13), and the new, cheap, and 
reliable methods in functional genomics such as gene expression analysis present 
the potential for disease marker discovery. Most of the markers show significantly 
different expression profiles between healthy people and patients, or among the 
patients with different progress stages/subtypes/outcomes, characterizing disease 
at the molecule level and for diagnosis and prognosis prediction. They can be 
further analyzed as the potential disease targets which normally play key roles in 
disease initiation (14) or disease progress (15, 16). The disease targets can be used 
in developing disease targeting molecules such as antibodies and small molecules 
based on the antibody-antigen interaction and protein-small molecule interaction 
(17). 
 
Disease targeting molecule design aims to identify small molecules or antibodies 
that bind strongly to the disease targets (15, 16). The understanding of the 
interaction of targets and therapeutic molecules are crucial for disease targeting 
molecule design. The rapid progress in human genome project and functional 
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genomics provides an ever-increasing number of potential therapeutic targets, and 
the computational analysis of protein-protein interaction or ligand-protein 
interaction should facilitate the therapeutic molecule design. 
 
1.2 Current progress in disease marker discovery 
1.2.1 Introduction to disease differentiation 
Generally genetic diseases such as cancer are differentiated according to their 
gross morphological appearance of the cells and the surrounding tissues. However, 
such a differentiation criterion has some limitations. First, it relies on a subjective 
review of the tissue, which depends on the knowledge and experience of a 
pathologist, and may not be consistent or reproducible (18, 19). Second, this 
method provides discrete, rather than continuous classification of disease into 
broad groups with limited ability to determine the treatment regime of individual 
patients. Third, disease with identical pathology may have different origins and 
respond differently to treatment (20). Last but not the least, current pathology 
reports offer little information about the potential treatment regime which a 
disease will respond to. Therefore, new disease differentiation method is needed 
for accurate diagnosis and treatment. 
 
Fortunately, disease differentiation based on molecular profile of diseases can 
overcome those limitations (6, 21-24). Microarray technology, which is capable of 
providing the expression profile information on thousands of genes 
simultaneously, has become a very important component of disease molecular 
differentiation. The gene expression profiles can be applied to identify markers 
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which are closely associated with early detection/differentiation of disease, or 
disease behavior (disease progression, response to therapy), and could serve as 
disease targets for drug design (25). This strategy is widely used in cancer 
research for the identification of cancer markers, and provide new insights into 
tumorigenesis, tumor progression and invasiveness (5, 6, 26-29). 
 
1.2.2 Approaches of disease marker discovery  
1.2.2.1 Traditional gene discovery method 
Two approaches, the candidate gene approach and positional cloning 
approach, have traditionally been used to discover genes underlying human 
diseases. 
 
Candidate gene method is based on prior biochemical knowledge about the genes, 
such as putative functional protein domain of genes and tissues in which genes are 
expressed (30, 31). Genes underlying familial hypertrophic cardiomyopathy (32), 
Li-Fraumeni syndrome (33), retinitis pigmentosa (34, 35), hereditary prostate 
cancer risk (31), metastasis of hepatocellular carcinoma (36), and breast cancer 
risk (37) were discovered in this manner. However very limited well-characterized 
genes are currently available (30), and most genes can not be analyzed in this 
manner due to the limitation of biochemical knowledge. 
 
In contrast to candidate gene method, positional cloning identifies genes without 
any prior knowledge about gene function. This method is performed in patients 
and their family members using DNA polymorphisms. Alleles of markers that are 
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in close proximity to the chromosome location of the disease genes can be 
determined by genetic linkage analysis, and critical region can be defined by 
haplotype analysis. The candidate genes residing in the critical regions can be 
identified (9, 30). This method was applied in identifying genes related with 
asthma (38), cardiovascular disorders (9, 10), and diabetes mellitus (8). However, 
the nature of positional cloning limits its resolution to relatively large regions of 
the genome (30). The candidate genes within a certain critical region need to be 
filtered from the relatively large regions of the genome by identifying mutations in 
genes that segregate with the disease (30). 
 
1.2.2.2 Proteomics method 
Most recent developed proteomics offers the most direct approach to 
understanding disease and its molecular markers (39-41). Proteomics refers to the 
systematic analysis of protein, protein complexes, and protein-protein interactions 
(42). This approach provides complementary information that can be useful in 
studying disease processes, such as cardiomyopathies (43), autosomal recessive 
malignant infantile osteopetrosis (44-46), lung cancer (40) and prostate cancer 
(47). However, this newly-developed and immature method makes limited data 
available for comparison and analysis. 
 
1.2.2.3 Genomics method 
Genomics method is another new gene discovery method. Two kinds of 
technology, phylogenetic profiles and global profiles of gene expression, are 
widely used in this approach.  
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Based on sequencing technology, phylogenetic profiles is a powerful 
computational strategy that infers gene function from the completed genome 
sequences (48-51). This technology assumes that function-related genes are 
evolving in a correlated way, so that they are more likely to share homologs 
among organisms. Six possible Bardet-Biedel syndrome genes were identified by 
this technology (52, 53). 
 
Currently the most important method for disease gene discovery is global profiles 
of gene expression based on genomic knowledge. This method discovers disease 
genes from the expression level of a set of genes in particular tissues or cell types. 
Serial analysis of gene expression (SAGE) (54) is a method which produces a 
snapshot of mRNA population in a sample by a sequence-based sampling 
technique. Another technology is the newly-developed microarray technology. 
Probably as the richest source of gene expression data, microarray data is used in 
this study for gene selection. Microarray measures the expression profiles of 
thousands of genes at the same time and have been explored for deriving disease 
genes or disease markers (5, 26, 55-62), elucidating pathogenesis of disease (55, 
60, 63-66), deciphering mechanism of drug action (67-69), determining 
treatment-strategies (70, 71), and characterizing genomic activity during various 
cellular processes (72-75). The markers in colorectal tumors (76) and 
non-Hodgkin’s lymphoma (77), and prognostic markers of acute myeloid 
leukemia (78) were identified by using microarray technology. 
 
Chapter 1 Introduction 
7 
1.2.3 Brief introduction to microarray technology 
1.2.3.1 Introduction to microarray experiments 
Microarray technology, also known as DNA chip, gene ship or biochip, is one 
of the indispensable tools in monitoring genome wide expression levels of genes 
in a given organism. Microarrays measure gene expression in many ways, one of 
which is to compare expression of a set of genes from cells maintained in a 
particular condition A (such as disease status) with the same set of genes from 
reference cells maintained under conditions B (such as normal status).  
 
Figure 1-1 shows a typical procedure of microarray experiments (79, 80). A 
microarray is a glass substrate surface on which DNA molecules are fixed in an 
orderly manner at specific locations called spots (or features). A microarray may 
contain thousands of spots, and each spot may contain a few million copies of 
identical DNA molecules (probes) that uniquely correspond to a gene. The DNA 
in a spot may either be genomic DNA (81), or synthesized oligo-nucleotide 
strands that correspond to a gene (82-84). This microarray can be made by the 
experimenters themselves (such as cDNA array) or purchased from some suppliers 
(such as Affymetrix GeneChip). The actual microarray experiment starts from the 
RNA extraction from cells. These RNA molecules are reverse transcribed into 
cDNA, labeled with fluorescent reporter molecules, and hybridized to the probes 
formatted on the microarray slides. At this step, any cDNA sequence in the sample 
will hybridize to specific spots on the glass slide containing its complementary 
sequence. The amount of cDNA bound to a spot will be directly proportional to 
the initial number of RNA molecules present for that gene in both samples. 
Following, an instrument is used to read the reporter molecules and create 
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microarray image. In this image, each spot, which corresponds to a gene, has an 
associated fluorescence value, representing the relative expression level of that 
gene. Then the obtained image is processed, transformed and normalized. And the 
analysis, such as differentially expressed gene identification, classification of 
disease/normal status, and pathway analysis, can be conducted. 
 
Figure 1-1 Procedure of microarray experiment 
 
1.2.3.2 Public repository for microarray data 
Thanks to the variety of journals and funding agencies which have established 
Microarray making Hybridization  
+ 
mRNA reverse transcription 
Fluorescentlabeling 
Sample A Sample B 
RNA extraction 
RNA sample A RNA sample B
Microarray hybridization 
Microscope glass slides
DNA molecules 
amplified by PCR
Spotting
microarray 
Image acquisition and analysis 
Identification of 
differentially 
expressed genes 
Classification Other analyses (e.g. 
pathway analysis) 
Cy3 labeled sample A 
(green) 
Cy5 labeled sample B 
(red) 
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and enforced microarray data submission standards, currently, a wealth of 
microarray data is now available in different databases such as the Stanford 
Microarray Database (SMD) (85), Gene Expression Omnibus (GEO) (86), and 
Array Express (EBI) (87). Table 1-1 gives a list of public available microarray 
databases. Many of those databases require a minimum information about a 
microarray experiment (MIAME)-compliant manner in order to interpret the 
experiment results unambiguously and potentially be able to reproduce the 
experiment (88). As a public resource, these expression databases are valuable 
substrates for statistical analysis, which can detect gene properties that are more 
subtle than simple tissue-specific expression patterns. 
 
1.2.3.3 Statistical analysis of microarray data 
Since microarray contains the expression level of several thousands of genes, 
it requires sophisticated statistical analysis to extract useful information such as 
gene selection. Theoretically, one would compare a group of samples of different 
conditions and identify good candidate genes by analysis of the gene expression 
pattern. However, microarray data contain some noises arising from measurement 
variability and biological differences (70, 89). The gene-gene interaction also 
affects the gene-expression level. Furthermore, the high dimensional microarray 
data can lead to some mathematical problems such as the curse of dimensionality 
and singularity problems in matrix computations, causing data analysis difficult. 
Therefore choosing a suitable statistical method for gene selection is very 
important. 
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Table 1-1 A list of public microarray databases. 
Database Website* Description Organism References
ArrayExpress http://www.ebi.ac.uk/arrayexpress/ 
A public repository for 
microarray based gene 
expression data 
European 
Bioinformatics 
Institute 
(87) 
ChipDB http://chipdb.wi.mit.edu/chipdb/public/ 
A searchable database of gene 
expression 
Massachusetts 
Institute of 
Technology 
(90) 
ExpressDB http://twod.med.harvard.edu/ExpressDB/ 
A relational database 
containing yeast and E. coli 
RNA expression data 
Harvard Medical 
School (91) 
Gene Expression 
Atlas 
http://symatlas.gnf.or
g/SymAtlas/ 
A database for gene expression 
profile from 91 normal human 
and mouse samples across a 
diverse array of tissues, organs, 
and cell lines 
Novartis Research 
Foundation (92) 
Mouse Gene 
Expression 
Database (GXD) 
http://www.informati
cs.jax.org/menus/exp
ression_menu.shtml 
An extensive and easily 
searchable database of gene 
expression information about 
the mouse 
The Jackson 
Laboratory, Bar 
Harbor, Maine 
(93) 
Gene Expression 
Omnibus (GEO) 
http://www.ncbi.nlm.
nih.gov/geo/ 
Microarray database containing 
tens of millions of expression 
profiles 
National Center for 
Biotechnology 
Information 
(86) 
GermOnline http://www.germonline.org/index.html 
Information and microarray 
expression data for genes 
involved in mitosis and 
meiosis, gamete formation and 
germ line development across 
species 
Biozentrum and 
Swiss Institute of 
Bioinformatics 
(94) 
Human Gene 
Expression 
(HuGE) Index 
database 
http://www.biotechno
logycenter.org/hio/ 
A comprehensive database to 
understand the expression of 
human genes in normal human 
tissues 
Boston University (95) 
MUSC DNA 
Microarray 
Database 
http://proteogenomic
s.musc.edu/ma/musc
_madb.php?page=ho
me&act=manage 
A web-accessible archive of 
DNA microarray data 
Medical University 
of South Carolina (96) 
RIKEN 
Expression Array 
Database (READ) 
http://read.gsc.riken.g
o.jp/ 
A database of expression 
profile data from the RIKEN 
mouse cDNA microarray 
RIKEN Yokohama 
Institute (97) 
Rice Expression 
Database (RED) 
http://red.dna.affrc.go
.jp/RED/ 
Expression profiles obtained by 
the Rice Microarray Project 
and other research groups 
National Institute 
of Agrobiological 
Sciences, Japan 
(98) 
RNA Abundance 
Database (RAD) 
http://www.cbil.upen
n.edu/RAD/php/inde
x.php 
A public gene expression 
database designed to hold data 
from array-based and 
nonarray-based (SAGE) 
experiments 
University of 
Pennsylvania (99) 
Saccharomyces 
Genome Database 
(SGD): 
Expression 
Connection 
http://db.yeastgenom
e.org/cgi-bin/expressi
on/expressionConnec
tion.pl 
A gene expression database of 
Saccharomyces genome 
Stanford 
University (100) 
Stanford 
Microarray 
Database (SMD) 
http://genome-www5
.stanford.edu/ 
Raw and normalized data from 
microarray experiments, as 
well as their corresponding 
image files 
Stanford 
University (85) 
Yale Microarray 
Database (YMD) 
http://info.med.yale.e
du/microarray/ 
A microarray database for 
large-scale gene expression 
analysis. 
Yale University (101) 
yeast Microarray 
Global Viewer 
(yMGV) 
http://www.transcript
ome.ens.fr/ymgv/ 
A database for yeast gene 
expression 
Ecole Normale 
Superieure, Paris, 
France 
(102) 
*accessible at Apr 06, 2007 
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The statistical methods in microarray data analysis can be classified into two 
groups: unsupervised learning methods and supervised learning methods. 
Unsupervised analysis of microarray data aims to group relative genes without 
knowledge of the clinical features of each sample (103). A commonly-used 
unsupervised method is hierarchical clustering method. This method groups genes 
together on the basis of shared expression similarity across different conditions, 
under the assumption that genes are likely to share the same function if they 
exhibit similar expression profiles (104-107). Hierarchical clustering creates 
phylogenetics trees to reflect higher-order relationship between genes with similar 
expression patterns by either merging smaller clusters into larger ones, or by 
splitting larger clusters into smaller ones. A dendogram is constructed, in which 
the branch lengths among genes also reflect the degree of similarity of expression 
(108, 109). By cutting the dendogram at a desired level, a clustering of the data 
items into the disjoint groups can be obtained. Hierarchical clustering of gene 
expression profiles in rheumatoid synovium identified 121 genes associated with 
Rheumatoid arthritis I and 39 genes associated with Rheumatoid arthritis II (110). 
Unsupervised methods have some merits such as good implementations available 
online and the possibility of obtaining biological meaningful results, but they also 
possess some limitations. First, unsupervised methods require no prior knowledge 
and are based on the understanding of the whole data set, making the clusters 
difficult to be maintained and analyzed. Second, genes are grouped based on the 
similarity which can be affected by input data with poor similarity measures. 
Third, some of the unsupervised methods require the predefinition of one or more 
user-defined parameters that are hard to be estimated (e.g. the number of clusters). 
Changing these parameters often have a strong impact on the final results (113).  
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In contrast to the unsupervised methods, supervised methods require a priori 
knowledge of the samples. Supervised methods generate a signature which 
contains genes associated with the clinical response variable. The number of 
significant genes is determined by the choice of significance level. Support vector 
machines (SVM) (114) and artificial neural networks (ANN) (115) are two 
important supervised methods. Both methods can be trained to recognize and 
characterize complex pattern by adjusting the parameters of the models fitting the 
data by a process of error (for example, mis-classification) minimization through 
learning from experience (using training samples). SVM separates one class from 
the other in a set of binary training data with the hyperplane that is maximally 
distant from the training examples. This method has been used to rank the genes 
according to their contribution to defining the decision hyperplane, which is 
according to their importance in classifying the samples. Ramaswamy et al. used 
this method to identify genes related to multiple common adult malignancies (6). 
ANN consists of a set of layers of perceptrons to model the structure and behavior 
of neutrons in the human brain. ANN ranks the genes according to how sensitive 
the output is with respect to each gene’s expression level. Khan et al identified 
genes expressed in rhabdomyosarcoma from such strategy (27).  
  
In classification of microarray datasets, it has been found that supervised machine 
learning methods generally yield better results (116), particularly for smaller 
sample sizes (89). In particular, SVM consistently shows outstanding performance, 
is less penalized by sample redundancy, and has lower risk for over-fitting (117, 
118). Furthermore, some studies demonstrated that SVM-based prediction system 
was consistently superior to other supervised learning methods in microarray data 
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analysis (119-121). SVM for microarray data analysis are used in this study. 
 
Feature selection in microarray data analysis 
No matter whether the supervised or unsupervised methods are used, one 
critical problem encountered in both methods is feature selection, which has 
become a crucial challenge of microarray data analysis. The challenge comes from 
the presence of thousands of genes and only a few dozens of samples in currently 
available data. From the mathematical view, thousands of genes are thousands of 
dimensions. Such a large number of dimensions leads microarray data analysis to 
problems such as the curse of dimensionality (122, 123) and singularity problems 
in matrix computations. Therefore, there is a need of robust techniques capable of 
selecting the subsets of genes relevant to a particular problem from the entire set 
of microarray data both for the disease classification and for the disease target 
discovery. 
 
Gene selection from microarray data is to search through the space of gene subsets 
in order to identify the optimal or near-optimal one with respect to the 
performance measure of the classifier. Many gene selection methods have been 
developed, and generally fall into two categories: filter method and wrapper 
method (124). Figure 1-2 shows how these two methods work.  
 
In brief, the filter method selects genes independent of the learning algorithms 
(125-127). It evaluates the goodness of the genes from simple statistics computed 
from the empirical distribution with the class label (128). Filter method has some 
pre-defined criteria. Mutual information and statistical testing (e.g. T-test and 
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F-test) are two typical examples of filter method (5, 125, 129-133). Filter method 
can be easily understood and implemented, and needs little computational time. 
But the pitfall of this method is that it is based on the assumption that genes are 
not connected to each other, which is not true in real biological process.  
 
Figure 1-2 Filter method versus wrapper method for feature selection 
 
Wrapper method generates genes from the evaluation of a learning algorithm. It is 
conducted in the space of genes, evaluating the goodness of each gene or gene 
subsets by such criteria as cross-validation error rate or accuracy from the 
validation dataset (134). The wrapper method is very popular among machine 
learning methods for gene discovery (124, 135, 136). Although the wrapper 
method needs extensive computational resources and time, it considers the 
gene-gene interaction and its accuracy is normally higher than the filter method 
(124, 135, 136). Recursive feature elimination (RFE) is a good example of the 
 
 
The filter method for feature selection 
Training dataset: 
All features 
Feature subset selection 
Learning algorithm 
The Wrapper method for feature selection 
Training dataset: 
All features 
Performance evaluation 
Learning algorithm 
Feature evaluation 
Feature subset generation 
Training dataset and test dataset: 
Final performance evaluation 
Training dataset and test dataset:
Performance evaluation 
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wrapper method for disease gene discovery. The RFE method uses the prediction 
accuracy from SVM to determine the goodness of a selected subset. This thesis 
will employ RFE for disease gene discovery from microarray data.  
 
1.2.4 The problems of current marker selection methods 
The methodology of SVM and RFE will be discussed in Chapter 2 in details. 
Here, some problems encountered in current marker discovery from microarray 
data analysis are discussed. One problem is to specify the number of genes for 
differentiating disease. The number of derived colon cancer genes and leukemia 
genes ranges from 1 to 200 (5, 137-142). 50 genes were arbitrarily chosen for 
differentiating acute myeloid leukemia (AML) from acute lymphoblastic leukemia 
(ALL) by Golub et al, since they supposed that 50 genes might reflect the 
difference between AML and ALL (5). In most cases, the gene number was 
decided by the classification performance of different gene combinations. The 
gene combination which produced the highest classification accuracy constituted 
the gene signature. This strategy might produce small sets of genes (one or two 
genes) that formed accurate classifier (140-142). For example, Slonim et al 
reported that the classifier consisting of one gene (HOXA9) outperformed all of 
other classifiers consisting of other gene combinations for recurrence prediction in 
AML patients (142). Li and Yang showed that one gene (Zyxin) constituted the 
best classifiers for AML/ALL differentiation (140). Nevertheless these results 
were only obtained and tested on one dataset. Considering that the number of 
genes should correlate with the disease situation, the selected genes should be 
large enough to be robust against noise and small enough to be readily applied in 
clinical settings. Therefore, it is not appropriate to use the arbitrary gene number. 
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Similarly, to use just one dataset to decide the optimal gene number may not be 
satisfactory, because the optimal gene number varies with the different sample 
sizes and sample combinations (70, 143, 144).  
 
Another problem in gene discovery is the gene signatures were highly unstable 
and strongly depended on the selection of patients in the training sets (5, 27, 58, 
59, 70, 89, 145, 146) (70, 143, 144), despite the use of sophisticated class 
differentiation and gene selection methods by various groups. The unstable 
signatures were observed in most microarray datasets including colon cancer, lung 
adenocarcinoma, non-Hodgkin lymphoma, acute lymphocytic leukemia, acute 
myeloid leukemia, breast cancer, medulloblastoma, and hepatocellular carcinoma 
(70, 108, 119, 124, 127, 145, 147-150). While these signatures display high 
predictive accuracies, the highly unstable and patient-dependent nature of these 
signatures diminishes their application potential for diagnosis and prognosis (70). 
Moreover, the complex and heterogenic nature of disease such as cancer may not 
be adequately described by the few cancer-related genes in some of these 
signatures. The unstable nature of these signatures and their lack of 
disease-relevant genes also limit their potential for target discovery. The instability 
of derived signatures is likely caused by the noises in the microarray data arising 
from such factors as the precision of measured absolute expression levels, 
capability for detecting low abundance genes, quality of design and probes, 
annotation accuracy and coverage, and biological differences of expression 
profiles (89, 151). Apart from enhancing the quality of measurement and 
annotation, strategies for improving signature selection have also been proposed. 
These strategies include the use of multiple random validation (70), large sample 
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size (152), known mechanisms (153), and robust signature-selection methods 
which is insensitive to noises (55, 89, 154). 
 
This thesis will explore a new signature selection method aiming at reducing the 
chances of erroneous elimination of predictor-genes due to the noises contained in 
microarray dataset. Multiple random sampling and gene-ranking consistency 
evaluation procedures will be incorporated into RFE signature selection method. 
The consistent genes obtained from the multiple random sampling method may 
give us a better understanding to the disease initiation and progress, and may 
provide potential disease targets. 
1.3 Current progress in disease targeting molecule prediction, 
antibody as a case study 
1.3.1 Overview of disease-targeting molecule 
As introduced in the previous section, Microarray data can be employed to 
discover markers closely related to disease initiation and progression and can 
provide candidate disease targets. The interaction between disease targets and 
therapeutic molecules is crucial for drug discovery. Therapeutic molecule can 
attach its specific molecule targets involving in pathogenesis and disease progress 
without damaging other tissues (155, 156). The rationally design of therapeutic 
molecules has therefore become a very important area in current drug design.  
 
1.3.1.1 Small molecules  
The therapeutic molecules include small molecules and antibodies (15, 16). 
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Table 1-2 gives an overview of US Food and Drug Administration (FDA) 
approved anticancer small molecular drugs in recent ten years. A kind of 
important small molecule drugs for therapeutic application is protein kinase 
inhibitors, which specifically act on their disease targets - protein kinases (16, 
157), which are implicated in a wide range of diseases. Protein kinases can 
catalyze protein phosphorylation, which is one of the most significant signal 
transduction mechanisms, and by which crucial intercellular processes are 
regulated. Currently the protein kinase family is the second largest enzyme family 
and the fifth largest gene family in the human genome (157). 520 protein kinase 
genes, corresponding to about 1.7% of all human genes, were identified in humans 
(157). The key role of protein kinase in regulating signal transduction in the 
context of multiple cellular processes and environments and the regulatory 
approval in clinical applications makes kinase as a readily accepted druggable 
protein (16). Nevertheless, one significant obstacle to the rational design of 
specific kinase inhibitors is the high level of sequence and structural similarity in 
the human kinase types (158). Furthermore, kinases tend to conformational 
changes when drugs bind (158). Currently around 11% successful rate achieved 
for this kind of drugs (159) from the first use in humans to regulatory approval.  
 
1.3.1.2 Antibodies 
Antibodies, another frequently used therapeutic molecules, can specifically 
act on the disease-causing targets (antigens) (15) on many diseases such as cancer 
(16), heart disease (160) and rheumatic diseases (161). Antibodies have a unique 
characteristic that small molecules don’t have, - the ability to exquisitely 
discriminate diverse disease-related molecules (specificity) and the ability to 
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tightly bind to their targets (affinity). These two capabilities make antibody fight 
disease with an efficient, little toxically manner and a good side-effect profile 
compared to small molecules. Therefore the therapeutic antibodies can achieved 
18−29% successful rate (162). This thesis will utilize antibodies as an example for 
therapeutic molecule design. 
 
Table 1-2 US FDA-approved molecule targeting drugs (small molecules) 
between 1996 to 2006 (163, 164). 
Year Drugs Drug Types Molecular Target Disease Indication Therapeutic Application Company 
Sprycel 
(dasatinib) 
Tyrosine kinase 
inhibitor BCR-ABL, SRC 
Chronic myeloid 
leukemia (CML) 
Treatment of 
imatinib-resistant 
chronic myeloid 
leukemia 
Bristol-Myers 
Squibb 
Sutent 
(sunitinib) 
Tyrosine kinase 
inhibitor 
PDGFR, VEGFR, 
KIT, FLT3, 
CSF-1R, RET 
Kidney Cancer; 
Gastrointestinal 
Stromal Tumors 
Treatment of kidney 
cancer and 
gastrointestinal stromal 
tumors 
Pfizer 
2006 
Gardasil  
 
Quadrivalent 
recombinant vaccine 
Human 
papillomavirus 
types 6, 11, 16, and 
18 
For the 
prevention of 
cervical cancer 
associated with 
human 
papillomavirus 
For the prevention of 
cervical cancer 
associated with human 
papillomavirus 
Merck 
Nexavar 
(sorafenib) Multikinase inhibitor 
VEGFR, PDGFR, 
c-KIT 
Renal Cell 
Carcinoma 
Treatment of Renal Cell 
Carcinoma Bayer/ Onyx 
2005 
Arranon 
(nelarabine)1 
Cytotoxic 
deoxyguanosine 
analogue 
DNA Leukemia, lymphoma 
For the treatment of 
lymphoblastic leukemia 
and T-cell lymphoblastic 
lymphoma 
GlaxoSmithKli
ne 
Tarceva 
(erlotinib,  
OSI 774) 
Tyrosine kinase 
inhibitor HER1, EGFR 
Non-small cell 
lung cancer 
(NSCLC) 
Treatment of advanced 
refractory metastatic 
non-small cell lung 
cancer 
Genentech, OSI 
Pharmaceuticals
Alimta 
(pemetrexed) Enzyme Inhibitors 
Dihydrofolate 
reductase, 
Glycinmaide 
ribonucleotide 
formyl transferase, 
thymidylate 
synthase 
Mesothelioma 
For the treatment of 
malignant pleural 
mesothelioma 
Eli Lilly 
Clolar 
(clofarabine) 
Purine nucleoside 
analog DNA 
Lymphoblastic 
leukemia 
For the treatment of 
acute lymphoblastic 
leukemia in pediatric 
patients 
Genzyme 
Sensipar 
(cinacalcet) Allosteric activators 
Calcium-sensing 
receptor 
Parathyroid 
carcinoma 
For the treatment of 
secondary 
hyperparathyroidism and 
hypercalcemia in 
parathyroid carcinoma 
patients 
Amgen 
2004 
VESANOID 
(Tretinoin, 
ATRA) 
Cell Stimulants and 
Proliferants 
Alpha retinoic acid 
Receptors 
(RAR)-alpha 
Acute 
promyelocytic 
leukemia (APL) 
For the treatment of 
acute promyelocytic 
leukemia (APL) 
Roche 
2003 Iressa (gefitinib) 
Tyrosine kinase 
inhibitor EGFR 
Non-small cell 
lung cancer 
(NSCLC) 
The second-line 
treatment of 
non-small-cell lung 
cancer 
AstraZeneca 
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Velcade 
(bortezomib) Proteasome inhibitor 26S proteasome 
Multiple 
Myeloma 
Injectable agent for the 
treatment of multiple 
myeloma patients who 
have received at least 
two prior therapies 
Millennium 
Pharmaceuticals
Aloxi 
(palonosetron) 
Serotonin 5-HT3 
receptor antagonist 
(GPCR antagonist) 
Serotonin 5-HT3 
receptor (GPCR) 
Chemotherapy 
side effects 
For the prevention of 
nausea and vomiting 
associated with 
emetogenic cancer 
chemotherapy 
MGI Pharma, 
Helsinn 
Healthcare 
Emend 
(aprepitant) 
P/neurokinin 1 (NK1) 
receptor antagonists 
(GPCR antagonists) 
Neurokinin 
receptors (GPCR) 
Chemotherapy-ind
uced Nausea and 
Vomiting 
For the treatment of 
nausea and vomiting 
associated with 
chemotherapy 
Merck 
Plenaxis 
(abarelix) 
Gonadotropin-releasi
ng hormone (GnRH) 
antagonist 
 
Gonadotropin-relea
sing hormone 
(GnRH) 
Prostate Cancer 
For treatment of 
advanced prostate 
cancer 
Praecis 
Pharmaceuticals
UroXatral 
(alfuzosin 
HCl) 
Antagonist of 
post-synaptic 
alpha1-adrenorecepto
rs 
Alpha1-adrenorecep
tor 
Benign Prostatic 
Hyperplasia 
For the treatment of of 
the signs and symptoms 
of benign prostatic 
hyperplasia 
Sanofi-Synthelab
o 
Gleevec 
(imatinib 
mesylate) 
Protein-tyrosine 
kinase inhibitor PDGF, SCF, c-kit, 
Positive 
inoperable 
and/or metastatic 
malignant 
gastrointestinal 
stromal tumors 
(GISTs) 
Treatment of 
gastrointestinal stromal 
tumors (GISTs) 
Novartis 
Faslodex 
(fulvestrant) 
Estrogen receptor 
antagonist Estrogen receptor 
Hormone 
receptor positive 
metastatic breast 
cancer 
Treatment of hormone 
receptor positive 
metastatic breast cancer 
AstraZeneca 
Eligard 
(leuprolide 
acetate) 
Luteinizing 
hormone-releasing 
hormone (LHRH) 
agonist, 
Luteinizing 
hormone-releasing 
hormone (LHRH) 
Prostate cancer 
For the palliative 
treatment of advanced 
prostate cancer 
Atrix 
Laboratories 
Eloxatin 
(oxaliplatin/5-f
luorouracil/leu
covorin) 
Synthases inhibitor Thymidylate synthetase 
Metastatic colon 
or rectum 
carcinomas 
For the treatment of 
colon or rectum 
carcinomas 
Sanofi-Synthelab
o 
SecreFlo 
(secretin) Diagnostic Agents Secretin receptor gastrinoma 
To aid in the diagnosis 
of pancreatic 
dysfunction and 
gastrinoma 
Repligen 
2002 
Zometa 
(zoledronic 
acid) 
Bisphosphonate, 
Antihypocalcemic 
Agents 
Farnesyl 
pyrophosphate 
synthetase 
Multiple 
myeloma; bone 
metastases from 
solid tumors 
For the treatment of 
multiple myeloma and 
bone metastases from 
solid tumors 
Novartis 
Gleevec 
(imatinib 
mesylate) 
Protein-tyrosine 
kinase inhibitor c-kit, PDGFR 
Chronic myeloid 
leukemia (CML) 
Oral therapy for the 
treatment of chronic 
myeloid leukemia 
Novartis 
Femara 
(letrozole) Enzyme inhibitor Aromatase enzyme Breast cancer 
First-line treatment of 
postmenopausal women 
with locally advanced or 
metastatic breast cancer 
Femara 
(letrozole) 
Tablets 
Kytril 
(granisetron) 
serotonin 5-HT3 
receptor antagonist 
(GPCR antagonist) 
serotonin 5-HT3 
receptor (GPCR) 
Side effect of 
cancer therapy 
For the prevention of 
nausea and vomiting 
associated with cancer 
therapy 
Kytril 
(granisetron) 
Solution 
Trelstar LA Repressor gonadotropin Prostate cancer 
Intramuscular injection 
for the treatment of 
advanced stage prostate 
cancer 
Trelstar LA 
Xeloda2 Synthases inhibitor Thymidylate synthetase Colorectal cancer
Chemotherapy for the 
treatment of metastatic 
colorectal cancer 
Xeloda 
2001 
Zometa 
(zoledronic 
acid) 
bisphosphonate osteoclasts Hypercalcemia of malignancy 
For the treatment of 
hypercalcemia of 
malignancy 
Zometa 
(zoledronic acid)
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Trelstar 
(Triptorelin 
Pamoate) 
Repressor gonadotropin  Prostate cancer 
For the palliative 
treatment of advanced 
prostate cancer 
Debio 
Rechereche 
Pharmaceutique, 
Target Research 
Associates 
Trisenox 
(arsenic 
trioxide) 
Homeopathic Agents 
 
 
PML-RAR Alpha 
Protein 
Acute 
Promyelocytic 
Leukemia 
For the induction of 
remission and 
consolidation in patients 
with acute 
promyelocytic leukemia 
(APL) 
Cell Therapeutics2000 
Viadur 
(leuprolide 
acetate) 
Testosterone 
suppressor, 
luteinizing 
hormone-releasing 
hormone (LH-RH) 
agonist 
Gonadotropin Prostate Cancer 
For pain relief in men 
with advanced prostate 
cancer 
Alza 
Aromasin 
(Exemestane) 
Oxidoreductase 
inhibitor Aromatase Breast cancer 
Treatment of breast 
cancer 
Pharmacia & 
Upjohn 
Busulflex Alkylating agent DNA Leukemia For use for the treatment of leukemia Orphan Medical
Doxil 
(doxorubicin 
HCl liposome 
injection) 
Nucleic acids 
intercalator Topoisomerase II 
Breast cancer, 
ovarian cancer 
Treatment for ovarian 
cancer that is refractory 
to other first-line 
therapies 
Alza 
Ellence 
(epirubicin 
hydrochloride) 
Anthracycline 
cytotoxic agent DNA Helicase Breast cancer 
For treatment of axillary 
node tumor involvement 
for primary breast 
cancer 
Pharmacia & 
Upjohn 
Ethyol 
(amifostine) 
Radiation-Protective 
Agents 
Alkaline 
phosphatase 
Side effect of 
cancer therapy 
Treatment for 
xerostomia (dry mouth) 
due to radiation 
U.S. Bioscience, 
Alza 
Temodar 
(temozolomide
) 
Cytotoxic alkylating 
agent, DNA 
Anaplastic 
astrocytoma 
Treatment for refractory 
anaplastic astrocytoma Schering-Plough
UVADEX 
(methoxsalen) Inhibitor DNA 
Cutaneous T-cell 
lymphoma 
Treatment of the skin 
manifestations of 
cutaneous T-cell 
lymphoma (CTCL) 
Therakos 
1999 
Zofran ODT 
(ondansetron) 
Serotonin 5-HT3 
receptor antagonist 
Serotonin 5-HT3 
receptor 
Chemotherapy 
side effect 
Treatment for the 
prevention of 
chemotherapy and 
radiation-induced nausea 
GlaxoWellcome
Actiq 
(Fentanyl) Opiate Agonists 
Opioid mu Receptor 
(OP3) Cancer Pain 
Treatment for Cancer 
Pain 
Anesta 
Corporation 
Anzemet 
(Dolasetron) 
Serotonin 5-HT3 
receptor Antagonists 
Serotonin 5-HT3 
receptor 
Side effect of 
cancer therapy 
Treatment for the 
prevention of nausea and 
vomiting associated with 
chemotherapy and 
surgery 
Hoechst Marion 
Roussel 
Camptosar 
(Irinotecan) Enzyme Inhibitors 
DNA 
Topoisomerase I Colorectal 
Treatment for Colon or 
Rectal Cancer 
Pharmacia & 
Upjohn 
Gemzar 
(Gemcitabine) 
Immunosuppressive 
Agents 
Ribonucleoside-dip
hosphate reductase 
large subunit 
Lung cancer Treatment for Lung Cancer Eli Lilly 
Neupogen 
(Filgrastim) 
Immunomodulatory 
Agents 
Granulocyte colony 
stimulating factor 
receptor (CD114 
antigen) 
Low white blood 
cell recovery 
following 
chemotherapy 
Treatment for slow 
white blood cell 
recovery following 
chemotherapy 
Amgen 
Nolvadex 
(tamoxifen 
citrate) 
Nuclear receptor 
modulator Oestrogen receptor Breast cancer 
Treatment for Breast 
Cancer 
Zeneca 
Pharmaceuticals
Photofrin 
(Porfimer) 
Photosensitizing 
agent 
Low density 
lipoproteins (LDL) Lung cancer 
Treatment for 
early-stage, 
microinvasive 
endobronchial non-small 
cell lung cancer 
QLT 
1998 
Proleukin 
(Aldesleukin) Human interleukin 2 
Interleukin-2 
receptor beta chain 
(IL-2-RB) 
Metastatic 
melanoma 
Treatment for metastatic 
melanoma 
Chiron 
Corporation 
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Valstar 
(Valrubicin) Antibiotic 
DNA 
Topoisomerase II Bladder Cancer 
Treatment for Bladder 
Cancer 
Anthra 
Pharmaceuticals
Xeloda 
(Capecitabine) Antimetabolites 
Thymidylate 
synthase Breast cancer 
Treatment for advanced 
breast cancer tumors Roche 
Zofran 
(Ondansetron) 
Serotonin 5-HT3 
receptor antagonist 
Serotonin 5-HT3 
receptor 
Chemotherapy 
side effect 
Treatment for 
postoperative vomiting 
and nausea in adults 
GlaxoWellcome
Xibrom 
(Bromfenac) 
Anti-Inflammatory 
Agents, COX-1 
Side effect of 
cancer therapy 
Management of acute 
pain 
Duract, 
Wyeth-Ayerst 
Laboratories 
Femara 
(Letrozole) Aromatase Inhibitors Aromatase Breast cancer 
Treatment for breast 
cancer Novartis 
Gliadel 
(polifeprosan 
20 with 
carmustine 
implant) 
bifunctional 
alkylating agent 
Glutathione 
reductase 
(mitochondrial) 
recurrent 
glioblastoma 
multiforme 
Treatment for brain 
cancer 
Rhone-Poulenc 
Rorer, Guilford 
Pharmaceuticals
Intron A 
(interferon 
alfa-2b, 
recombinant) 
for 
Immunomodulatory 
Agents 
Interferon receptor 
IFNAR2c 
 
 
  
Non-Hodgkin's 
lymphoma 
Treatment for 
non-Hodgkin's 
lymphoma 
Schering-Plough
Kytril 
(Granisetron) 
Verotonin 5-HT3 
receptor antagonist 
Serotonin 5-HT3 
receptor 
Side effect of 
cancer therapy 
Prevention of nausea 
and vomiting associated 
with chemotherapy 
SmithKline 
Beecham 
Lupron Depot 
Gonadotropin 
releasing hormone 
(GnRH) analogs 
Leutinizing-hormon
e-releasing 
hormone 
Prostate cancer Treatment for prostate cancer 
TAP 
Pharmaceuticals
Neumega 
(Oprelvekin) Thrombotics 
Interleukin-11 
receptor alpha chain 
(IL-11R-alpha) 
  
Platelet deficiency 
in cancer patients
Treatment for 
thrombocytopenia Genetics Institute
1997 
Taxol 
(Paclitaxel) 
Taxoid antineoplastic 
agent 
Apoptosis regulator 
Bcl-2 (Tubulin 
beta-1 chain) 
Kaposi's Sarcoma
Treatment for 
AIDS-related Kaposi's 
Sarcoma 
Bristol-Myers 
Squibb 
Anexsia 
(Acetaminoph
en) 
Antipyretics 
Prostaglandin G/H 
synthase 1 
precursor 
Chronic pain Treatment for chronic pain 
Mallinckrodt 
Group 
Arimidex 
(anastrozole) Aromatase Inhibitors Aromatase Breast cancer 
Treatment for advanced 
breast cancer in 
postmenopausal women 
Zeneca 
Pharmaceuticals
Elliotts B 
Solution 
(buffered 
intrathecal 
electrolyte/dex
trose injection) 
Calcium Channel 
Blockers 
Voltage-dependent 
calcium channel 
gamma-1 subunit 
Leukemia, 
lymphoma 
Treatment of meningeal 
leukemia or lymphocytic 
lymphoma 
Orphan Medical
Eulexin 
(flutamide) 
Androgen 
Antagonists Androgen receptor Prostate cancer 
Treatment for prostate 
cancer Schering-Plough
Gemzar 
(Gemcitabine 
HCl) 
nucleoside analogue DNA Pancreatic cancer Treatment for pancreatic cancer Eli Lilly 
Hycamtin 
(topotecan 
hydrochloride) 
Topoisomerase I 
inhibitor Topoisomerase I Ovarian cancer 
Treatment for metastatic 
ovarian cancer 
SmithKline 
Beecham 
Kadian 
(Morphine) Opiate Agonists 
Mu-type opioid 
receptor 
Chronic pain of 
cancer patients 
Treatment for chronic 
moderate to severe pain 
Purepac 
Pharmaceutical 
Leukine 
(sargramostim) 
Immunomodulatory 
Agents 
Granulocyte-macro
phage colony 
stimulating factor 
receptor 
(GM-CSF-R-alpha 
or CSF2R) 
Replenishment of 
white blood cells
Treatment for the 
replenishment of white 
blood cells 
Immunex 
1996 
Taxotere 
(Docetaxel) 
Radiation-Sensitizing 
Agents 
Apoptosis regulator 
Bcl-2 Breast cancer 
Treatment for locally 
advanced or metastatic 
breast cancer 
Rhone Poulenc 
Rorer 
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Zoladex 
(goserelin 
acetate) 
Decapeptide analogue 
Luteinizing 
Hormone-Releasing 
Hormone (LH-RH) 
Receptor 
Prostate cancer Treatment for advanced prostate cancer 
Zeneca 
Pharmaceuticals
1 Nelarabine is demethoxylated by adenosine deaminase to ara-G, and converted by cellular kinases to the active 5'-triphosphate, ara-GTP. 
Incorporation of ara-GTP into DNA leads to inhibition of DNA synthesis and cell death (165) 
2Once in the body, Xeloda is converted into fluorouracil (5-FU) by the naturally produced enzyme thymidine phosphorylase (TP).  
 
1.3.2 Introduction to therapeutic antibody 
Antibody is a kind of highly specific, naturally evolved molecules that 
recognize and eliminate pathogenic and disease antigens (166). The past 40 years 
of antibody research have hinted at the promising of new versatile therapeutic 
agents to fight cancer, autoimmune disease and infections. Currently antibody is 
one of the largest classes of drugs (167).  
 
Antibodies are large glycoprotein molecules produced by B lymphocytes of the 
human immune system, with the capability to recognize a specific molecular 
structure on a target known as an antigen. The specificity of antibodies is that they 
are capable of distinguishing the sublet of molecular differences. The basic unit of 
all antibodies is a four-chain structure, which is composed of two identical light 
chains (lambda or kappa) and two identical heavy chains (IgA, IgD, IgG, IgE or 
IgM). Both the heavy and light chains can be divided into two regions based on 
the variability in the amino acids sequence. The regions include variable region of 
light chain (VL, approximately 110 amino acids), constant region of light chain 
(CL, approximately 110 amino acids), variable region of heavy chain (VH, 
approximately 110 amino acids), and constant region of heavy chain (CH, 
approximately 330 to 440 amino acids). The antibodies bind to antigens via 
variable regions. Constant regions interact with other components of the immune 
system and initiate the appropriate biological response, such as phagocytosis, 
Chapter 1 Introduction 
24 
cytolysis or initiation of complement cascade followed by cell lysis, to eliminate 
the target pathogen or neutralize toxins.  
 
Antibody is an essential component of the human immune system and a part of 
human body’s principle defense mechanism against disease, and using antibody to 
fight disease is just a logical extension of their natural role. Even in one century 
ago, Paul Enrich proposed that antibody could be used as “magic bullets” to target 
and treat human diseases. However, only when the hybridoma technology was 
utilized in monoclonal antibodies production in 1975 and revolutionized the 
potential application of antibodies both for research, clinical diagnosis and 
treatment of disease (168), it makes antibody an important drug class (162, 167). 
The first successful use of a monoclonal antibody for cancer treatment was 
reported in 1982 (169) and the first US FDA-approved antibody for therapeutic 
usage was OKT3 in 1986 (170-174). Several years later, another antibody Reopro 
was approved (175). Currently 18 antibodies have been approved by FDA (Table 
1-3) and at least 400 additional antibodies are in clinical development (176). The 
annual sales of antibody drugs was predicted to reach $16.7 billion in 2008 
(177-179). 
 
The successful application of antibody in the therapeutics makes antibody design 
an impressive research area. The popular wet-lab technologies such as 
phage-display technology (180) and transgenic technology (181) are available for 
antibody design. However, much effort is needed to identify the specificities of the 
antibody for these methods. A key challenge of current antibody rational design is 
to make an antibody for a specific antigen but not a vast number of other 
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molecules. Therefore it is very important to dissect the antibody-antigen 
recognition and interaction.  
 
Table 1-3 US FDA-approved therapeutic antibody drugs. 
Year Drugs Target Antigen  
Type of 
Antibody  Isotype
Kd 
(nM)
FDA-Approved 
Indication(s)  Company  Reference 
1986 
Orthoclone 
OKT3 
(muromonab-
CD3) 
CD3 Murine antibody IgG2a 0.83
For treatment of 
acute allograft 
rejection 
Johnson & 
Johnson 
(162, 163, 
167) 
1994 ReoPro (abciximab)  
GP IIb/IIIa 
receptor 
Fab 
fragment of 
a chimeric 
antibody  
IgG1 5 
Used for 
prevention of 
cardiac ischemia 
complications  
Johnson & 
Johnson 
(162, 163, 
167) 
Rituxan/ 
MabThera 
(rituximab)  
CD20  Chimeric antibody 
IgG1, 
kappa 8 
For treatment of 
CD20-positive, 
B-cell 
non-Hodgkin’s 
lymphoma 
(NHL) 
Genentech, 
Roche, and 
Biogen Idec  
(162, 163, 
167) 
1997 
Zenapax 
(daclizumab)  CD25 
Humanized 
antibody  
IgG1, 
kappa 0.3 
For prophylaxis 
of acute organ 
rejection in renal 
transplant 
patients.  
Hoffmann-L
a Roche  
(162, 163, 
167) 
Simulect 
(basiliximab)  CD25 
Chimeric 
antibody  
IgG1, 
kappa 0.1 
For prophylaxis 
of acute organ 
rejection 
Novartis  
(162, 163, 
167) 
Synagis 
(palivizumab)  RSV gpF 
Humanized 
antibody  
IgG1, 
kappa 0.96
For prevention of 
serious lower 
respiratory tract 
disease caused by 
respiratory 
syncytial virus 
(RSV)  
MedImmune  
(162, 163, 
167) 
Remicade 
(infliximab)  TNF-alpha  
Chimeric 
antibody 
IgG1, 
kappa 0.1 
For treatment of 
rheumatoid 
arthritis, Crohn’s 
disease, 
ankylosing 
spondylitis, 
psoriatic arthritis, 
and ulcerative 
colitis.  
Johnson & 
Johnson  
(162, 163, 
167) 
1998 
Herceptin 
(trastuzumab)  
HER2 
protein  
Humanized 
antibody  
IgG1, 
kappa 5 
For treatment of 
metastatic breast 
cancer  
Genentech 
and Roche  
(162, 163, 
167) 
2000 
Mylotarg 
(gemtuzumab 
ozogamicin)  
CD33 
Humanized 
antibody-dr
ug 
(cytotoxic 
antitumor 
antibiotic 
calicheamici
n) conjugate
IgG4, 
Kappa 0.08
Treatment of 
CD33 positive 
acute myeloid 
leukemia (AML)
Wyeth 
Pharmaceuti
cals 
(162, 163, 
167) 
2001 Campath (alemtuzumab) CD52 
Humanized 
antibody 
IgG1, 
kappa 10 ~ 32
Injectable 
treatment of 
B-cell chronic 
lymphocytic 
leukemia 
Berlex 
Laboratories 
(162, 163, 
167) 
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Zevalin 
(ibritumomab 
tiuxetan)  
CD20 
Radiolabele
d (Yttrium 
90) murine 
antibody 
IgG1, 
kappa 14 ~ 18
Treatment of 
non-Hodgkin's 
lymphoma 
IDEC 
Pharmaceuti
cals 
(162, 163, 
167) 
2002 
Humira 
(adalimumab)  TNF-alpha  
Human 
antibody  
IgG1, 
kappa 0.1 
For treatment of 
adults with 
rheumatoid 
arthritis and 
psoriatic arthritis. 
Abbott 
Laboratories  
(162, 163, 
167) 
Xolair 
(omalizumab)  IgE  
Humanized 
antibody 
IgG1, 
kappa 0.17
For treatment of 
adults and 
adolescents with 
moderate to 
severe persistent 
asthma.  
Genentech, 
Novartis, 
Tanox and 
Roche 
(162, 163, 
167) 
Raptiva 
(efalizumab)  CD11a  
Humanized 
antibody 
IgG1, 
kappa 3 
For treatment of 
adults with 
chronic moderate 
to severe plaque 
psoriasis 
Genentech 
and Roche  
(162, 163, 
167) 
2003 
Bexxar 
(Tositumomab 
and Iodine I 
131Tositumom
ab) 
CD20 Murine antibody 
IgG2a, 
lambda 1.4 
Treatment of 
patients with 
CD20 positive, 
follicular, 
non-Hodgkin's 
lymphoma 
following 
chemotherapy 
relapse 
Corixa 
(162, 163, 
167) 
Avastin 
(bevacizumab)  VEGF 
Humanized 
antibody IgG1 1.1 
Treatment of 
metastatic 
carcinoma of the 
colon or rectum 
Genentech 
(162, 163, 
167) 
2004 
Erbitux 
(cetuximab)  EGFR 
Chimeric 
antibody 
IgG1, 
kappa 0.2 
Treatment of 
EGFR-expressing 
metastatic 
colorectal cancer
Imclone, 
Bristol 
-Myers 
Squibb 
(162, 163, 
167) 
Vectibix 
(panitumumab
) 
EGFR Human antibody 
 IgG2, 
kappa 0.05
Treatment of 
colorectal cancer Amgen 
(163, 182, 
183) 
 
Herceptin* 
(trastuzumab) ERBB2 
Humanized 
antibody  IgG1  0.1
A second- or 
third-line therapy 
for patients with 
metastatic breast 
cancer 
Genentech 
(163, 184, 
185) 
2006 
Lucentis 
(ranibizumab) VEGF 
Humanized 
antibody 
fragment 
IgG1,
kappa  
treat the "wet" 
type of 
age-related 
macular 
degeneration 
(ARMD), a 
common form of 
age-related vision 
loss 
Genentech 
(163, 186) 
*First approved October 1998, used extended 2006 
 
Much effort has been spent on the recognition of antibody-antigen interaction in 
structure level (187-193), whereas little research has been conducted on the 
sequence level to study the interaction between antibody and antigen. However, 
the availability of structure information of antigen and antibody is much less than 
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that of sequence information. 42,627 protein structures information exists in 
Protein Data Bank (PDB) (accessed at 03-Apr-2007) (194). This number is less 
than 1% of the proteins with sequence information from SwissProt (4,495,647 
protein sequences, Release 35.2, 03-Apr-2007) (195). Therefore the antibody 
rational design may benefit from the huge number of sequence information and 
the major advances in informatics technology (196). Publicly accessible resources, 
includes the rapidly increasing number of bioinformatics databases especially 
immunoinformatics database and their strategies, should be useful for antibody 
design.  
 
The rapid development of computational tools has also offered a new solution to 
speed up the antibody design. Since both antibody and antigen are special classes 
of proteins, the strategies for studying protein-protein interaction may be applied 
in antibody-antigen interaction to find the mechanism of antibody-antigen 
interaction and facilitate antibody design. 
 
1.3.3 The need for development of antibody-antigen interaction databases 
A number of antibody and/or antigen databases had been developed for 
providing information about various aspects of antibodies and antigens (Table 1-4). 
Kabat database (197) is the oldest antibody database started in 1970 (198) and 
now a comprehensive immunoinformatics database, comprising of nucleotide 
sequences, sequences of antibody, T cell receptors for antigens (TCR) and major 
histocompatibility complex (MHC) molecules. VIR II provides an interface of 
Kabat database with the antibody sequences (107). The ImMunoGeneTics (IMGT) 
database provides annotated listings and alignments of immunoglobulins, TCR, 
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MHC of all vertebrate species (199-201). FIMM database contains protein 
antigens, MHC, T- and B-cell epitopes and relevant disease associations (202). 
Molecular Modeling Database (MMDB) (203) contains the crystal structure of 
antibody and HLA obtained from the PDB (194). JenPep is a database of 
quantitative binding data for immunological protein-peptide interactions (204). 
IEDB (205) contains data related to antibody, T cell epitopes, MHC binding data 
for human and some animal species. HaptenDB (206) provides comprehensive 
information about the Hapten molecules and ways to raise corresponding 
antibodies. Although these databases provide valuable information about the 
antibodies and antigens, such as sequences (IMGT, KABAT, FIMM, BCIPEP), 
structures (IMGT, IEDB, MMDB, SACS), epitope information (IEDB, FIMM, 
Epitome, CED), binding information (IEDB, JenPep, AntiJen, Epitome) and 
disease implication (IMGT, FIMM). It tends to be difficult to extract the 
information of targeted diseases, the therapeutic indications and sequence-level 
recognition data (i.e. which antibody sequence recognizes which antigen sequence 
or sequences) from these databases. Although other database such as the epitome 
database (207) contains sequence-specific information about antibody and antigen 
interactions, it only covers a limited number of Ab-Ag pairs obtained from protein 
Databank (194). As a result, there is a need to develop a database capable of 
providing both easily accessible information and more comprehensive coverage of 
sequence-specific Ab-Ag recognition to complement existing databases. 
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Table 1-4 Public antibody and antigen databases.  
Database Description URL Reference
KABAT 
The oldest antibody database, and now 
a comprehensive immunoinformatics 
database including nucleotide 
sequences, sequences of antibody, 
TCR and MHC molecules 
 (197, 198)
SYFPEITHI Sequences of T-cell epitopes and MHC ligands http://www.syfpeithi.de/ (208) 
VIR 
Public 3D-structure of known 
antibodies and an interface with the 
antibody sequences in the Kabat 
database 
http://www.ibt.unam.mx/vir/
structure/structures.html (107) 
the international 
ImMunoGeneTics 
information system 
(IMGT) 
A high-quality integrated knowledge 
resource specialized in the 
immunoglobulins (IG), T cell receptors 
(TCR), major histocompatibility 
complex (MHC), immunoglobulin 
superfamily (IgSF) and MhcSF. It 
consists of sequence databases 
(IMGT/LIGM-DB, IMGT/MHC-DB, 
IMGT/PRIMER-DB), genome 
database (IMGT/GENE-DB) and 
structure database 
(IMGT/3Dstructure-DB) 
http://imgt.cines.fr/ (199-201)
Functional 
molecular 
immunology 
database (FIMM) 
MHC, antigens, T- and B-cell epitopes http://research.i2r.a-star.edu.sg/fimm/ (202) 
Summary of 
Antibody Crystal 
Structures (SACS) 
All antibody structures in the Protein 
Databank 
http://www.bioinf.org.uk/abs
/sacs/ (209) 
Molecular 
Modeling 
Database (MMDB)
3D macromolecular structures, 
including antibody, HLA, TCRs 
http://www.ncbi.nlm.nih.gov
/Structure/MMDB/mmdb.sht
ml 
(203) 
JenPep 
Quantitative binding data for 
immunological protein-peptide 
interactions 
http://www.jenner.ac.uk/JenP
ep (204) 
HLA Sequence 
Database HLA sequence 
http://www.anthonynolan.org
.uk/HIG/index.html (210) 
MHCBN MHC binding, non-binding peptides and T-cell epitopes 
http://www.imtech.res.in/rag
hava/mhcbn/ (211) 
dbMHC DNA and clinical data related to HLA http://www.ncbi.nlm.nih.gov/mhc/MHC.cgi?cmd=init (212) 
Blood Group 
Antigen Gene 
Mutation Database 
(BGMUT) 
Variations in genes that directly or 
indirectly affect our blood groups. 
Allelic genes of blood group antigens 
http://www.ncbi.nlm.nih.gov
/gv/mhc/xslcgi.fcgi?cmd=bg
mut/home 
(213) 
BCIPEP  B cell epitope database  http://www.imtech.res.in/raghava/bcipep (214) 
VBASE2 
Germ-line sequences of human and 
mouse immunoglobulin variable (V) 
genes 
http://vbase.mrc-cpe.cam.ac.
uk (215) 
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The Immune 
Epitope Database 
and Analysis 
Resource (IEDB) 
Data related to antibody and T cell 
epitopes, MHC binding data for human 
and some animal species 
www.immuneepitope.org (205) 
TumorAntigen 
database 
A listing of human tumor antigens 
recognized by T cells 
http://sdmc.i2r.a-star.edu.sg/
Templar/DB/cancer_antigen/ (216) 
HIV molecular 
immunology 
database  
A collection of HIV-1 cytotoxic and 
helper T-cell epitopes and antibody 
binding sites 
http://www.hiv.lanl.gov/cont
ent/immunology/index.html (217) 
HCV Immunology 
database  
A collection of HCV cytotoxic and 
helper T-cell epitopes and antibody 
binding sites 
http://hcv.lanl.gov/content/i
mmuno/immuno-main.html (218) 
EPIMHC 
A relational database of MHC-binding 
peptides and T cell epitopes that are 
observed in real proteins 
http://bio.dfci.harvard.edu/ep
imhc/ (219) 
AntiJen  Quantitative binding data for B cell epitopes  
http://www.jenner.ac.uk/Anti
Jen/ (220) 
HaptenDB  
A listing of haptens, structural 
similarity searches, and antibody and 
biological information  
http://bioinformatics.uams.ed
u/raghava/haptendb/ (206) 
epitome database 
All known antigenic residues and 
corresponding antibodies from PDB 
entries 
http://www.rostlab.org/servic
es/epitome/ (207) 
CED A conformational epitope database http://web.kuicr.kyoto-u.ac.jp/~ced/ (221) 
 
1.3.4 Current progress in antibody-antigen interaction prediction 
A number of studies have demonstrated the capability of combining 
experimental results with computational methods in understanding 
antibody–antigen interactions. Padlan et al (1993) and Garman et al (2000) (187, 
188) employed structure model to study IgE/receptor interactions. Friedman et al 
(1994) (190) utilized Metropolis Monte Carlo algorithm to dock the antigen to 
antibody, showing distinct roles for the "lock-and-key" (recognition) and the 
"handshake" (binding) paradigms in antibody-antigen interaction. Irnaten et al 
(1998) (191) developed a molecule modeling method for predicting epitopes. 
Tenette-Souaille et al (2000) (222) modeled antibody-antigen complex structure in 
the absence of X-ray crystallographic information of antibody, which was 
agreeable with the experimental data. Choulier et al (2002) (192) applied QSAR 
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model to the prediction of Ab-Ag interaction kinetics as measured by BIACORE. 
Chen et al (2007) (223) applied SVM to identify linear B-cell epitopes using 
amino acid pair antigenicity scale.  
 
Since antibody-antigen interactions are representative of a broad class of 
protein-protein interactions involving both specificity and affinity, the method 
used in protein-protein interaction prediction could be extended to 
antibody-antigen interaction. SVM has been recently been used for prediction 
protein-protein interaction from sequence-based properties (224-227). The 
sequence information of Ab-Ag interaction can also be used to develop SVM 
models for prediction antibody sequence from antigen sequence in a manner 
similar to the prediction of protein-protein interaction from individual sequences. 
This thesis will use SVM to develop a prototype model for predicting antibody 
from the sequence-recognition information of Ab-Ag. 
 
1.4 Scope and research objective 
The purpose of this thesis is to design bioinformatics tools for disease marker 
discovery from microarray data and to perform therapeutic molecule prediction 
for facilitating drug discovery. 
 
A disease marker discovery system is developed by using gene selection strategies 
from microarray data. This system aims to provide gene signatures which should 
produce good prediction performance for disease differentiation, and show a 
certain level of stability with the variation of sampling method. The strategies 
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include the incorporation of multiple random sampling method and the evaluation 
of gene-consistency into RFE gene selection procedure. The stable gene 
signatures may help us understand the mechanism of disease initiation and process, 
and may provide an insight for diagnosing disease, predicting disease types, 
prognosis of the outcome of a specific therapeutic strategy, and drug resistance 
before drug treatment. In this thesis colon cancer gene selection and lung 
adenocarcinoma survival marker selection are used as case studies to evaluate the 
performance of the system. The stable gene signatures provide the biologists an 
opportunity to further investigate the role of derived genes in the initiation and 
progress of a disease, and give suggestions about potential disease targets for 
therapeutic molecule design.  
 
This thesis also develops a bioinformatics tool for predicting therapeutic 
molecules which act on disease targets. Antibody, as a well-established therapeutic 
molecule, is selected in this study. All therapeutic applications of antibodies are 
based on their ability to recognize specific target molecules – antigens. Currently 
much effort has been put to understand the antibody-antigen interaction in order to 
generation and optimization of antibodies to improve their potential in the 
prevention and treatment of disease. The rapid advances in informatics technology 
and computational technology may be helpful for us to understand the 
antibody-antigen interaction. Therefore, an antibody-antigen sequence-recognition 
resource will be described and a prediction system of disease gene targeting 
antibody from antibody-antigen sequence-recognition information will be 
developed. The prediction system could be helpful for therapeutic antibody 
design. 
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This thesis is divided into six chapters. Chapter one provides the background and 
current progress for disease marker, disease targeting molecules and their 
discovery method. Chapter two describes the methodology of this study. Support 
vector machine is described at the beginning of Chapter two since this method is 
used in both disease marker discovery and disease targeting molecule design. The 
strategies for disease marker discovery and disease targeting molecule design are 
described in the following sections of this Chapter. The application of the disease 
marker discovery is described in Chapter three and Chapter four. Chapter five 
gives a case study of therapeutic molecule discovery. Chapter six presents 
conclusion and future work.  
Chapter 2 Methodology 
34 
2 Methodology 
This chapter introduces the methodologies for (1) gene selection from 
microarray data and (2) bioinformatics tool development for therapeutic 
molecular prediction. Firstly a classification method –support vector machines, 
which is used in both gene selection and therapeutic molecule prediction, is 
described (Section 2.1). The following two sections present other strategies used 
for marker selection from microarray data (Section 2.2) and bioinformatics tool 
development for therapeutic antibodies (Section 2.3). 
 
2.1 Support Vector Machines 
2.1.1 Theory and algorithm 
Support vector machines (SVM) is a relatively new machine learning method 
proposed by Vapnik (114, 228, 229). It defines a mapping, or a decision function, 
from feature vector space to the class label space. Over the past decades, SVM has 
become a popular supervised learning method in variety applications including 
image classification and object detection (230, 231), text categorization (232), 
prediction of protein solvent accessibility (233), microarray data analysis (120, 
121, 138, 149), protein fold recognition (234), protein secondary structure 
prediction (235), prediction of protein-protein interaction (224) and protein 
functional class classification (236).  
 
SVM can be divided into linear and non-linear SVM. Linear SVM directly 
constructs a hyperplane in the feature space to separare positive examples from 
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negative examples. On the other hand, non-linear SVM projects both positive and 
negative examples into a higher-dimensional feature space and then separates 
them in that space.  
 
Linear SVM is the simpleast form of SVM, in which the data represented as a 
p-dimensional vector (a list of p numbers) can be separated by a p-1 dimensional 
hyperplane. On each side of this p-1 hyperplane, two parallel hyperplanes can be 
constructed (Figure 2-1). The separating hyperplane is the one that maximizes the 
distance between these two parallel hyperplanes. Many linear hyperplanes (also 
called classifiers) can separate the data. However, only one achieves maximum 
separation. Under the assumption that the larger the margin or distance between 
these two parallel hyperplanes the better the generalization error of the classifier 
will be (237), the maximum separating hyperplane (also known as 
maximum-margin hyperplane) is clearly of interest (Figure 2-1). 
 
Mathematically, supposed the training set is composed of n examples with two 
classes, it could represent as  
)},()...,,((),,{( 2211 nn yxyxyx=χ ,  i=1, 2, …, n,            (1) 
where Ni Rx ∈  is an N-dimensional real vector and }1,1{ +−∈iy  indicates class 
label.  
The separating hyperplane can be described by equation:  
0=+• bxw               (2) 
where w=(w1,w2,…, wn)T is a unit vector of n elements and b is a constant, and the 
relative two parallel hyperplanes can be described by equations 
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Figure 2-1 Margins and hyperplanes 
 
 
1+=+• bxw  for 1+=iy          (3) 
1−=+• bxw  for 1−=iy          (4) 
If the training data are linearly separable, we can select those two parallel 
hyperplanes with no data point between them and try to maximize their distance. 
By using geometry, we find the distance between the two parallel hyperplanes is 
2/|w|. Therefore, to obtain the solution of SVM, |w| should be minimized.  
To exclude data points between the two parallel hyperplanes, we need to ensure 
that for all i either 
1+≥+• bxw  for 1+=iy  or         (5) 
1−≤+• bxw  for 1−=iy          (6) 
It can be rewritten as  
Small margin 
Large margin 
Two parallel hyperplanes 
Separating hyperplane 
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,1)( ≥+• bxwy ii  ni ≤≤1          (7) 
The problem now is to minimize |w| subject to the above constraint. More clearly,  
Minimize 
2
2
1 w
           (8) 
Subject to ,1)( ≥+• bxwy ii  ni ≤≤1  
This is a quadratic programming (QP) optimization problem.  
 
Such optimization problem could be efficiently solved with the introduction of 
lagrangian multiplier ai,  
∑ −+••−= )1))(((21),,( 2 bwxywabwL iiip α     (9) 
where 0≥iα .  
The solution to this QP optimization problem requires that the gradient of   
L(w,b,α) with respect to w and b vanishes,  
0),,( =∂
∂ abwL
w p  and          (10) 
0),,( =∂
∂ abwL
b p            (11) 
resulting in the following conditions:  
∑
=
=
n
i
iii xyaw
1  and           (12) 
0
1
=∑
=
n
i
ii ya
              (13) 
By substituting Equations (12) and (13) into Equation (9), the QP problem 
becomes the maximization of the following expression: 
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under the constraints 
0
1
=∑
=
n
i
ii ya
 , 0≤αi≤C, i=1, 2, …, n. C is a penalty for 
training errors for soft-margin SVM and is eual to infinity for hard-margin SVM. 
 
The points located on the two optimal margins will have nonzero coefficients αi 
among the solutions to Equation (14), and are called Support Vectors (SV). The 
bias b0 can be calculated as follows: 
{ } { } ⎭⎬
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i
yx
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                   (15) 
After determination of support vectors and bias, the decision function that 
separates two classes can be written as:  
⎥⎦
⎤⎢⎣
⎡ +=⎥⎦
⎤⎢⎣
⎡ += ∑∑
= SV
ii
n
i
ii byasignbyasignxf 0
1
0)( .xx.xx ii          (16) 
 
When the examples are inseparable by linear SVM, nonlinear SVM can be applied, 
which projects the input data to a higher dimensional feature space by using a 
kernel function K(x,y). The linear SVM procedure is then applied to the featrue 
vectors in this feature space. After the determination of w and b, a given vector x 
can be classified by using  
⎥⎦
⎤⎢⎣
⎡ += ∑
SV
iii b).xxKyasignxf 0()(                         (17) 
A positive or negative value indicates that the vector x belongs to the posive or 
negative class respectively.  
In equation (17), kernel function K(x,y) represents a legitimate inner product in the 
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input space:  
)()(),( yxyxK φφ ⋅=                                     (18) 
A number of kernel functions have be used in SVM. Examples of the most 
popular ones are:  
Polynomial kernel pjiji xxxxK )1(),( +⋅=      (19) 
Sigmoid kernel  )tanh(),( cxxxxK jiji += κ      (20) 
Radial basis function (RBF) 
22 2/||||),( σij xxji exxK
−−=        (21) 
 
In practice, RBF kernel is the most widely used kernel function due to three 
reasons. First, linear kernel and sigmoid kernel can be treated as special cases of 
RBF kernel since RBF kernel in certain parameters has the same performance as 
the linear kernel (239) or sigmoid kernel (240). Second, comparing with 
polynomial kernel, RBF kernel has few parameters which influence the 
complexity of model selection. Third, RBF function has less computational cost 
compared with polynomial kernels in which kernel values may go to infinity or 
zero while the degree is large. Based on these reasons, this thesis mainly used 
RBF kernel.  
 
Several specialized algorithms can be used to solve the QP problem of SVM by 
heuristically breaking the problem down into smaller, more-manageable chunks. 
Table 2-1 listed some popular SVM software tools. In our case, we modified the 
source code of libSVM to fit our program requirements. libSVM is a sequential 
minimal optimization (SMO) algorithm(238), which breaks the problem down 
into 2-dimensional sub-problems that may be solved analytically, eliminating the 
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need for a numerical optimization algorithm such as conjugate gradient methods. 
 
Figure 2-2 Architecture of support vector machines  
 
Table 2-1  List of some popular used support vector machines softwares 
Software URL 
SVM-Light http://svmlight.joachims.org/ 
LIBSVM http://www.csie.ntu.edu.tw/~cjlin/libsvm/ 
mySVM http://www-ai.cs.uni-dortmund.de/SOFTWARE/MYSVM/index.
html 
BSVM http://www.csie.ntu.edu.tw/~cjlin/bsvm/ 
WinSVM http://www.cs.ucl.ac.uk/staff/M.Sewell/winsvm/ 
LS-SVMlab http://www.esat.kuleuven.ac.be/sista/lssvmlab/ 
GIST SVM 
Server 
http://svm.sdsc.edu/svm-intro.html 
 
2.1.2 Performance evaluation 
The performance of SVM can be measured as true positive TP (the number of 
positive examples which are correctly predicted as positive), false negative FN 
(the number of positive examples which are incorrectly predicted as negative), 
true negative TN (the number of negative examples which are correctly predicted 
as negative) and false positive FP (the number of negative examples which are 
incorrectly predicted as positive) (Table 2-2). 
 
1−=+• bxw
1=+• bxw
0=+• bxw
w
2
Chapter 2 Methodology 
41 
The simplest way to evaluate the performance of a classification is overall 
accuracy (Q), which measures the proportion of the total number of the correctly 
predicted examples.  
FPTNFNTP
TNTPQ +++
+=
        (22) 
Another two concepts, sensitivity (SE) and specificity (SP), which measure the 
positive and negative prediction performance respectively, are also frequently 
used in classification.  
FNTP
TPSE +=           (23) 
FPTN
TNSP +=           (24) 
In some cases such as epidemiology and the evaluation of diagnostic tests (241), 
positive predictive value (PPV, also called precision rate) and negative predictive 
value (NPV) are very important.  
FPTP
TPPPV +=           (25) 
FNTN
TNNPV +=          (26) 
 
Table 2-2 Relationships among terms of performance evaluation. 
 
Condition  True false  
Positive True positive (TP) 
False positive 
(FP) 
ÆPositive predictive value 
(PPV) Test 
outcome Negative False negative (FN) 
True negative 
(TN) 
ÆNegative predictive value 
(NPV) 
 
↓ 
Sensitivity 
(SE) 
↓ 
Specificity 
(SP) 
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2.2 Methodology for gene selection from microarray data 
2.2.1 Preprocessing of microarray data 
2.2.1.1 Missing data estimation 
Missing values is a common issue existing in microarray data. The missing 
values arise from experimental errors due to spotting problems (cDNA), dust, 
poor hybridization, inadequate resolution, fabrication errors (e.g. scratch) and 
image corruption (242, 243). They could also come from the suspicious data with 
low expression (e.g. background is stronger than signal) or censored data (26). 
Repeating experiments could be a solution but often not be a realistic option 
because of economic reasons or limitations in biological material (121, 244). 
However, many microarray data analysis methods, such as classification, 
clustering and gene selection methods, require complete data matrix. Therefore in 
many microarray projects, one needs to determine how to estimate missing values. 
Proper missing value estimation can significantly improve performance of the 
analysis methods (245-247). The simplest way is to remove all genes and arrays 
with missing values, or to replace missing values with an arbitrary constant 
(usually zero), row (gene) average or column (array) average. The better 
approaches had also been proposed such as k-nearest neighbors method (KNN) 
(247), least square methods (LS) (244, 248), and principal component analysis 
(PCA) (249, 250). Among these estimation methods, KNN is the most widely 
used and is also a standard method for missing value estimation currently (85, 245, 
247).  
 
The KNN-based method for missing value estimation involves selecting k 
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neighbor genes with similar expression profiles to the target gene (the gene with 
missing values in one or more arrays), and estimating the missing value of the 
target gene in specific array as the weighted mean of the expression levels of the k 
neighbor genes in this array. A popular KNN-based method is KNNimpute (247), 
which is the only imputation method available in many microarray data analysis 
tools for missing value estimation (251-253). KNNimpute can be downloaded 
from Stanford Microarray Database (85, 254). In this thesis, KNNimpute is 
employed if the microarray data contains missing values. 
 
2.2.1.2 Normalization 
The purpose of normalization is to remove systematic variations from the 
expression values, so that biological difference can be easily distinguished and the 
comparison of expression levels across samples can be performed. In microarray 
experiments, all the values are fluorescent intensities, which are directly 
comparable. Therefore the normalization among genes and arrays (120) are both 
possible.  
 
The popular normalization methods for microarray experiments include global 
normalization using all genes on the array, and housekeeping genes normalization 
using constantly expressed housekeeping/invariant genes (80). Since 
Housekeeping genes are not as constantly expressed as assumed previously (255), 
using housekeeping genes normalization might introduce extra potential sources 
of error. It was further approved that normalization using a reduced subset of 
genes was less statistically robust than the normalization using the entire gene set 
(256). Currently, a typical normalization procedure is (1) normalizing the 
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expression levels of each sample to zero-mean and unit variance, and then (2) 
normalizing the expression levels of each gene to zero-mean and unit variance 
over all the samples. This normalization method have been shown to perform well 
(257, 258) and is applied in this thesis. 
 
2.2.2 Gene selection procedure 
2.2.2.1 Overview of the gene selection procedure 
A novel gene selection procedure method based on Support Vector Machines 
classifier, recursive feature elimination, multiple random sampling strategies and 
multi-step evaluation of gene-ranking consisitency was established (Figure 2-3): 
(1) After preprocessing the original data, by using random sampling method, a 
large number of training-test sample combinations are generated from the original 
data set. 
(2) The large number of sample combinations is divided into n groups, and each 
group contains 500 sample combinations. 
(3) In each training-test sample combination of each group, SVM and RFE are 
used to classify the samples (SVM classifiers) and rank the genes (RFE gene rank 
criteria). Therefore 500 gene ranking sequences are formed. 
(4) The consistency evaluation can be performed based on the 500 sequences and 
a certain number of genes (for example, k genes) can be eliminated.  
(5) Step (3) and (4) can be iteratively done until no gene can be eliminated.  
(6) The gene subset which gives us the highest overall accuracies of the 500 test 
sample sets can be selected as gene signatures of this group. By this way, we can 
obtain n gene signatures.  
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Figure 2-3 Overview of the gene selection procedure 
 
Multiple random sampling  
Data preprocess (missing value estimation, normalization) 
 
Gene signature 1  Gene signature n 
… 
… 
Stability evaluation of the n gene signatures 
m1= m1-k1 
Data sample group 1 (500 training-test sets) 
k1 genes are eliminated
Gene ranking consistency evaluation 
RFE-SVM 
SVM classifier 1
(m1 genes) 
RFE Gene ranking 1
RFE-SVM 
SVM classifier 500
(m1 genes) 
RFE Gene ranking 500
RFE-SVM 
SVM classifier 2
(m1 genes) 
RFE Gene ranking 2
… 
Gene selection procedure in group n 
mn=mn-kn 
Data sample group n (500 training-test sets) 
kn genes are eliminated
Gene ranking consistency evaluation 
RFE-SVM 
SVM classifier 1
(mn genes) 
RFE Gene ranking 1
RFE-SVM 
SVM classifier 500 
(mn genes) 
RFE Gene ranking 500 
RFE-SVM 
SVM classifier 2
(mn genes) 
RFE Gene ranking 2
… 
Gene selection procedure in group 1 
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(7) The stability evaluation of the gene signatures can be performed by looking 
into the overlap gene rate of the n gene signatures. 
 
Below Recursive feature elimination is introduced first and followed by a detailed 
introduction of the whole feature selection procedure. 
 
2.2.2.2 Recursive feature elimination 
During gene selection procedure, the genes ranked according to their 
contribution to the SVM classifiers. The contributions of genes are calculated by 
Recursive feature elimination (RFE) procedure, which sort genes according to a 
gene-ranking function generated from SVM classifier. As described in Section 2.1, 
SVM training process needs to find the solution for the optimum problem (also 
known as objective function or cost function) shown in equation (14), which can 
be rewritten as 
1
2
1 TT HJ ααα −=
          (27) 
Under the constraints 
0
1
=∑
=
n
i
ii ya
 and 0≥iα , i=1,2,…n. 
Where ),(),( jiji xxKyyjiH = , K is the kernel function. 
 
The gene-ranking function of RFE can be defined as the change in the objective 
function J upon removing a certain gene. When a given feature is removed or its 
weight wk is reduced to zero, the change in the cost function J(k) is 
2
2
2
)(
2
1)( k
k
Dw
w
JkDJ ∂
∂=
         (28) 
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where the change in weight Dwk=wk - 0 corresponds to the removal of feature k.  
 
Under the assumption that the removal of one feature will not significantly 
influence the values of αs, the change of cost function can be estimated as  
αααα )(
2
1
2
1)( kHHkDJ TT −−=
       (29) 
Where H is the matrix with elements ),( jiji xxKyy , and H (-k) is the matrix 
computed by using the same method as that of matrix H but with its kth 
component removed.  
 
The change in the cost function indicates the contribution of the feature to the 
decision function, and serves as an indicator of gene ranking position (259).  
 
2.2.2.3 Sampling, feature elimination and consistency evaluation 
In order to present statistical meaning, gene selection is conducted based on 
multiple random sampling. Each random sampling divide all microarray samples 
into a training set which contains half number of samples and an associates test set 
which contains another half number of samples. This sampling method can be 
treated as a special case of the bootstrap technique. Many researchers showed that 
bootstrap-related techniques present more accurate estimation than 
cross-validation on small sample sets (260, 261). By using this random sampling, 
thousands of training-test sets, each containing a unique combination of samples, 
are generated. These thousands of randomly generated training-test sets are 
randomly divided into several sampling groups, with equal number of training-test 
sets (such as 500 traing-test sets) in each group. Every sampling group is then 
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used to derive a signature by RFE-SVM. 
 
In every training-test sampling group generated by multiple random sampling, 
each training-set (totally 500 training-test sets) is used to train a SVM 
class-differentiation system and the genes are ranked by using Recursive feature 
elimination (RFE), according to the contribution of genes to the SVM classifier. In 
order to derive a gene-ranking criterion consistent for all iterations and all the 500 
training-test sets in this group, a SVM class-differentiation system with a 
universal set of globally optimized parameters, which give the best average 
class-differentiation accuracy over all of the 500 test sets in this group, is applied 
by RFE gene-ranking function at every iteration step and for every training-test 
set. 
 
To further reduce the chance of erroneous elimination of predictor-genes, 
additional gene-ranking consistency evaluation steps are implemented on top of 
the normal RFE procedures in each group: 
(1) For every training-set, subsets of genes ranked in the bottom (which give least 
contribution to the SVM classification procedure) with combined score lower than 
the first few top-ranked genes (which give highest contribution to the SVM 
classification procedure) are selected such that collective contribution of these 
genes less likely outweigh top-ranked ones.  
(2) For every training-set, the step (1) selected genes are further evaluated to 
choose those not ranked in the upper 50% in previous iteration so as to ensure that 
these genes are consistently ranked lower.  
(3) A consensus scoring scheme is applied to step (2) selected genes such that only 
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those appearing in most of the 500 testing-sets were eliminated.  
 
For each sampling group, different SVM parameters are scanned, various RFE 
iteration steps are evaluated to identify the globally optimal SVM parameters and 
RFE iteration steps that give the highest average class-differentiation accuracy for 
the 500 testing-sets.  
 
The several signatures derived from these sampling-groups are then applied to 
evaluate the stability and performance. 
 
2.2.3 The development of therapeutic target prediction system  
To evaluate the possibility of the identified markers as therapeutic targets, a 
therapeutic target prediction system is applied. Target identification is an 
important first step in target-based drug discovery processes (262, 263). 
Computational methods have been used for facilitating target identification by 
predicting therapeutic targets, whose activity can be regulated by drug-like 
molecules (264) and play key roles in a disease, from genomic, structural and 
functional information (264-267). Proteins can be divided into therapeutic target 
and non-therapeutic target classes. Thus machine learning methods (SVM, PNN, 
kNN, decision tree) can be used for predicting therapeutic target (268, 269). 
Among these methods, SVM showed the best performance (268). Therefore, this 
thesis uses SVM classifier to predict the possible therapeutic targets from 
identified disease markers. 
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2.2.3.1 Outline of prediction strategy 
One strategy for predicting therapeutic targets from their sequences without 
sequence similarity is to use a sequence-independent classifier generated from the 
analysis of known druggable targets that share some characteristics but may be 
significantly different in sequence, structure and function (264, 270). Each 
therapeutic target or non- therapeutic target is represented by a feature vector, 
which is composed of sequence-derived descriptors representing its structural and 
physicochemical properties. SVM classifies these proteins by projecting their 
feature vectors into a multi-dimensional space in which therapeutic targets and 
non-therapeutic targets are separated by a hyperplane. A protein can be predicted 
as therapeutic target or non-therapeutic target depending on whether its feature 
vector is projected onto the therapeutic target or non- therapeutic target projected 
at the side of the hyper-plane (Figure 2-4).  
 
Figure 2-4 Architecture of therapeutic target prediction system 
 
Positive data 
(Therapeutic targets) 
Negative data 
(Non-therapeutic targets) 
Transform protein sequence into numerical vector (molecular description) 
Train a SVM model 
Prediction of new incoming protein based on the model developed 
Feature mapping 
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2.2.3.2 The selection of therapeutic target and non- therapeutic target 
Sufficiently diverse sets of therapeutic targets and non-therapeutic targets are 
needed for training a SVM model for predicting possible therapeutic targets. 1,484 
therapeutic targets in the TTD database (271) with available sequence information 
forms the therapeutic target class. There are 6,637 protein families in the protein 
domain family Pfam database (272) found to contain unknown target at present. 
Therefore, without substantially reducing SVM prediction performance, putative 
non-therapeutic targets can be tentatively derived from these non-target 
representing families (270). Their representative proteins form a non-therapeutic 
target class.  
 
2.2.3.3  Molecular descriptors  
In using SVM for predicting therapeutic targets, each protein is represented 
by a multi-dimensional feature vector whose components are protein descriptors 
encoding various constitutional and physicochemical properties of that protein 
(273). Web servers such as PROFEAT (274) and ProtParam (275) have been 
developed for facilitating the computation of these descriptors from amino acid 
sequence of proteins. The descriptors used for predicting therapeutic targets (270) 
include a constitutional descriptor, amino acid composition, and several 
physicochemical descriptors that describe the composition, transition and 
distribution of hydrophibicity ( h ), polarity ( p ), polarizibility ( z ), charge ( c ), 
secondary structures ( s ), solvent accessibility ( a ), surface tension ( t ), and 
normalized Van der Waals volumes ( v ) (236).  
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Amino acid composition is the fraction of each kind of amino acid in a 
sequence /k kf N N= , where k =1, 2, 3, …, 20 is the index of amino acids, kN  
is the number of a particular kind of amino acid and N  is sequence length. For 
computing the descriptors of each of the physicochemical properties, amino acids 
are divided into three types. For instance, for hydrophobicity descriptors, amino 
acids can be divided into hydrophobic (CVLIMFW), neutral (GASTPHY), and 
polar (RKEDQN) types. Three descriptors, composition ( qC ), transition ( qT ), and 
distribution ( qD ), are introduced to describe global composition of each of the 
physicochemical properties, where , , , , , ,q h p z c s a t= and v . 
31 2( , , )qq qq
NN N
C
N N N
=
 represent the percentage of each type of residues in a 
sequence, where Nqi is the number of type i residue. 
13 2312( , , )
1 1 1
q qq
q
T TT
T
N N N
= − − −  
characterizes the percent frequency of transition between different types of 
residues, where Tqij is the number of type i to j transitions and N-1 is the total 
number of transitions. These transitions are considered to be undirected such 
that ij jiq q
T T=
. 1 2 3( , , )q q q qD D D D= with 
0 25 50 75 100( , , , , )i i i i i
i
q q q q q
q
P P P P P
D
N N N N N
=
measures the chain length within which the first, 
25%, 50%, 75% and 100% of the amino acids of a particular group is located 
respectively, where ikqP  is the length within which k% of type i residues are 
located. Overall, each physicochemical property is represented by 21 elements: 3 
for qC , 3 for qT  and 15 for qD . The complete feature vector is composed of 
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188 elements that include 20 elements for amino acid composition and 8×21 
elements of the physicochemical properties. All generated vectors have equal 
length. 
  
2.3 Methodology for therapeutic molecule prediction 
2.3.1 Database development 
In order to develop bioinformatics tools for therapeutic molecule design, a 
bioinformatics database is developed. Database is an organized collection of data 
and relationships among the data items. Generally database development is a 
complicated and time-consuming process, including determination of database 
objective, collection of related information, design of database scheme, 
development of database, design of database interface (Figure 2-5). A 
stage-by-stage discussion of general database development is discussed below. 
 
Figure 2-5 Flowchart of database design 
 
 
Objective determination 
Information collection 
Database construction 
Database interface development 
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2.3.1.1 The objective of database development 
Clear objective of the database will help us focus on the relevant information 
and discard the unnecessary parts. Generally, a successful database should meet 
the expectations of their corresponding researchers, afford them what they want, 
and help them further information they want to know more about. 
 
As described in Chapter one, the antibody-antigen interaction plays a very 
important role in disease treatment, vaccine design and therapeutic antibody 
design. It is essential for biomedical researcher to know more about the disease- 
related antibody, and their counterpart – antigen, especially their interaction in 
molecular level.  
 
2.3.1.2 The collection of related information 
Normally, a knowledge-based database is supposed to provide enough domain 
knowledge around a specific subject. For instance, therapeutic antibody database 
will let users know about some biological information such as antibody 
information, the corresponding antigen target information, targeted disease and 
potential diagnosis, and therapeutic indications of the antibody. Thus, for every 
database entry, there are several different knowledge domains. Some of them 
provide basic introduction to entries themselves, and some others give information 
derived from entries or relevant to entries.  
 
The information mentioned above can be selected from a comprehensive search of 
available literatures including journal articles and a large number of other 
publications. With respect to different type of information, we use different 
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collecting methods. The subject of databases, such as disease target antibody is the 
primary focus. Thus, in the first step, we collect reliable subject information. At 
present, no single index or library is available and almost all the relevant 
information is scattered in various biological and medical literatures. Therefore, 
literature information extraction is the only feasible way to collect the essential 
biological and medical information. It is generally agreed that literatures are 
typically unstructured data source. In addition, the names of the subject, which 
may be in some synonymous terms, various abbreviations, or totally different 
expression, are difficult to be recognized by automatic language processing. A 
fully automated literature information extraction system, thus, cannot be invented 
to gather useful information from literature efficiently.  
 
In this study, automatic text mining methods with manual reading process was 
combined. Simple automated text retrieval programs developed in PERL were 
used to screen the literature that contained the key word related to searching the 
subject via Medline (276). Since the purpose of the therapeutic antibody database 
is to provide sequence-specific recognition of antibodies and their recognitions, at 
the first step, only those literatures that contain both the antibody sequence and the 
corresponding antigen or antigens were selected and constructed as the basis of 
the database. The sequence of the corresponding antigen or antigens were 
obtained either from the respective literature (if it is described in that literature) or 
retrieved from the protein sequence database Swiss-Prot based on the name and 
host species of the antigen or antigens. Other useful information was picked up 
manually from Medline by using keyword searching. If necessary, the full 
literature was referred to facilitate information searching.  
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After information collection, a consideration how to store, organize and manage 
the data by using database techniques should be considered. In the next section, 
the database construction is described. 
 
2.3.1.3 The construction of database  
There are a number of different ways to construct database to store and 
present data and data relationships. Some of the more common database types 
include hierarchical database, object database and relational database. 
 
The hierarchical database arranges data in a tree format. This database organizes 
data into different groups, which in turn may be divided into different subgroups. 
These subgroups also can have sub-subgroups. This forms a hierarchy of parent 
and child data segments. This strategy may make it difficult to identify complex 
multiple relationships between individual data items because there is no obvious 
link between two data if they are not in the same parent data segment.  
 
Object database stores data in discreet, self-contained units – objects, which have 
specific data, attributes and behaviors. Object-oriented programming languages 
are normally used to access the data. This tightly entwined property of database 
and its application increases the complexity of accessing the data outside of the 
application, and limited the application of object database. 
 
While hierarchical database arranges data in a tree format, relational database 
arranges them in a tabular format. A relational database creates formal definitions 
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of all the included items in a database, setting them out in tables, and defines the 
relationship among them. Using IDs or keys, the tables can be related between 
each other. Such database is called 'relational' because they explicitly define these 
connections. Currently relational database is the most common form of database.  
 
The relational model has been used in our therapeutic antibody databases. It 
represents relevant data in the form of two-dimension tables. Each table represents 
relevant information collected. The two-dimensional tables for the relational 
database include entry ID list table (Table 2-3), main information table (Table 2-4), 
which contains a record for the basic information of each entry, data type table 
(Table 2-5), which demonstrates the meaning represented by different number, and 
reference information table (Table 2-6), which gives the general reference 
information following by different PubMed ID in Medline (277).  
 
Table 2-3 Entry ID list table 
Entry ID Entry Name 
... … 
 
Table 2-4 Main information table 
Entry ID  Data type ID Data content Reference ID 
…  …  …  …  
 
Table 2-5 Data type table 
Data type ID Data type 
... … 
 
Table 2-6 Reference information table 
Reference ID Reference 
... … 
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Table 2-7 Logical view of the database 
Entry ID  Data type ID Data content Reference ID 
…  …  …  …  
 
 
 
 
 
Figure 2-7 is the general logical view of database we developed. It shows the 
organization of relevant data into relational tables. In these tables, certain fields 
may be designated as keys, by which the separated tables can be linked together 
for facilitating to search specific values of that field. Commonly, in relational table, 
the key can be divided into two types. One is primary key, which uniquely 
identifies each record in the table. Here it is a normal attribute that is guaranteed 
to be unique, such as entry ID in Table 2-3 with no more than one record per entry. 
The other is foreign key, which is a field in a relational table that matches the 
primary key column of another table. The foreign key can be used to 
cross-reference tables. For example, in tables of our databases, there are two 
foreign keys: Data type ID and Reference ID. According to Figure 2-7, a 
connection between a pair of tables is established by using a foreign key. The two 
foreign keys make three tables relevant. Generally, there are three basic types of 
relationships of related table: one-to-one, one-to-many, and many-to-many. In our 
case, these databases belong to one-to-many case.  
 
Most relational databases now make use of Structured Query Language (SQL) to 
handle queries. SQL is widely used by relational databases to define queries and 
help to generate reports. SQL has become a dominant standard in the world of 
Data type ID Data type 
... … 
Reference ID Reference
... … 
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database development, since it allows developers to use the same basic 
constructions to query data from a wide variety of systems.  
 
By using relational database software (e.g. Oracle, Microsoft SQL Server) or even 
personal database systems (e.g. Access), the relational database can be organized 
and managed effectively. This kind of data storage and retrieval system is called 
Database Management System (DBMS). An Oracle 9i DBMS is used to define, 
create, maintain and provide controlled access to the antibody-antigen interaction 
databases and the repository. All entry data from the related tables described in 
previous section are brought together for user display and output using SQL 
queries. 
 
2.3.1.4 The design of the database interface 
The database provides information for users to access. So it is very important 
to design a friendly interface which mediates the interaction between the database 
and its users. 
 
Normally two or three layers are used in most bioinformatics database. The main 
user interface provides querying tools to find specific entries. The entry layer 
provides detail information of the entries. An optional searching lists the searching 
results with some specific matching rules.  
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2.3.2 Predictive system development 
2.3.2.1 Outline of prediction strategy  
Knowledge of sequence-level Ab-Ag recognitions can be used to develop 
machine learning (ML) models for predicting the sequence of an antigen-targeting 
antibody based on the sequence of a specific antigen in a manner similar to the 
prediction of protein-protein interactions (224-226, 278, 279). In this study, each 
protein-pair is represented by a feature vector composed of sequence-derived 
descriptors which indicate the structural and physicochemical properties. Popular 
ML models, such as SVM which was introduced in Section 2.1 in this chapter, are 
used to predict interacting protein-pairs by projecting their feature vectors on a 
multi-dimensional space of protein features in which interacting and 
non-interacting protein-pairs are separated by a hyperplane (280). Known 
interacting protein-pairs and non-interacting ones are applied to train a SVM 
model in order to determine the hyper-plane. A protein-pair is predicted to be 
interacting or non-interacting depending on whether its feature vector is projected 
on the interacting side of or on the non-interacting side of the hyper-plane. For 
instance, given the sequence of a protein A, the sequence of its interacting protein 
B can be determined by searching protein databases or generated sequences in 
such a way that the pair of protein A and the target sequence (protein B, in this 
occasion) can be classified into the interacting class. 
 
This approach can be potentially extended to the prediction of antibody sequence 
from antigen sequence or vice versa. The architecture of antibody prediction 
system was shown in Figure 2-8.  
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Figure 2-8 Architecture of disease targeting antibody prediction system 
 
 
 
2.3.2.2 Selection of antibody-antigen pairs and non-antibody-antigen pairs 
The sequences for both antibody-antigen pairs (positive data) and 
non-antibody-antigen pairs (negative data) are required for building such model. 
The diversity of such data is very important for an unbiased model development. 
Known Ab-Ag pairs in the antibody-antigen information resources can be 
employed as the training sets to develop machine learning prediction models. The 
putative non-Ab-Ag pairs can be tentatively generated from random combination 
of antibodies with antigens of other antibody. Most of these putative non-Ab-Ag 
pairs are expected to be valid because multi-antigen antibodies or multi-antibody 
Positive data 
(Ab-Ag pairs) 
Negative data 
(Non-Ab-Ag pairs) 
Transform antibody VH and VL region sequence and 
antigen sequence into numerical vector 
Train a SVM model 
Prediction of new incoming Ab-protein based on the model developed 
Feature mapping 
Molecular description generation  
(Ab VH vector – Ab VL vector – Ag vector) 
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antigens constitute a small percentage of Ab-Ag pairs. Therefore, the prediction 
error due to the potential inclusion of “wrong” non-Ab-Ag pairs in SVM training 
process is expected to be relatively low. 
 
2.3.2.3 Feature vector construction 
In using SVM for predicting Ab-Ag pairs, each Ab-Ag or non-Ab-Ag pair is 
represented by a multi-dimensional feature vector composed of sequence-derived 
descriptors that encode constitutional and physicochemical properties of antibody 
and antigen (273). An antibody consists of two chains: heavy chain and light chain, 
and each chain has variable region and constant region. Consequently, the 
descriptors of each antibody are derived from the combination of the variable 
region of the heavy chain sequence and the variable region of the light chain 
(VH-VL). The descriptors of each Ab-Ag pair are generated by the descriptors of 
the antibody followed by those of the corresponding antigen. The descriptors of 
antibody VH and VL region and antigen sequence are generated as the similar 
manner as the molecular descriptors generated for therapeutic target prediction 
(Section 2.2.3.3 in this chapter). These descriptors include a constitutional 
descriptor, amino acid composition, physicochemical descriptors, transition and 
distribution of hydrophobicity, polarity, polarizability, charge, secondary 
structures, solvent accessibility, surface tension, and normalized Van der Waals 
volumes (236). 
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3 Colon cancer marker selection from microarray data 
This chapter describes a disease–related gene selection method from 
microarray data. Colon cancer-related gene selection are used here as a case 
study. By using randomly sampling method, we generate 20 sets of colon cancer 
gene signatures. The predictive ability of the cancer genes shared by all of the 20 
sets is evaluated by SVM models on an independent dataset collected from 
Stanford Microarray Database. Unsupervised hierarchical clustering analysis 
provides additional indication of the predictive ability of selected signatures. A 
therapeutic target prediction system is further applied to identify the possible 
cancer genes and possible therapeutic targets from the selected markers.  
 
3.1 Introduction 
Knowing what causes a disease is the first step in understanding the abnormal 
course of disease and helps the treatment of the disease. It has been found that 
some diseases such as cancer (2-4) and diabetes (7) are caused by some specific 
gene defects or mutations. Therefore, disease gene discovery is very important for 
disease diagnosis and treatment.  
 
The simple and direct way to identify disease genes is through analyzing the 
change of expression level across a series of samples. There are around 25,000 
genes in human genome (1). Therefore, Microarray becomes a very important tool 
for disease gene discovery because microarray can measure the gene expression 
profiles of tens of thousands of genes at one time. By discovering the differences 
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in gene expression between normal and disease tissues, we can focus on the genes 
with different expressions and those genes that might be activated or inactivated in 
association with a particular disease.  
 
Since disease is a kind of broad class, to be specific, colon cancer was chosen in 
this study. Our rational is that the study on colon cancer gene discovery will 
provide a platform to study other diseases in similar way. 
 
Cancer is the leading cause of death around the world. In United States, each year 
more than 1 million individuals were diagnosed as some kind of tumor (281, 282). 
Around 38% of cancers become metastasis and cause the death of the individuals 
(282). Colon cancer is the third leading cause of death from cancer in the US. It is 
estimated that colon cancer affects or will affect more than 145,000 individuals in 
2007 (282). Up to 30% of these cases exhibit familial clustering, which means that 
tens of thousands of individuals have a disease with a potentially definable genetic 
component (283). Identification of the genes that cause the colon cancer is thus 
very important for colon cancer diagnosis and colon cancer treatment. Currently 
microarray technique has becoming a powerful tool for colon cancer diagnosis 
and colon cancer genes identification (76, 108, 124, 127, 137, 138, 147-150, 259). 
However, comparing colon cancer gene signatures from these groups (119, 124, 
127, 147-150), there are little overlap between one and another. From the same 
62-sample dataset (108), 10 different colon cancer gene signatures were derived 
by using different sampling methods (Table 3-1) (119, 124, 127, 147-150). Only 
1~5 of the 4~60 selected colon cancer genes in each signatures were present in 
more than half of the other 9 signatures (Table 3-1), and 2~20 of the colon cancer 
genes in each signatures were cancer-related (Table 3-2) (119, 124, 127, 147-150).  
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Table 3-1 Statistics of the colon cancer gene signatures for differentiating colon cancer patients from normal people by 10 different studies that 
used the same microarray dataset. The dataset is from (108). 
No. of genes selected by other N studies 
Study (Reference) 
No. of selected 
genes in 
signature 
Class differentiation 
method Signature selection method 
Validation 
method 
Prediction 
accuracy 9 8 7 6 5 4 3 2 1 0 
Zhou and Mao 2005 (147) 15 LS-SVM LS Bound measure bootstrap <85% 0 0 0 1 0 1  1 1 11 
Ding and Peng 2005 (127) 60 NB, SVM, LDA, LR Filter method (MRMR) LOOCV 93.55% 0 0 0 3 2 1 1 4 4 45 
Isabelle Guyon 2002 (119) 7 SVM (linear kernel) Wrapper method (RFE) LOOCV 98% 0 0 0 0 0 1 1 2 0 3 
Inza, Larranaga et al. 2004 (124) 5 decision tree1 wrapper method LOOCV 87.1% 0 0 0 3 2 0 0 0 0 0 
Inza, Larranaga et al. 2004 (124) 4 decision tree2 wrapper method LOOCV 88.81% 0 0 0 0 0 1 1 2 0 0 
Bo and Jonassen 2002 (148)  50 linear discriminant gene pair ranking LOOCV L-31-OCV
87.8% 
85.9% 0 0 0 3 2 1 2 7 8 27 
Huang and Kecman 2005 (149) 10 SVM1 Wrapper method (RFE) LOOCV Not indicated 0 0 0 3 2 0 0 5 0 0 
Huang and Kecman 2005 (149) 10 SVM2 Wrapper method (RFE) LOOCV 88.84% 0 0 0 3 0 0 0 2 2 3 
Huang and Kecman 2005 (149) 10 SVM3 Wrapper method (RFE) LOOCV 88.1% 0 0 0 3 2 0 0 4 0 1 
Liu, Krishnan et al. 2005 (150) 6 clustering method Filter method (mutual information) LOOCV 91.9% 0 0 0 2 2 0 0 0 2 0 
Total Number of uniquely selected genes = 107 Number of unique genes selected by only one study =83 
1. LS Bound measure: a hybrid of filter and wrapper methods  
2. SVM: Support Vector Machines 
3. LS-SVM: Least Square SVM 
4. MRMR: Minimum Redundancy-Maximum Relevance feature selection framework 
5. NB: Naïve Bayes classifier 
6. LDA: Linear Discriminant analysis  
7. LR: logistic Regression 
8. LOOCV: Leave-One-Out Cross Validation 
9. RFE: recursive feature selection 
10. SVM1, SVM2, and SVM3: Support Vector machines classifiers with 
different parameters 
11. Decision tree 1, decision tree 2: decision tree classifiers with different 
parameters 
12. NB, SVM, LDA, LR: the authors tried these four methods, and choose 
those one which showed the highest accuracy 
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Table 3-2 Distribution of the selected colon cancer genes of the 10 studies in Table 3-1 with respect to different cancer-related classes 
Cancer genes 
 
Study (Reference) Anticancer 
target Oncogene 
Tumor-suppressor 
genes 
Angiogenesis 
genes 
other 
types
Tumor 
marker 
Interacting 
partner of 
cancer gene 
Cancer 
pathway 
affiliated 
gene 
Gene having 
possible 
implication in 
any cancer 
Zhou and Mao 2005 (LS-SVM) (147) 2 0 0 0 5 0 0 0 0 
Ding and Peng 2005 (NB, SVM, 
LDA, LR) (127)  1 0 1 0 5 1 4 2 1 
Isabelle Guyon 2002 (SVM) (259) 1 0 0 0 0 0 0 1 0 
Inza, Larranaga et al. 2004(decision 
tree1) (124) 0 0 0 0 1 0 0 1 0 
Inza, Larranaga et al. 2004 (decision 
tree2) (124) 0 0 0 0 0 0 0 0 0 
Bo and Jonassen 2002 (linear 
discriminant) (148) 2 2 2 0 4 0 7 3 0 
Huang and Kecman 2005 (SVM1) 
(149) 0 0 0 0 2 0 2 1 0 
Huang and Kecman 2005 (SVM2) 
(149) 0 0 2 0 1 0 1 2 0 
Huang and Kecman 2005 (SVM3) 
(149) 0 0 0 0 1 0 2 1 0 
Liu, Krishnan et al. 2005 (clustering 
method) (150) 1 0 0 0 0 0 1 1 0 
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This discrepancy increases the difficulty of applying those cancer genes in clinics.  
 
In this chapter, we explored a new gene selection method aiming at reducing the 
chances of erroneous elimination of predictor-genes. We employed the recursive 
feature selection method based on a model built from support vector machines to 
identify novel molecular signatures with respect to the interactions among genes. 
Derived from the consensus scoring of multiple random sampling and the 
evaluation of gene-ranking consistency embedded in the recursive feature 
selection system, totally 104 genes were selected after 20 times of experiments. 
The gene signatures are fairly stable with 80% of top-50 and 69%~93% of all 
predictor-genes shared by all 20 signatures. These shared predictor-genes include 
48 cancer-related and 16 cancer-implicated genes, as well as 50% of the 
previously-derived predictor-genes. The derived signatures outperform all 
previously-derived signatures in predicting colon cancer outcomes from an 
independent dataset collected from the Stanford Microarray Database. The 
differential expression and function analysis of the identified marker genes 
implies that the selected genes should play important roles in colon cancer 
initiation and progress. 
 
3.2 Materials and methods  
3.2.1 Colon cancer microarray datasets  
Two independent data sets of colon cancer were used for colon cancer gene 
discovery and for validating the effect of our selected genes. The first dataset was 
reported in previous publication (108). Another dataset was collected from 
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Stanford Microarray Database (SMD) (284).  
 
The dataset for colon cancer gene discovery was Alon’s dataset (108, 285), which 
contained the expression levels of 40 colon cancer patients and 22 normal patients. 
This dataset was obtained by using the Affymetrix Hum6000 array (Affymetrix 
Inc) (84). This array contained about 65,000 features, each containing around 107 
strands of a DNA 25-mer oligonucleotide, and these features represented the 
sequences from about 3,200 full-length human cDNAs and 3,400 ESTs that have 
some similarity to other eukaryotic genes (therefore some genes are non-human). 
2000 genes with the highest minimal intensity across the samples were 
pre-selected from the 6500 genes by Alon et al (108, 285).This colon microarray 
data have been analyzed in several previous studies using a number of statistical 
approaches (124, 127, 147-150, 259).  
 
In order to evaluate the performance of selected genes, the expression profiles of 
34 colon cancer cell lines and 8 normal colon tissues were collected from Stanford 
Microarray Database (SMD) (284). Appendix S1 shows the detailed information 
of collected samples.  
 
3.2.2 Colon cancer gene selection procedure 
By using repeated random sampling (70), 10,000 training-testing sets were 
generated, each constituted a training set which contains 31 samples and an 
associates test set which contains the other 31 samples from Alon’s colon cancer 
dataset (108). These 10,000 randomly generated training-testing sets were 
randomly placed into 20 sampling groups, and each group contains 500 
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training-testing sets. 
 
Each of the 20 sampling groups was used to derive a signature. In the 500 
training-testing sets in every sampling group, each training-set was used to select 
genes by RFE based on SVM system. For all iterations and testing-sets, SVM 
system employed a set of globally modified parameters which gave the best 
average class-differentiation accuracy over the 500 testing-sets. 
 
On every sampling group, three gene-ranking consistency evaluation steps were 
implemented on top of the normal RFE procedures in all sampling groups: 
(1) For every training-set, subsets of genes ranked in the bottom 10% (if no gene 
was selected in current iteration, this percentage was gradually increased to the 
bottom 40%) with combined score lower than the first top-ranked gene were 
selected such that collective contribution of these genes less likely outweighed 
higher-ranked ones.  
(2) For every training-set, the step (1) selected genes was further evaluated to 
choose those not ranked in the upper 50% in previous iteration so as to ensure 
that these genes were consistently ranked lower.  
(3) A consensus scoring scheme was applied to step (2) selected genes such that 
only those appearing in >90% (if no gene was selected in current iteration, this 
percentage was gradually reduced to 60%) of the 500 training-sets were 
eliminated.  
 
3.2.3 Performance evaluation of signatures 
The predictive capability and robustness of gene signatures was evaluated by 
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using several microarray data analysis methods on independent SMD microarray 
datasets (Appendices S1) (284) and the Alon’s microarray dataset (108). The 
microarray data analysis methods included hierarchical clustering and SVM.  
 
By using hierarchical clustering analysis, the performance of gene signatures was 
analyzed. As a popular unsupervised method, hierarchical clustering analysis 
groups genes and samples which have similar expression in the microarray data. 
Typically, the analysis begins with each gene/sample considered as a separate 
cluster. They are successively merged until one large cluster comprising the whole 
dataset is achieved. Later, these clusters are displayed in the form of a branching 
tree diagram, which can be broken into distinct clusters by cutting across the tree 
at a particular height. Hierarchical cluster analysis was carried out using the 
selected signatures by the software from Eisen et al (109, 286). The results from 
hierarchical clustering were displayed by TreeView, which was also provided by 
Eisen et al (109, 286).  
 
In SVM evaluation system, 500 random-generated training-test set were generated. 
The performance of the gene signatures was evaluated by overall accuracies Q 
(Equation 2-22 ) from the associated 500 test sets of the 500 SVM classification 
systems.  
 
3.3 Results and discussion 
3.3.1 System of the disease marker selection 
The aim of this study was to identify the important gene signatures with 
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regard to the intrinsic complex interactions of genes in disease initiation. 
Moreover, considering the noise in the microarray data arising from measurement 
variability and biological differences, the selected important gene signatures 
should be stable with regarding to such kind of variations. Based on the above 
concerns, recursive feature elimination method based on SVM was used to 
identify the different signatures from the multiple random combinations of 
samples. 20 sets of survival marker signatures were obtained by using RFE-SVM 
from 500 training-testing datasets with random sampling methods. SVM 
classifiers and hierarchical cluster analysis were used to evaluate the prediction 
system constructed from selected signatures (Figure 3-1).  
 
Figure 3-1 The system of colon cancer genes derivation and colon cancer 
differentiation 
 
3.3.2 Consistency analysis of the identified disease markers 
The consistency level of the 20 derived signatures was estimated from the 
percentage of predictor-genes shared by them. 104 genes were shared by all of 20 
Microarray data (2000 genes, 62 samples)
Disease gene 
signature 1  
Disease gene 
signature 2 
… Disease gene 
signature 20 
Genes shared by all of the twenty signatures 
SVM prediction system 
Hierarchical cluster analysis 
Evaluation on the independent dataset 
collected from Stanford Microarray database 
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signatures (Table 3-3) in which the number of disease genes ranged from 112 to 
157 (Table 3-4, Appendices Table S2), indicating that 69%~93% of all genes in 
each signature were shared by 20 signatures. Moreover 80% of the top-50 ranked 
genes in each signature were shared by 20 signatures. Comparing to 10 sets of 
signatures derived from the same dataset of 62 samples (108) by other groups, our 
selected signatures are stabler. Whereas, the results from other groups showed that 
only 1~5 of the 4~60 selected predictor-genes in each of these sets are present in 
more than half of the other 9 sets (Table 3-1) (119, 124, 127, 147-150).  
 
There are two aspects explaining why our selected gene signatures possess better 
stability. First, a SVM class-differentiation system with a universal set of globally 
optimized parameters, which gave the best average class-differentiation accuracy 
over the 500 testing-sets, was used to derive RFE gene-ranking function at every 
iteration step and for every testing-set. As such, the effect from the 
parameter-dependence of conventional gene selection can be reduced dramatically. 
In earlier studies using RFE or other wrapper methods for selecting signatures, 
non-predictor-genes have been eliminated in multiple iterations, and at every 
iteration step a different class-differentiation system, characterized by a different 
set of optimized parameters, has been constructed (117, 259). As gene-elimination 
is parameter-dependent, these selected predictor-genes are likely path-dependent 
and heavily influenced by sampling method, composition, order of gene 
evaluation, computational algorithm and parameters. These characteristics partly 
explain the highly unstable and patient-dependent characteristics of the 
previously-derived signatures (108). Second, an additional gene-ranking 
consistency evaluation was performed on top of the normal RFE procedure to 
reduce the variations of erroneous eliminations of predictor-genes. 
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The optimal SVM parameters for the 20 sample-sets were in a narrow range of 
17~18 and the highest average accuracies were 92.2%~92.8% for colon cancer 
patients and 90.4%~91.1% for normal people respectively (Table 3-5). At these 
parameters, the accuracies for the individual testing-sets ranged from 82.4~100% 
for colon cancer patients and 77.0%~100% for normal people. Further deviation 
from these optimal parameters had relatively small effect on prediction accuracy 
and composition of predictor-genes. The relatively small variations of optimal 
SVM parameters and prediction accuracies across the 20 sampling-sets suggests 
that the performance of the SVM class-differentiation systems constructed by 
using globally optimized parameters and RFE iteration steps are fairly stable 
across different sampling combinations. 
 
Our signatures include 52 of the 104 previously-derived predictor-genes, and 
those selected by a higher number of other studies tend to be ranked higher by our 
gene-ranking function (Table 3-3, Appendix Table S2). Regardless of their 
possible roles in cancer, these genes have shown proven capability for colon 
cancer outcome prediction. It is not surprising that they are included in our 
signatures. 
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Table 3-3 Gene information for colon cancer genes shared by all of the 20 signatures  
EST accession 
number 
(Included in this 
number of 
previously 
derived 
signatures by 
other groups)1 
gene Name Gene description Gene aliases relationship with cancer2 
Interacting partner (bold: partner related to 
cancer) 3 Other Information
4 
U14631 (1) HSD11B2 
Hydroxysteroid 
(11-beta) 
dehydrogenase 2 
AME, AME1, 
HSD11K, HSD2 
successful tumor 
target   
Decrease of HSD11B2 mRNA abundance and enzyme 
activity is associated with colorectal cancer (287) 
R46753 (2) CDKN1A Cyclin-dependent kinase inhibitor 1A 
CAP20, CDKN1, 
CIP1, MDA-6, 
P21, SDI1, WAF1, 
p21CIP1 
research tumor target, 
Cancer pathway 
affiliated gene (p53 
signaling, PI3k 
signaling, G1-S 
phase transition (Rb), 
Cyclins and Cell 
Cycle Regulation) 
TP53,SMAD4, CDKN1B, CDK4, STAT3, 
CDK2, CCNB1, CCND1, MYC, CCNE1, 
CCNA2, CCNA1,CREBBP, HIF1A, 
HDAC1, RB1, TP73, SET, PCNA, 
CSNK2A1, CSNK2B, PSMA3, POLD2, 
SMARCA4, MUC1, HIST4H4, 
GADD45A, MITF, CDC2, APEX1, SP1, 
FOXO1A, IBRDC2, PIAS2, PIM1, 
PPARBP 
This protein is a regulator of the cell division cycle (288, 
289). Its expression of level is tightly controlled by the 
tumor suppressor protein p53 and can mediate the 
p53-dependent cell cycle G1 phase arrest in response to a 
variety of stress stimuli (290). 
T41204 (0) MMP9 Matrix metallopeptidase 9 CLG4B, GELB research tumor target
LCN2, COL4A6, CD44, PZP, COL1A2, 
BTC, TIMP3, COL4A1, COL4A2, 
COL1A1, COL4A3, MMP7, COL4A5, 
COL4A4, AREG, RECK, FN1, THBS1, 
CXCL5, THBS2 
The balance between MMPs/TIMPs regulates the 
extracellular matrix (ECM) turnover and remodeling during 
normal development and pathogenesis (291) 
J03040 (0) SPARC 
Secreted protein, 
acidic, cysteine-rich 
(osteonectin) 
ON research tumor target
VEGF, TGFB1, Collagen, COL13A1, 
Fibrinogen, HSPG2, TGM2, PLG, 
Procollagen type I, PLAT, Laminin, PDGF 
alpha, THBS1, SDC2,  
This protein inhibits cell-cycle progression, and influences 
the synthesis of extracellular matrix (ECM). It was suggested 
that this protein plays a dual role in the VEGF functions, 
tumor angiogenesis, and extravasation of tumors mediated 
by the increased permeability of endothelial barrier function 
(292) 
X14958 (1) HMGA1 High mobility group AT-hook 1 
HMG-R, HMGIY, 
MGC12816, 
MGC4242, 
MGC4854 
Oncogene 
JUN, HIPK2, POU3F1, SUFU, INSR 
locus, ATF2, INSR, Casein kinase 2, NFYA, 
CEBPB, SP1, IRF1,RNF4 
HMGA1 is a novel MYCN (myc myelocytomatosis viral 
related oncogene) target gene relevant for neuroblastoma 
tumorigenesis (293) 
J04102 (1) ETS2 V-ets erythroblastosis virus E26 oncogene  
oncogene, Cancer 
pathway affiliated 
gene(PI3k signaling) 
BRCA1, ETS1, SMARCA4, ERG, JUN, 
SRC, EP300, NCOA3, TTRAP, EAPII, 
ZMYND11, CDK10, GATA3, NCOR1, 
SMARCA4, NR3C1 
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X77548 (0) NCOA4 Nuclear receptor coactivator 4 
ARA70, 
DKFZp762E1112, 
ELE1, PTC3, RFG
oncogene, research 
tumor target RXRA, PPARG, TFIIB, RNF14, PCAF, AR
This protein induces the secretion of myeloid growth and 
chemotactic factors and potent mitogenicity of this protein 
correlates with its prevalence in tall-cell variant of papillary 
thyroid carcinoma (294) 
R67343 (0) CNNM4 Cyclin M4 CNNM4, ACDP4, KIAA1592 
tumor-suppressor 
gene   
Cyclins activate crucial protein kinases and thereby help 
control progression from one stage of the cell cycle to 
another (295) 
X12369 (2) 
Z24727 (0) TPM1 Tropomyosin1 
HTM-alpha, 
TMSA, 
TPM1-alpha 
tumor-suppressor 
genes EPB41, TPM2 
Silencing of the TPM1 gene by DNA methylation alters 
tumor suppressor function of TGF-beta (296). Loss of 
expression of TPM1, a novel class II tumor suppressor that 
induces anoikis, was observed in primary breast tumors 
(297). 
U15212 (0) CDX1 
Caudal type 
homeobox 
transcription factor 1 
MGC116915 tumor-suppressor gene   
DNA methylation down-regulates CDX1 gene expression in 
colorectal cancer cell lines. CDX1 inhibits proliferation of 
intestinal epithelial cells and regulates intestine-specific 
genes involved in differentiation. The expression of CDX1 is 
aberrantly down-regulated in colorectal cancers and colon 
cancer-derived cell lines (298) 
X63629 (2) CDH3 Cadherin 3, type 1, P-cadherin 
CDHP, HJMD, 
PCAD 
tumor-suppressor 
gene, Cancer 
pathway affiliated 
gene (WNT 
signaling, Cell 
adhesion molecules 
(CAMs)) 
Caspase, CTNNB1,CTNND1, Alpha 
catenin 
Cadherin cell–cell adhesion proteins play an important role 
in modulating the behavior of tumor cells. Smad4 induces 
the tumor suppressor E-cadherin and P-cadherin in colon 
carcinoma cells (299). It was reported that CDH3 may 
present at an increased level in colon cancer cells (300, 301). 
R33481 (0) CREB5 
CAMP responsive 
element binding 
protein 5 
CRE-BPA tumor-suppressor gene JUN, CREB5, ATF2 
This protein contributes to ovarian tumorigenesis in humans 
(302) 
H49870 (1) 
L07648 (1) MXI1 MAX interactor 1 
MAD2, 
MGC43220, 
MXD2, MXI 
tumor-suppressor 
gene (transcriptional 
repressor) 
Mmip1, MAX 
Expression of the gene, which produces an oncogenic 
transcription factor, is tightly regulated in normal cells but is 
frequently deregulated in human cancers. Defects in this 
gene are frequently found in patients with prostate tumors 
T51493 (0) PPP2R5C 
Protein phosphatase 
2, regulatory subunit 
B (B56), gamma 
isoform 
B56G, MGC23064
tumor-suppressor 
gene, Cancer 
pathway affiliated 
gene(MAPK 
PPP2CA, PPP2R1B 
This protein is an important regulator of Wnt/beta-catenin 
pathway activity in colorectal cancer cell (Oncogene. 2006 
Jul 31) and is functionally inactivated in blast crisis CML 
through the inhibitory activity of the BCR/ABL-regulated 
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signaling; Cyclins 
and Cell Cycle 
Regulation, Wnt / 
beta-catenin 
pathway) 
SET protein (303) 
X07767 (0) PRKACA 
Protein kinase, 
cAMP-dependent, 
catalytic, alpha 
MGC102831, 
MGC48865, 
PKACA 
tumor-suppressor 
gene, Cancer 
pathway affiliated 
gene (MAPK 
signaling pathway, 
Apoptosis, Wnt 
signaling pathway, 
Hedgehog signaling 
pathway ) 
EGFR, MGMT, PKIA, PKA, AKAP8L, 
AKIP1a, NMT1, NPR1, IFNAR1, 
cPKA-RI, SLC9A3R2, C11orf17, AKAP14, 
NIN 
This protein is a signaling molecule important for a variety 
of cellular functions 
Z49269 (0) CCL14 chemokine (C-C motif) ligand 14 
CC-1, CC-3, 
CKb1, HCC-1, 
HCC-3, MCIF, 
NCC-2, NCC2, 
SCYA14, SCYL2, 
SY14 
angiogenesis gene, 
Cancer pathway 
affiliated gene (PI3k 
signaling, JAK/STAT 
Pathway, 
Cytokine-cytokine 
receptor interaction) 
CCBP2, CCR5, CCR3, DDX39, CCR1 
Chemokines play an important role in leukocyte 
mobilization, hematopoiesis, and angiogenesis. 
Tissue-specific expression of particular chemokines also 
influences tumor growth and metastasis (304) 
L34657 (0) PECAM1 
platelet/endothelial 
cell adhesion 
molecule 
CD31, PECAM-1 
angiogenesis gene, , 
Cancer pathway 
affiliated gene(Cell 
adhesion molecules 
(CAMs)) 
LYN, YES1, HCK, ITGA5, CSK, LCK, 
PLCG1, PTPN6, CTNNB1, SRC, CD38, 
FYN, DSP 
This protein participates in adhesive and/or signaling 
phenomena required for the motility and organization of 
endothelial cells (305) 
T54303 (0) KRT8 
Keratin 8, cytokeratin 
8; keratin, type II 
cytoskeletal 8 
CARD2, CK8, 
CYK8, K2C8, K8, 
KO 
tumor marker, Cancer 
pathway affiliated 
gene(Cell 
Communication) 
EGFR, HSPA5, BYSL, KRT18, ANXA1, 
PLAT, PKP1, PNN 
This protein alters the epidermal cell differentiation, favors 
the neoplastic transformation of cells, and is ultimately 
responsible of the invasive behavior of transformed 
epidermal cells leading of conversion of benign to malignant 
tumors (306) 
T51571 (0) S100A11 
S100 calcium 
binding protein A11 
(calgizzarin) 
MLN70, S100C Tumor marker NCL, ANXA1, Actin, S100B   
M94132 (1) MUC2 Mucin 2 MLP Tumor marker (colon) GALNT14, PLEKHM1, GALNT12 
MUC2 expression was regulated in human colon cancer cells 
at the level of transcription via AP-1 activation (307). 
Reduction of MUC2 expression may be associated with the 
occurrence and progression of colorectal carcinomas (308) 
H78386 (0) IL1R2 Interleukin 1 receptor, type II 
CD121b, IL1RB, 
MGC47725 
immune tolerance, 
research therapeutic 
target, Cancer 
pathway affiliated 
IL1RAP, IL1A, IL1RN . 
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gene (MAPK 
signaling pathway, 
Cytokine-cytokine 
receptor interaction) 
M23115 (0) ATP2A2 
ATPase, Ca++ 
transporting, cardiac 
muscle, slow twitch 2
ATP2B, DAR, 
DD, MGC45367, 
SERCA2 
Interacting partner of 
cancer gene 
BCL2, TNFRSF1A, GSH, PLN, TRADD, 
S100A1, TRAF6, TNFRSF1B 
This enzyme is involved in regulation of the 
contraction/relaxation cycle 
T62947 (3) C15orf15 
Chromosome 15 
open reading frame 
15 
HRP-L30-iso, 
L30, RLP24, 
RPL24, RPL24L 
Cancer pathway 
affiliated gene 
(Ribosome) 
   
D45887 (0) CALM2 
Calmodulin 2 
(phosphorylase 
kinase, delta) 
CALM2, CAMII, 
PHKD, PHKD2 
Interacting partner of 
cancer gene, Cancer 
pathway affiliated 
gene (Calcium 
signaling pathway) 
MYOD1, NEUROD1, ESR2, ASCL2, 
IQCB1, PPEF1, GRM7, KCNQ2, KCNQ3, 
KCNQ5, GRM5, TCF4, MYF6, MYF5, 
PCNT, MARCKS, INVS, CALD1, RAB3B, 
PPEF2, EDF1, ESR1, MYOG 
Upregulated of CALM2 might be associated with the 
oncogenesis of ALCL (309) 
U26312 (0) CBX3 Chromobox homolog 3 
HECH, 
HP1-GAMMA, 
HP1Hs-gamma 
Interacting partner of 
cancer gene 
PIM1, CBX5, SP100, MKI67, CBX3, 
CBX1, DNMT3B, C20orf172, 
TRIM24,MIS12, LBR 
  
R33367 (0) CD46 
CD46 molecule, 
complement 
regulatory protein 
MCP, MGC26544, 
MIC10, TLX, 
TRA2.10 
Interacting partner of 
cancer gene 
SRC, YES1, TSPAN4, C4B, U48, DLG4, 
ITGB1, MSN, LLGL1, C3 
The level of CD46 protein expression is associated with 
tumor epithelial cell population, suggesting that CD46 
should be evaluated as a novel prognostic indicator (310) 
X54942 (2) CKS2 
CDC28 protein 
kinase regulatory 
subunit 2 
CKSHS2 Interacting partner of cancer gene CCNB1, ESPL1, CCNB1, CDC2 
CKS2 protein binds to the catalytic subunit of the cyclin 
dependent kinases and is essential for their biological 
function.  
T64885 (0) CNOT1 
CCR4-NOT 
transcription 
complex, subunit 1 
AD-005, CDC39, 
DKFZp686E0722, 
FLJ90644, 
KIAA1007, 
NOT1, NOT1H 
implication in cancer CNOT8 
The Ccr4-Not complex is a global regulator of gene 
expression that is conserved from yeast to human, as a 
regulatory platform that senses nutrient levels and stress 
(311) 
U37012 (0) CPSF1 
Cleavage and 
polyadenylation 
specific factor 1 
CPSF160, 
HSU37012 
Interacting partner of 
cancer gene 
RNA polymerase II, TAFII100, TAFII28, 
TAFII18, MCM2, hCIP1, Poly A 
polymerase, HEAB, BAT2, TAFII20, TAF7
  
M76378 (5) CSRP1 cysteine and glycine-rich protein 1
CRP, CRP1, 
CSRP, CYRP, 
D1S181E, 
DKFZp686M148 
implication in cancer Alpha-actinin 
This protein may be involved in regulatory processes 
important for development and cellular differentiation with 
critical functions in gene regulation, cell growth, and 
somatic differentiation 
M63391 (7) DES desmin 
CMD1I, CSM1, 
CSM2, FLJ12025, 
FLJ39719, 
FLJ41013, 
FLJ41793 
Cancer pathway 
affiliated gene (Cell 
Communication) 
S100A1, DMN, S100B, CAPN1, DSP, 
SPTAN1, SYNC1, Syncoilin   
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X60489 (0) EEF1B2 
Eukaryotic 
translation elongation 
factor 1 beta 2 
EEF1B, EEF1B1, 
EF1B implication in cancer VARS, AARS, EF-1-beta, HARS 
This protein is involved in regulation of the cell cycle, 
normal and pathological (312) 
R54097 (2) EIF2S2 
Eukaryotic 
translation initiation 
factor 2 
DKFZp686L1819
8, EIF2, EIF2B, 
EIF2beta, 
MGC8508 
Interacting partner of 
cancer gene 
NCK1, EIF2B5, CSNK2A1, CK2beta, 
CSNK2B, EIF5, EIF2B4,PRKDC, 
CK2alpha 
This protein functions in the early steps of protein synthesis 
H06524 (1) GSN 
Gelsolin 
(amyloidosis, Finnish 
type) 
GSN, 
DKFZp313L0718 
Interacting partner of 
cancer gene, Cancer 
pathway affiliated 
gene (Regulation of 
actin cytoskeleton) 
BCAR1,LIMK2, PIK3, ACTN4, ACTB, 
Tropomyosin, VCL, TNIK, CLIC5, 
VDAC1,PXN, VASP, APP, ACTA1, 
PTK2B, FN1, G-actin, tax, AR 
GSN functions as a switch that controls E- and N-cadherin 
conversion via Snail. Knockdown of GSN leads to EMT in 
human mammary epithelial cells and possibly to the 
development of human mammary tumors (313) 
M96233 (0) GSTM4 glutathione S-transferase M4 
GSTM4-4, GTM4, 
MGC131945, 
MGC9247 
implication in cancer GSTM4 A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer (314) 
Z50753 (6) GUCA2B 
Guanylate cyclase 
activator 2B 
(uroguanylin) 
GCAP-II, UGN implication in cancer GUCY2D 
This protein synthesizes cGMP, which concentration of 
human colon tumors was higher than that of the surrounding 
mucosa (315) 
X12671 (1) HNRPA1 
heterogeneous 
nuclear 
ribonucleoprotein A1
HNRNPA1, 
MGC102835 implication in cancer
TTF2, ELAVL1, PTMA, MAP3K14, 
RIPK3, FEN1, PTMA, BAT5, PRKCZ, 
TNPO1, SFRS12, SAFB, UPF3A, BAT2 
This protein may contribute to maintenance of telomere 
repeats in cancer cells with enhanced cell proliferation and 
the quantitative alteration of this protein could facilitate 
colon epithelial cell transformation through transcriptional 
and translational perturbation (316) 
T51023 (1) HSP90AB1
Heat shock protein 
90kDa alpha 
(cytosolic), class B 
member 1 
D6S182, 
FLJ26984, 
HSP90-BETA, 
HSP90B, HSPC2, 
HSPCB 
Cancer related gene WASL, STARD13, PPID, TRADD, MAP3K7 
This protein is important for signaling by types I and II 
interferons (317) 
M22382 (2) HSPD1 
Heat shock 60kDa 
protein 1  
(chaperonin) 
CPN60, GROEL, 
HSP60, HSP65, 
HuCHA60, 
SPG13 
Interacting partner of 
cancer gene 
BAK1, CA2, HSPE1, p21ras, PRNP, 
HIST2H2BE, CASP9, integrin, DHFR, 
CASP6, CASP3, PKA C, RASA1, ALDH2 
This protein may function as a signaling molecule in the 
innate immune system  
X02492 (0) IFI6 
Interferon, 
alpha-inducible 
protein 6 
FAM14C, G1P3, 
IFI-6-16, IFI616 Cancer related gene p-G1P3, ACTB, HIST4H4, POLR2A 
This protein may have function as a cell survival protein by 
inhibiting mitochondrial-mediated apoptosis (318) 
D14812 (1) MORF4L2 Mortality factor 4 like 2 
KIAA0026, 
MORFL2, MRGX
Interacting partner of 
cancer gene 
HDAC1, RB1, Sin3A, TLE, C20orf20, 
PAM14, MRFAP1   
T71025 (2) MT1G Metallothionein 1G MGC12386, MT1, MT1K 
Interacting partner of 
cancer gene 
HDAC1, RB1, RBL1; RBL2(P107), 
RBL(P130), E2F1, E2F2, E2F3, E2F4, 
E2F5, ECRG2, SPINK7, MTF1 
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R87126 (7) MYH9 
Myosin, heavy 
polypeptide 9, 
non-muscle 
DFNA17, EPSTS, 
FTNS, 
MGC104539, 
MHA, 
NMHC-II-A, 
NMMHCA 
Cancer related gene, 
Cancer pathway 
affiliated gene (Tight 
junction, Regulation 
of actin cytoskeleton)
S100A4, CD163, GRIN1   
H20709 (2) MYL6 
Myosin, light 
polypeptide 6, alkali, 
smooth muscle and 
non-muscle 
MYL6, ESMLC, 
LC17-GI, 
LC17-NM, 
LC17A, LC17B, 
MLC1SM, 
MLC3NM, 
MLC3SM 
Cancer pathway 
affiliated gene(Focal 
adhesion, Tight 
junction) 
CHUK, TNFRSF1A, IKBKE, RIPK3, 
IKBKG, NFKB1, MAP3K3   
X73424 (0) PCCB 
Propionyl Coenzyme 
A carboxylase, beta 
polypeptide 
PCCB, 
DKFZp451E113 implication in cancer   
This protein is an important source of energy for colonocytes 
(319) 
T94350 (0) PMP22 Peripheral myelin protein 22 
CMT1A, CMT1E, 
DSS, GAS-3, 
HMSNIA, HNPP, 
MGC20769, 
Sp110 
implication in colon 
cancer PEX19, CNX, MPZ 
The level of this protein was significantly decreased in 
various types of tumors including the colon carcinoma (320) 
U21090 (0) POLD2 Polymerase (DNA directed), delta 2  
Cancer pathway 
affiliated gene(DNA 
repair mechanism) 
PCNA, POLDIP2, POLDIP3, POLD3, 
DNA polymerase delta CDKN1A, POLD1, 
KCTD13 
  
D13665 (0) POSTN Periostin, osteoblast specific factor 
MGC119510, 
MGC119511, 
OSF-2, 
PDLPOSTN, PN, 
RP11-412K4.1 
implication in colon 
cancer   
This protein potently promotes metastatic growth of colon 
cancer by augmenting cell survival via the Akt/PKB pathway 
(321) 
T86444 (0) PPP1R9B 
Protein phosphatase 
1, regulatory subunit 
9B, spinophilin 
FLJ30345, 
PPP1R6, PPP1R9, 
SPINO 
Interacting partner of 
cancer gene, Cancer 
pathway affiliated 
gene 
CDKN2A, ACTC, ADRA1A, DRD2, 
PPP1R2, PPYR1, TGOLN2, TIAM1, DCX, 
PPP1R9A 
This protein is involved in the regulation of a variety of 
cellular processes, such as cell division, glycogen 
metabolism, muscle contractility and protein synthesis 
D15049 (0) PTPRH 
Protein tyrosine 
phosphatase, receptor 
type, H 
FLJ39938, 
MGC133058, 
MGC133059, 
SAP-1 
Interacting partner of 
cancer gene BCAR1, PTK2, MAPK1, PXN, DOK1 
This protein was found to be expressed in several cancer cell 
lines, but not in the corresponding normal tissues. This 
protein induce apoptosis by stomach cancer-associated 
protein-tyrosine phosphatase-1 (322). Overexpression of this 
protein can be found in human colorectal cancers (323) 
T47377 (3) S100P S100 calcium binding protein P MIG9 Cancer related gene 
VIL2, CACYBP, ECD, AGER, S100Z, 
Melittin 
This protein involved in the regulation of a number of 
cellular processes such as cell cycle progression and 
differentiation. 
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T51261 (1) SERPINE2 
Serpin peptidase 
inhibitor, clade E 
(nexin, plasminogen 
activator inhibitor 
type 1), member 2 
GDN, PI7, PN1, 
PNI implication in cancer
COL4A6, COL4A1, COL4A2, COL4A3, 
COL4A5, COL4A4 
This protein promotes extracellular matrix production and 
local invasion of pancreatic tumors in vivo (324) 
U22055 (1) SND1 
Staphylococcal 
nuclease domain 
containing 1 
p100 Interacting partner of cancer gene 
RNA pol II, PIM1,STAT6, MYB, 
MYBL2, TFIIE, GTF2E2,RBPSUH, 
POLR2A, GTF2E1 
This protein recruits histone acetyltransferase activity to 
STAT6 and mediates interaction between the CREB-binding 
protein and STAT6 (325) 
U19969 (1) TCF8 
Transcription factor 8 
(represses interleukin 
2 expression) 
AREB6, BZP, 
MGC133261, 
NIL-2-A, NIL-2A, 
ZEB, ZEB1, 
ZFHEP, ZFHX1A 
Interacting partner of 
cancer gene, Cancer 
pathway affiliated 
gene (WNT 
signaling) 
CDH1, SMAD2, SMAD3, HTATIP, 
CTBP2, DRAP1 
In colon cancer patients, the correlation between the 
expression of SNAIL and the downregulation of E-cadherin 
(CDH1) is lost when ZEB1 is overexpressed (326). This 
protein plays a role in repressing E-cadherin and MUC1 in 
epithelial cells (327) 
H81068 (0) WASF2 
WAS protein family, 
member 2, 
suppressor of 
cyclic-AMP receptor 
(WASP-family) 
SCAR2, WAVE2, 
dJ393P12.2 
Interacting partner of 
cancer gene, Cancer 
pathway affiliated 
gene (Adherens 
junction, Regulation 
of actin cytoskeleton)
CDC42, GRB2, Syndapin I, ACTR3, 
PSTPIP1, DOCK1, BAIAP2, FYN, Actin, 
ACTR2, BTK 
This protein involved in transducing signals that involve 
changes in cell shape, motility or function 
T92451 (3) TPM2 Tropomyosin 2 (beta) AMCD1, DA1, TMSB 
Interacting partner of 
cancer gene 
JUN, TPM1, ACTB, PDLIM7, S100A4, 
RRAD, S100A2  
X86693 (3) SPARCL1 SPARC-like 1 (mast9, hevin) PIG33, SC1 implication in cancer     
R62549 (0) 
U09564 (0) SRPK1 
SFRS protein kinase 
1 SFRSK1 implication in cancer
MBP, SFRS6, B1C8, SFRS1, U2AF1, 
SFRS3, C20orf42, U2AF2, SFRS4, 
YWHAG, SFRS12, SAFB, SFRS5, PRM1, 
SFRS2IP, LBR 
SRPK1 gene expression was increased in 
oxaliplatin-resistant HT29 colon cancer cells. 
H64489 (1) TSPAN1 Tetraspanin 1 NET-1, RP11-322N21 implication in cancer   
This proteins mediate signal transduction events that play a 
role in the regulation of cell development, activation, growth 
and motility 
R55310 (0) UQCRC1 
Ubiquinol-cytochrom
E C reductase core 
protein I 
D3S3191 implication in cancer RTN4, CYCS, UQCRH This protein was highly expressed in breast (74%) and ovarian tumors (34%) (328) 
L32977 (0) UQCRFS1 
ubiquinol-cytochrom
E C reductase, Rieske 
iron-sulfur 
polypeptide 1 
RIS1 implication in cancer   This protein is related to breast cancer 
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T64012 (0) WDR7 
WD repeat domain 7, 
TGF-beta resistance 
associated gene; 
rabconnectin-3 beta 
KIAA0541, 
TRAG implication in cancer RAB3GAP1 
This protein involved in a variety of cellular processes, 
including cell cycle progression, signal transduction, 
apoptosis, and gene regulation.  
T58861 (0) RPL30 Ribosomal protein L30  
Cancer pathway 
affiliated gene 
(Ribosome) 
    
T57619 (0) RPS6 Ribosomal protein S6  
Cancer pathway 
affiliated gene 
(Ribosome, mTOR 
signaling pathway, 
Insulin signaling 
pathway) 
RPS6KB1 
BMK1 pathway is crucial for tumor-associated angiogenesis 
through its role in the regulation of the RSK-RPS6 signaling 
module (329) 
D31885 (0) ARL6IP 
ADP-ribosylation 
factor-like 6 
interacting protein 
AIP1, ARL6IP1, 
ARMER, 
KIAA0069 
  ARL4D, ARL6 This protein may involve in cell survival (330) 
R36977 (1) GTF3A General transcription factor IIIA AP2, TFIIIA   OPTN, GTF3C2   
U31525 (0) GYG1 Glycogenin 1 GYG   GYG2, TRIM7   
X57351 (0) IFITM2 
Interferon induced 
transmembrane 
protein 2 (1-8D) 
1-8D   UPF3A   
R98842 (1) DTWD2 DTW domain containing 2 
FLJ33977, 
MGC138579, 
MGC138580 
    
R06601 (0) MT1M Metallothionein 1M 
MGC118949, 
MGC40498, MT1, 
MT1K 
      
J02854 (7) MYL9 
Myosin, light 
polypeptide 9, 
regulatory 
LC20, MYRL2, 
MRLC1, MLC2, 
MGC3505 
      
T65380 (0) PRPSAP1 
Phosphoribosyl 
pyrophosphate 
synthetase-associated 
protein 1 
PAP39   PRPS2, PRPS1   
R44301 (1) NR3C2 
Nuclear receptor 
subfamily 3, group C, 
member 2 
MCR, MR, MLR, 
MGC133092   
FKBP52, G actin, HSPA4, PIAS1, F actin, 
FKBP4, HSP90AA1, TRIM24, PTGES3, 
NR3C1 
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T95018 (0) PCNP 
PEST proteolytic 
signal containing 
nuclear protein 
PCNP, 
DKFZp781I24156   UHRF2   
T51534 (1) CST3 Cystatin C  MGC117328   C4A, Actinidin, PDZD2, CTSS, CTSB, Papain   
J05032 (3) DARS Aspartyl-tRNA synthetase 
DKFZp781B1120
2, MGC111579   EEF1A1, MAP3K7, MARS, EEF1D   
X56597 (1) FBL Fibrillarin FIB, FLRN, RNU3IP1   
PRMT1, U3 snoRNA, U3 snoRNP, 
PSMB6, PIN4, DDX5, RNU3, SNRPN 
NOP5/NOP58 
 
M80815 (1) FUCA1 fucosidase FUCA1       
T67077 (0) FXYD1 
FXYD domain 
containing ion 
transport regulator 
1(phospholemman) 
MGC44983, PLM   PKA, PPAP2A, Type 1phosphatase, ATP1A1, PPP1CA, ATP1B1   
M82919 (1) GABRB3 
Gamma-aminobutyri
c acid (GABA) A 
receptor 
MGC9051       
D42047 (1) GPD1L Glycerol-3-phosphate dehydrogenase 1-like
GPD1L, 
KIAA0089       
H25136 (0) ITPR3 
Inositol 
1,4,5-triphosphate 
receptor, type 3 
FLJ36205, IP3R3   TRPC5, TRPC6, TRPC4, TRPC3, TRPC2, OPRS1, TRPM2, CABP1, TRPC1   
U06698 (0) KIF5A Kinesin family member 5A 
D12S1889, 
MY050, NKHC, 
SPG10 
  KLC3, DTNB, KNS2  
X70326 (1) MARCKSL1 MARCKS-like 1 
F52, 
MACMARCKS, 
MLP, MLP1, MRP
  DCTN2   
H87135 (0) MGC22793 Hypothetical protein MGC22793        
D25217 (1) MLC1 
Megalencephalic 
leukoencephalopathy 
with subcortical cysts 
1 
KIAA0027, LVM, 
MLC, VL       
U17899 (0) CLNS1A 
Chloride channel, 
nucleotide-sensitive, 
1A 
CLCI, CLNS1B, 
ICln   PRMT5, Actin   
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D16294 (0) ACAA2 Acetyl-Coenzyme A acyltransferase 2  DSAEC   SCP2 
This protein catalyzes the last step of the mitochondrial fatty 
acid beta-oxidation spiral 
R88740 (3) ATP5J 
ATP synthase, H+ 
transporting, 
mitochondrial F0 
complex 
ATP5, ATP5A, 
ATPM, CF6, F6     This synthase involved in oxidative phosphorylation 
H43887 (1) CFD Complement factor D (adipsin) ADN, DF, PFD   SERPINF2   
H48072 (0) COX6A1 
Cytochrome c 
oxidase subunit VIa 
polypeptide 1 
COX6A, 
COX6AL, 
MGC104500 
      
T51250 (0) COX8A 
Cytochrome c 
oxidase subunit 8A 
(ubiquitous) 
COX VIII, COX 
VIII-L, COX8, 
COX8-2, COX8L 
      
X87159 (1) SCNN1B 
Sodium channel, 
nonvoltage-gated 1, 
beta (Liddle 
syndrome) 
ENaCb, 
ENaCbeta, 
SCNEB 
  STX1A, SCNN1A, WWP2, CNTN1, SCNN1G, NEDD4, NEDD4L, SCNN1D   
R84411 (1) SNRPB 
Small nuclear 
ribonucleoprotein 
polypeptides B and 
B1 
COD, SNRPB1, 
SmB/SmB', 
snRNP-B 
  
TOP3B, WBP4, GEMIN5, GEMIN7, 
STXBP2, STXBP3, SMN1, SMN2, 
GEMIN4, DDX20, PACT, SNRPD3, 
GEMIN6, LSM11, WDR77, CTDP1, pICln, 
COIL, DHX9, RBBP6 
 
M36634 (3) VIP Vasoactive intestinal peptide 
MGC13587, 
PHM27   VIPR1   
H08393 (4) WDR77 WD repeat domain 77 
HKMT1069, 
MEP50, 
MGC2722, 
Nbla10071, 
RP11-552M11.3 
  SNRPE, SNRPD1, SNRPD3, YWHAQ, SNRPB, PRMT5, SNRPF, SNRPD2   
H81558 (1) ZNF358 Zinc finger protein 358 
FLJ10390, 
ZFEND       
H73908 (0)  
similar to contains 
Alu repetitive 
element; contains 
THR repetitive 
element 
        
H11084 (1)  
ym09g08.s1 Soares 
infant brain 1NIB 
Homo sapiens cDNA 
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clone 
H40095 (1)  
similar to 
gb:L19686_rna1 
macrophage 
migration inhibitory 
factor (human) 
        
H64807 (1)  
similar to contains 
Alu repetitive 
element 
        
1The signatures selected by other groups was obtained from (119, 124, 127, 147-150), which were used to differentiate colon cancer patients from 
normal people by using the same microarray dataset as our used dataset (108). 
 
2Tumor target information was obtained from therapeutic target database (http://bidd.nus.edu.sg/group/cjttd/ttd.asp ) (270, 271). Most of the 
pathway information was obtained from KEGG database (http://www.genome.jp/kegg/pathway.html) (331), Reactome (http://www.reactome.org/ ) 
(332), and review articles (333-338). The information of cancer genes was obtained from the review articles (333-338). 
 
3Interacting partner information was obtained from Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene ) (339). 
 
4If no reference was indicated, the information was extract from Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene ) (339).
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Table 3-4 Statistics of the selected colon cancer genes from a colon cancer microarray dataset by class-differentiation systems constructed from 
20 different sampling-sets each composed of 500 training-testing sets generated by random sampling. The dataset is from (108). 
 
No of predictor-genes also included in N other signatures derived by using different sampling-set Sampling 
Set 
No of selected 
predictor genes 
in signature 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0
1 155 104 3 2 5 3 4 3 4 3 3 1 4 2 1 4 2 3 3 1 0
2 135 104 3 2 4 3 4 2 4 2 1 0 1 2 1 0 1 1 0 0 0
3 156 104 3 2 5 3 4 3 3 3 3 1 3 3 0 4 4 4 0 1 3
4 146 104 3 2 5 3 4 3 3 3 2 1 2 2 1 2 2 1 2 0 1
5 116 104 3 1 4 1 0 0 1 0 0 0 1 0 0 1 0 0 0 0 0
6 112 104 2 0 2 0 1 1 0 0 0 1 0 0 0 0 0 1 0 0 0
7 119 104 2 2 3 1 3 0 3 0 0 1 0 0 0 0 0 0 0 0 0
8 127 104 3 2 5 3 2 1 2 1 1 1 1 0 0 1 0 0 0 0 0
9 133 104 3 2 5 2 2 2 2 2 2 0 2 1 2 1 0 0 0 0 1
10 156 104 3 2 4 3 4 3 4 3 3 0 3 2 1 2 3 5 3 2 2
11 139 104 3 2 5 3 3 3 3 3 2 1 2 1 1 3 0 0 0 0 0
12 115 104 2 2 3 1 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0
13 144 104 3 2 5 3 4 3 3 2 3 1 2 2 1 3 0 1 2 0 0
14 157 104 3 2 5 3 4 3 4 3 3 0 3 2 2 3 2 3 3 3 2
15 149 104 3 2 4 3 4 3 3 3 3 0 3 2 0 3 1 3 2 0 3
16 136 104 3 2 5 3 4 3 3 2 0 0 3 2 1 0 0 0 1 0 0
17 136 104 3 2 5 3 3 2 3 1 3 0 2 1 1 0 1 1 1 0 0
18 127 104 3 2 4 3 2 3 1 0 1 0 2 0 0 1 1 0 0 0 0
19 146 104 3 2 5 2 4 3 4 3 2 1 2 2 1 1 3 1 1 1 1
20 122 104 3 1 2 2 2 1 1 2 1 1 0 0 1 1 0 0 0 0 0
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Table 3-5 Overall accuracies of 500 training-test sets on the optimal SVM parameters 
 
Overall performance in 500 training dataset Overall performance in 500 corresponding test dataset 
Colon cancer patient Normal people  Colon cancer patient Normal people Sampling set 
Optimal 
SVM 
parameter TP FN SE TN FP SP 
Q 
TP FN SE TN FP SP 
Q 
1 18 9448 632 93.7% 5140 280 94.8% 94.1% 9171 749 92.4% 5055 525 90.6% 91.8%
2 17 9543 611 94.0% 4963 383 92.8% 93.6% 9107 739 92.5% 5128 526 90.7% 91.8%
3 18 9463 597 94.1% 5093 347 93.6% 93.9% 9191 749 92.5% 5031 529 90.5% 91.8%
4 18 9425 667 93.4% 5067 341 93.7% 93.5% 9135 773 92.2% 5084 508 90.9% 91.7%
5 17 9447 708 93.0% 4906 439 91.8% 92.6% 9140 705 92.8% 5146 509 91.0% 92.2%
6 17 9416 658 93.5% 4972 454 91.6% 92.8% 9174 752 92.4% 5079 495 91.1% 92.0%
7 17 9434 648 93.6% 5007 411 92.4% 93.2% 9145 773 92.2% 5048 534 90.4% 91.6%
8 17 9433 677 93.3% 5037 353 93.5% 93.4% 9154 736 92.6% 5110 500 91.1% 92.0%
9 17 9453 665 93.4% 4979 403 92.5% 93.1% 9150 732 92.6% 5109 509 90.9% 92.0%
10 17 9638 477 95.3% 5047 338 93.7% 94.7% 9157 728 92.6% 5105 510 90.9% 92.0%
11 17 9434 627 93.8% 5147 292 94.6% 94.1% 9194 745 92.5% 5063 498 91.0% 92.0%
12 17 9470 672 93.4% 4902 456 91.5% 92.7% 9148 710 92.8% 5097 545 90.3% 91.9%
13 18 9463 652 93.6% 5021 364 93.2% 93.4% 9140 745 92.5% 5119 496 91.2% 92.0%
14 17 9528 559 94.5% 5111 302 94.4% 94.4% 9176 737 92.6% 5062 525 90.6% 91.9%
15 17 9515 587 94.2% 5067 331 93.9% 94.1% 9148 750 92.4% 5091 511 90.9% 91.9%
16 17 9554 599 94.1% 5058 289 94.6% 94.3% 9106 741 92.5% 5127 526 90.7% 91.8%
17 17 9512 618 93.9% 5009 361 93.3% 93.7% 9145 725 92.7% 5090 540 90.4% 91.8%
18 17 9483 624 93.8% 5017 376 93.0% 93.5% 9154 739 92.5% 5108 499 91.1% 92.0%
19 18 9472 656 93.5% 5049 323 94.0% 93.7% 9131 741 92.5% 5079 549 90.2% 91.7%
20 18 9386 671 93.3% 4989 454 91.7% 92.7% 9173 770 92.3% 5035 522 90.6% 91.7%
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3.3.3 The predictive performance of identified markers in disease 
differentiation 
To further evaluate the predictive capability of our selected genes sets, we 
collected the gene expression profiles of 34 colon cancer cell line and 8 normal 
colon tissues from Stanford Microarray Database (SMD) (Appendices Table S1) 
(284). The predictive capability of our selected and the 10 other 
previously-derived signatures were evaluated by using the SVM classification 
system and 500 randomly-generated training-test sets generated from this dataset. 
The performance was evaluated using the associated test set and are shown in 
Table 3-6. The overall accuracy for the 104 predictor-genes was 96.8% with the 
standard deviation of 3.3%. The accuracies for all predictor-genes were in the 
range of 95.8~97.4% with the standard deviation of 4.7~5.0%. Using genes 
selected by other methods, the overall accuracies were in the range of 
80.5%~94.9%, with the standard deviation of 2.9%~6.6%. These results suggest 
that the selected signatures using our system can perform well when compared 
with those selected by other methods. 
 
Table 3-6 Average colon cancer prediction accuracy and standard deviation of 
500 SVM class-differentiation systems constructed by 42 samples 
collected from Stanford Microarray Database (284) and by using 
signatures derived from this work and 10 previous works. The results 
were obtained from the overall accuracies of 500 test sets. 
Colon cancer tissue Normal tissue Signature 
(method) 
No of selected 
predictor-genes 
in signature TP FN SE TN FP SP 
Q STDEV
1* 155 8235 265 96.9% 1869 131 93.5% 96.2% 4.8%
2* 135 8266 234 97.2% 1840 160 92.0% 96.2% 4.8%
3* 156 8228 272 96.8% 1861 139 93.1% 96.1% 4.8%
4* 146 8342 158 98.1% 1885 115 94.3% 97.4% 4.8%
5* 116 8274 226 97.3% 1931 69 96.6% 97.2% 5.0%
6* 112 8246 254 97.0% 1979 21 99.0% 97.4% 5.0%
7* 119 8268 232 97.3% 1868 132 93.4% 96.5% 4.9%
8* 127 8272 228 97.3% 1875 125 93.8% 96.6% 4.8%
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9* 133 8250 250 97.1% 1905 95 95.3% 96.7% 5.0%
10* 156 8206 294 96.5% 1928 72 96.4% 96.5% 5.0%
11* 139 8337 163 98.1% 1770 230 88.5% 96.3% 4.9%
12* 115 8266 234 97.2% 1793 207 89.7% 95.8% 4.6%
13* 144 8366 134 98.4% 1847 153 92.4% 97.3% 4.8%
14* 157 8345 155 98.2% 1839 161 92.0% 97.0% 4.7%
15* 149 8375 125 98.5% 1792 208 89.6% 96.8% 4.8%
16* 136 8401 99 98.8% 1722 278 86.1% 96.4% 4.8%
17* 136 8322 178 97.9% 1896 104 94.8% 97.3% 4.8%
18* 127 8331 169 98.0% 1814 186 90.7% 96.6% 4.9%
19* 146 8343 157 98.2% 1810 190 90.5% 96.7% 4.7%
20* 122 8244 256 97.0% 1855 145 92.8% 96.2% 4.8%
104 genes 
selected by all 
of the 20 
signatures* 
104 8328 172 98.0% 1839 161 92.0% 96.8% 3.3%
Ding and 
Peng 2005 
(NB, SVM, 
LDA, LR) 
(127) 
60 8193 307 96.4% 1771 229 88.6% 94.9% 5.9%
Huang and 
Kecman 2005 
(SVM3)(149) 
10 8194 306 96.4% 1760 240 88.0% 94.8% 6.5%
Bo and 
Jonassen 2002 
(linear 
discriminant) 
(148) 
50 8145 355 95.8% 1788 212 89.4% 94.6% 6.5%
Huang and 
Kecman 2005 
(SVM2) (149) 
10 8130 370 95.6% 1708 292 85.4% 93.7% 6.5%
Huang and 
Kecman 2005 
(SVM1) (149) 
10 8207 293 96.6% 1579 421 79.0% 93.2% 6.6%
Liu, Krishnan 
et al. 2005 
(clustering 
method) (150) 
6 7973 527 93.8% 1771 229 88.6% 92.8% 6.7%
Zhou and 
Mao 2005 
(LS-SVM) 
(147) 
15 8345 155 98.2% 989 1011 49.5% 88.9% 6.0%
Inza, 
Larranaga et 
al. 2004 
(decision 
tree2) (124) 
4 8056 444 94.8% 974 1026 48.7% 86.0% 5.4%
Inza, 
Larranaga et 
al. 2004 
(decision 
tree1) (124) 
5 7526 974 88.5% 1178 822 58.9% 82.9% 4.3%
Isabelle 
Guyon 2002 
(SVM) (259) 
7 7434 1066 87.5% 1019 981 51.0% 80.5% 2.9%
* Gene signatures were selected by using our system. 
 
The predictive capability of our selected and the 10 other previously-derived 
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signatures (which was generated from the same dataset as ours) were further 
evaluated by using additional 500 randomly-generated training-test sets generated 
from the original Alon’s colon cancer microarray dataset (108) and contained 
different combinations of samples from those 10,000 training-test datasets used 
for gene signatures selection. By using the 500 training sets, we constructed 500 
SVM class-differentiation systems, each of which was tested by using the 
associated test set, and the results are shown in Table 3-7. The average 
cancer-differentiating accuracies of our signatures over these 500 testing sets are, 
respectively, 92.0% to 92.3%, 91.3% to 91.7%, 88.5% to 91.2%, 83.8% to 86.9% 
and 79.2% to 82.8% when all, top-100, top-50, top-30 and top-10 predictor-genes 
are used. The standard deviations of the individual accuracies are in the range of 
3.3% to 3.4%, 3.3% to 3.4%, 3.8% to 4.0%, 4.6% to 5.5% and 5.6% to 6.2% 
respectively. In contrast, the average accuracies and standard deviations of the 10 
previously-derived signatures are in the range of 75.3% to 87.1% and 4.2% to 
14.9%. These results further illustrate that the performance of the signatures 
selected by our system is better and stabler than those of signatures selected by 
using other strategies. The performances of top-50, top-30 and top-10 
predictor-genes are substantially less stable than those of all and top-100 
predictor-genes. 
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Table 3-7 Average colon cancer prediction accuracy and standard deviation of 
500 SVM class-differentiation systems constructed by using Alon’s 
colon cancer microarray dataset (108) and by using each of the 
signatures derived from this work and 10 previous works. 
Colon cancer tissue Normal tissue 
Signature 
(method) 
Number of 
selected 
cancer 
genes in 
signature 
TP FN SE TN FP SP 
Q STDEV
1* 155 9491 683 93.3% 4809 517 90.3% 92.3% 3.3%
2* 135 9491 683 93.3% 4783 543 89.8% 92.1% 3.3%
3* 156 9490 684 93.3% 4798 528 90.1% 92.2% 3.4%
4* 146 9494 680 93.3% 4792 534 90.0% 92.2% 3.4%
5* 116 9492 682 93.3% 4796 530 90.0% 92.2% 3.3%
6* 112 9487 687 93.2% 4798 528 90.1% 92.2% 3.4%
7* 119 9495 679 93.3% 4800 526 90.1% 92.2% 3.4%
8* 127 9494 680 93.3% 4798 528 90.1% 92.2% 3.4%
9* 133 9492 682 93.3% 4787 539 89.9% 92.1% 3.4%
10* 156 9495 679 93.3% 4806 520 90.2% 92.3% 3.3%
11* 139 9486 688 93.2% 4797 529 90.1% 92.1% 3.3%
12* 115 9490 684 93.3% 4791 535 90.0% 92.1% 3.4%
13* 144 9486 688 93.2% 4787 539 89.9% 92.1% 3.4%
14* 157 9488 686 93.3% 4813 513 90.4% 92.3% 3.3%
15* 149 9494 680 93.3% 4800 526 90.1% 92.2% 3.4%
16* 136 9493 681 93.3% 4806 520 90.2% 92.3% 3.4%
17* 136 9482 692 93.2% 4798 528 90.1% 92.1% 3.4%
18* 127 9493 681 93.3% 4814 512 90.4% 92.3% 3.3%
19* 146 9485 689 93.2% 4774 552 89.6% 92.0% 3.3%
20* 122 9490 684 93.3% 4793 533 90.0% 92.1% 3.4%
104 genes 
selected by all of 
the 20 
signatures* 
104 9478 696 93.2% 4779 547 89.7% 92.0% 3.3%
top 100 genes in 
signature 1* 100 9432 742 92.7% 4751 575 89.2% 91.5% 3.4%
top 100 genes in 
signature 2* 100 9429 745 92.7% 4773 553 89.6% 91.6% 3.4%
top 100 genes in 
signature 3* 100 9432 742 92.7% 4765 561 89.5% 91.6% 3.4%
top 100 genes in 
signature 4* 100 9435 739 92.7% 4754 572 89.3% 91.5% 3.5%
top 100 genes in 
signature 5* 100 9442 732 92.8% 4755 571 89.3% 91.6% 3.3%
top 100 genes in 
signature 6* 100 9433 741 92.7% 4767 559 89.5% 91.6% 3.3%
top 100 genes in 
signature 7* 100 9445 729 92.8% 4768 558 89.5% 91.7% 3.4%
top 100 genes in 
signature 8* 100 9443 731 92.8% 4753 573 89.2% 91.6% 3.3%
top 100 genes in 
signature 9* 100 9432 742 92.7% 4749 577 89.2% 91.5% 3.3%
top 100 genes in 
signature 10* 100 9429 745 92.7% 4776 550 89.7% 91.6% 3.3%
top 100 genes in 
signature 11* 100 9444 730 92.8% 4766 560 89.5% 91.7% 3.4%
top 100 genes in 
signature 12* 100 9427 747 92.7% 4743 583 89.1% 91.4% 3.3%
top 100 genes in 
signature 13* 100 9428 746 92.7% 4760 566 89.4% 91.5% 3.4%
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top 100 genes in 
signature 14* 100 9432 742 92.7% 4779 547 89.7% 91.7% 3.3%
top 100 genes in 
signature 15* 100 9421 753 92.6% 4767 559 89.5% 91.5% 3.4%
top 100 genes in 
signature 16* 100 9436 738 92.7% 4753 573 89.2% 91.5% 3.3%
top 100 genes in 
signature 17* 100 9430 744 92.7% 4789 537 89.9% 91.7% 3.3%
top 100 genes in 
signature 18* 100 9446 728 92.8% 4771 555 89.6% 91.7% 3.3%
top 100 genes in 
signature 19* 100 9431 743 92.7% 4726 600 88.7% 91.3% 3.3%
top 100 genes in 
signature 20* 100 9439 735 92.8% 4747 579 89.1% 91.5% 3.4%
Top 50 genes in 
signature 1* 50 9308 866 91.5% 4408 918 82.8% 88.5% 4.0%
Top 50 genes in 
signature 2* 50 9320 854 91.6% 4725 601 88.7% 90.6% 3.8%
Top 50 genes in 
signature 3* 50 9308 866 91.5% 4592 734 86.2% 89.7% 4.0%
Top 50 genes in 
signature 4* 50 9300 874 91.4% 4582 744 86.0% 89.6% 4.0%
Top 50 genes in 
signature 5* 50 9315 859 91.6% 4734 592 88.9% 90.6% 3.8%
Top 50 genes in 
signature 6* 50 9364 810 92.0% 4655 671 87.4% 90.4% 4.0%
Top 50 genes in 
signature 7* 50 9275 899 91.2% 4635 691 87.0% 89.7% 4.1%
Top 50 genes in 
signature 8* 50 9306 868 91.5% 4714 612 88.5% 90.5% 3.8%
Top 50 genes in 
signature 9* 50 9412 762 92.5% 4726 600 88.7% 91.2% 3.9%
Top 50 genes in 
signature 10* 50 9412 762 92.5% 4726 600 88.7% 91.2% 3.9%
Top 50 genes in 
signature 11* 50 9298 876 91.4% 4698 628 88.2% 90.3% 3.8%
Top 50 genes in 
signature 12* 50 9324 850 91.6% 4719 607 88.6% 90.6% 3.9%
Top 50 genes in 
signature 13* 50 9300 874 91.4% 4582 744 86.0% 89.6% 4.0%
Top 50 genes in 
signature 14* 50 9328 846 91.7% 4728 598 88.8% 90.7% 3.9%
Top 50 genes in 
signature 15* 50 9363 811 92.0% 4635 691 87.0% 90.3% 3.9%
Top 50 genes in 
signature 16* 50 9391 783 92.3% 4678 648 87.8% 90.8% 3.8%
Top 50 genes in 
signature 17* 50 9402 772 92.4% 4698 628 88.2% 91.0% 3.8%
Top 50 genes in 
signature 18* 50 9365 809 92.0% 4641 685 87.1% 90.4% 3.8%
Top 50 genes in 
signature 19* 50 9304 870 91.4% 4597 729 86.3% 89.7% 3.8%
Top 50 genes in 
signature 20* 50 9285 889 91.3% 4616 710 86.7% 89.7% 4.0%
Top 30 genes in 
signature 1* 30 9155 1019 90.0% 4021 1305 75.5% 85.0% 5.2%
Top 30 genes in 
signature 2* 30 9202 972 90.4% 4080 1246 76.6% 85.7% 4.6%
Top 30 genes in 
signature 3* 30 9155 1019 90.0% 4021 1305 75.5% 85.0% 5.2%
Top 30 genes in 
signature 4* 30 9080 1094 89.2% 3909 1417 73.4% 83.8% 5.5%
Top 30 genes in 
signature 5* 30 9180 994 90.2% 4065 1261 76.3% 85.5% 4.7%
Top 30 genes in 30 9207 967 90.5% 4046 1280 76.0% 85.5% 4.9%
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signature 6* 
Top 30 genes in 
signature 7* 30 9047 1127 88.9% 3904 1422 73.3% 83.6% 5.4%
Top 30 genes in 
signature 8* 30 9155 1019 90.0% 4092 1234 76.8% 85.5% 4.7%
Top 30 genes in 
signature 9* 30 9155 1019 90.0% 4021 1305 75.5% 85.0% 5.2%
Top 30 genes in 
signature 10* 30 9227 947 90.7% 4166 1160 78.2% 86.4% 4.5%
Top 30 genes in 
signature 11* 30 9110 1064 89.5% 4352 974 81.7% 86.9% 4.4%
Top 30 genes in 
signature 12* 30 9202 972 90.4% 4080 1246 76.6% 85.7% 4.6%
Top 30 genes in 
signature 13* 30 9170 1004 90.1% 4051 1275 76.1% 85.3% 5.2%
Top 30 genes in 
signature 14* 30 9155 1019 90.0% 4021 1305 75.5% 85.0% 5.2%
Top 30 genes in 
signature 15* 30 9147 1027 89.9% 4052 1274 76.1% 85.2% 4.9%
Top 30 genes in 
signature 16* 30 9180 994 90.2% 4049 1277 76.0% 85.3% 5.0%
Top 30 genes in 
signature 17* 30 9162 1012 90.1% 4053 1273 76.1% 85.3% 5.0%
Top 30 genes in 
signature 18* 30 9180 994 90.2% 4065 1261 76.3% 85.5% 4.7%
Top 30 genes in 
signature 19* 30 9079 1095 89.2% 4010 1316 75.3% 84.4% 4.9%
Top 30 genes in 
signature 20* 30 9127 1047 89.7% 4014 1312 75.4% 84.8% 4.4%
Top 10 genes in 
signature 1* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 2* 10 8794 1380 86.4% 3739 1587 70.2% 80.9% 5.9%
Top 10 genes in 
signature 3* 10 8866 1308 87.1% 3681 1645 69.1% 80.9% 6.1%
Top 10 genes in 
signature 4* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 5* 10 8901 1273 87.5% 3712 1614 69.7% 81.4% 5.9%
Top 10 genes in 
signature 6* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 7* 10 8743 1431 85.9% 3565 1761 66.9% 79.4% 6.2%
Top 10 genes in 
signature 8* 10 8970 1204 88.2% 3869 1457 72.6% 82.8% 5.6%
Top 10 genes in 
signature 9* 10 8901 1273 87.5% 3712 1614 69.7% 81.4% 5.9%
Top 10 genes in 
signature 10* 10 8901 1273 87.5% 3712 1614 69.7% 81.4% 5.9%
Top 10 genes in 
signature 11* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 12* 10 8794 1380 86.4% 3739 1587 70.2% 80.9% 5.9%
Top 10 genes in 
signature 13* 10 8794 1380 86.4% 3739 1587 70.2% 80.9% 5.9%
Top 10 genes in 
signature 14* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 15* 10 8730 1444 85.8% 3552 1774 66.7% 79.2% 5.9%
Top 10 genes in 
signature 16* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 17* 10 8842 1332 86.9% 3769 1557 70.8% 81.4% 6.0%
Top 10 genes in 
signature 18* 10 8807 1367 86.6% 3518 1808 66.1% 79.5% 6.0%
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Top 10 genes in 
signature 19* 10 8901 1273 87.5% 3712 1614 69.7% 81.4% 5.9%
Top 10 genes in 
signature 20* 10 8845 1329 86.9% 3723 1603 69.9% 81.1% 6.2%
Inza, Larranaga 
et al. 2004 
(decision tree2) 
(124) 
4 8239 1935 81.0% 3436 1890 64.5% 75.3% 6.5%
Inza, Larranaga 
et al. 2004 
(decision tree1) 
(124) 
5 8493 1681 83.5% 3615 1711 67.9% 78.1% 7.0%
Liu, Krishnan et 
al. 2005 
(clustering 
method) (150) 
6 8439 1735 82.9% 3792 1534 71.2% 78.9% 6.9%
Huang and 
Kecman 2005 
(SVM1) (149) 
10 8736 1438 85.9% 3760 1566 70.6% 80.6% 6.5%
Huang and 
Kecman 2005 
(SVM2) (149) 
10 8647 1527 85.0% 3921 1405 73.6% 81.1% 7.3%
Isabelle Guyon 
2002 (SVM) 
(259) 
7 8333 1841 81.9% 4250 1076 79.8% 81.2% 13.2%
Huang and 
Kecman 2005 
(SVM3) (149) 
10 8818 1356 86.7% 3937 1389 73.9% 82.3% 5.5%
Zhou and Mao 
2005 (LS-SVM) 
(147) 
15 8619 1555 84.7% 4601 725 86.4% 85.3% 14.9%
Ding and Peng 
2005 (NB, 
SVM, LDA, LR) 
(127) 
60 8934 1240 87.8% 4288 1038 80.5% 85.3% 4.7%
Bo and Jonassen 
2002 (linear 
discriminant) 
(148) 
50 9207 967 90.5% 4294 1032 80.6% 87.1% 4.2%
* Signatures were selected by using our system 
 
3.3.4 Hierarchical clustering analysis of samples  
Figure 3-2 shows the hierarchical cluster analysis of 62 samples based on the 
gene expression profiles from 104 selected genes. These 62 samples form two 
groups. One group contains 20 normal samples and three tumor samples T30, T33 
and T36. Another group contains 37 tumor samples and 2 normal samples N34 
and N36. These results are similar to Alon’s results (108), showing that 35 tumor 
and 3 normal samples form a cluster, and the left 19 normal and 5 tumor samples 
form another cluster.  
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3.3.5 Evaluation of sample labels 
Using the SVM method with leave-one-out validation, all except 6 samples 
were correctly classified (120). The 6 samples included three tumor samples (T30, 
T33, T36) which were more probably to be normal ones, whereas three normal 
samples (N8, N34, N36) which were more likely to be cancerous. This suggested 
that some samples in the colon cancer dataset might have been wrongly labeled. In 
our system, the average training accuracies of the best models, which were 
evaluated by the predictive accuracies from the test sets, was only in the range of 
92.6% to 94.7%. This result from hierarchical clustering analysis also indicated 
that some samples might be mistakenly labeled. In microarray experiments, 
mistakenly labeling may happen. For example, a normal ovarian tissue sample 
was mistakenly labeled as cancerous tissue in an ovarian cancer microarray 
experiment (120). A robust model should have the ability to identify the 
mislabeled samples. 
 
Using 10,000 SVM model constructed by 104 genes we selected, 5 samples were 
misclassified at most occasions. The three confusion tumor samples T33, T36 and 
T30 were misclassified as normal one in 92.9%, 92.8% and 90.1% of occasions 
respectively. The normal samples N36 and N34 were misclassified as cancer ones 
in 96.0% and 73.6% of occasions. Another normal sample N8 was misclassified in 
3.4% of occasions. The misclassification rates for other samples were all less than 
0.5%. Misclassification of T33, T36 and T30 into their opposite labels was 
actually consistent with the opinion that these were more likely normal tissues. 
Likewise, misclassification of N36 and N34 was consistent with the opinion that 
they were more likely cancerous. These results suggest that our method and 
derived SVM models are insensitive to incorrect labeling of a small percentage of 
Chapter 3 Colon cancer marker selection from microarray data 
95 
samples. 
 
To reduce the effect of mislabeling samples, 6 samples (T33, T36, T30, N8, N34, 
and N36) was excluded, and the hierarchical clustering analysis was conducted 
again from the expression profiles of the 104 selected colon cancer genes on the 
other 56 samples. The result is displayed in Figure 3-3. At this time the samples 
were separated into two distinct clusters: normal people and colon cancer patients 
with no error. It further suggests that our selected genes can predict the sample 
groups accurately by using the unsupervised cluster method.  
 
Figure 3-2 Hierarchical clustering analysis of 62 samples from the gene 
expression profile of 104 selected genes. 
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Figure 3-3 Hierarchical clustering analysis of 56 samples and 104 genes on 
colon cancer microarray. (Red color represents the higher relative 
expression level and green represents the lower relative expression 
level) 
 
Cluster 1 
Cluster 2 
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3.3.6 The function of the identified colon cancer markers  
It is now well known that cancer is caused and driven by mutations in DNA 
that change the signal pathways which normally operate to regulate proliferation 
and death in normal cell. The activation of oncogene (drive excessive proliferation 
of cells) and inactivation of tumor suppressor genes (lose the inhibitory effect 
which is crucial to prevent inappropriate growth) change the normal signal 
pathway and hence leads to various well-defined phenotypic traits of cancer 
(Figure 3-4) (15, 16). These traits include proliferation, inappropriate survival, 
immortalization, invasion, angiogenesis and metastasis (15, 16). Considering such 
complexity of tumorigenesis, the number of cancer genes in the signatures should 
not be very few. It was reported that there are 291 known cancer genes (333), 15 
cancer-associated pathways (334), and 34 angiogenesis genes (335, 336). Because 
of biological differences and complex nature of cancers, a signature applicable for 
many patients is expected to include a substantial percentage of these 
cancer-related genes, together with some of their interacting-partners and 
consequence-genes (333). Moreover, because of measurement variability, a certain 
number of irrelevant genes may be inevitably included in a signature. Therefore, it 
is not surprising that the number of selected predictor-genes in our signatures 
ranged from 112 to 157. Moreover, it is probably unrealistic to assume that only a 
few genes stand out from the thousands of gene with sufficient clarity allowing 
target selection (62), which is a very important application of gene selection from 
microarray analysis. 
 
Chapter 3 Colon cancer marker selection from microarray data 
98 
Figure 3-4 Classes of genes involved in oncogenic transformation 
 
The selected 104 predictor-genes shared by all 20 signatures (Table 3-3, Table 3-8) 
include 48 cancer-related genes (6 anticancer targets, 2 oncogenes, 8 
tumor-suppressors, 2 angiogenesis gene, 4 cancer-genes, 3 tumor-marker, 17 
cancer-gene interacting genes, and 6 cancer-pathway-affiliated genes). In our 
analysis, anticancer targets were obtained from the latest version of TTD database 
(271, 340). Tthe cancer-related genes and cancer-pathways were taken from recent 
publications (333-338) and references in Table 3-3.  
 
These 104 shared predictor-genes also include 16 genes possibly implicated in 
cancer (description and references in Table 3-3). They have been reported to be 
involved in cancer risk (GSTM4), promotion of metastatic growth (POSTN) and 
tumor invasion (SERPINE2), maintenance of telomere repeats in cancer cells 
(HNRPA1), energy metabolism in cancer cells (PCCB), regulation of cell cycle 
(CSRP1, EEF1B2, TSPAN1, WDR7) and gene expression (CNOT1), and 
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synthesis of signaling molecules with elevated levels in tumors (GUCA2B). 
Genes reported to have significantly altered expression level in tumors with 
unclear connection to cancer (PMP22, SRPK1, UQCRC1) were also included here 
because of their possible roles as cancer consequence-genes. 
 
Table 3-8 List of colon cancer genes shared by all 20 signatures.  
Gene Group 
Predictor-genes selected by both 
this work and other studies 
(number of studies)  
Predictor-genes selected by this 
work only 
Anticancer target 
(successful or research) CDKN1A(2), HSD11B2(1) 
MMP9, SPARC, NCOA4, 
IL1R2 
Cancer gene 
(Oncogene) HMGA1(1), ETS2(1)  
Cancer gene 
(Tumor-suppressor) MXI1(1), TPM1(2), CDH3(2) 
CDX1, PRKACA, CREB5, 
PPP2R5C, CNNM4 
Cancer gene 
(angiogenesis gene)  PECAM1, CCL14 
Cancer gene (other 
types) 
MYH9(7), S100P(3), 
HSP90AB1(1) IFI6 
Tumor marker MUC2(1) S100A11, KRT8 
Interacting partner of 
cancer gene 
TPM2(3), CKS2(2), EIF2S2(2), 
HSPD1(2), MT1G(2), GSN(1), 
MORF4L2(1), SND1(1), TCF8(1) 
ATP2A2, CD46, CPSF1, 
PTPRH, WASF2, PPP1R9B, 
CALM2, CBX3 
Cancer pathway 
affiliated gene DES(7), C15orf15(3), MYL6(2) RPS6, RPL30, POLD2 
Gene having possible 
implication in cancer 
GUCA2B(6), CSRP1(5), 
SPARCL1(3), HNRPA1(1), 
SERPINE2(1), TSPAN1(1) 
CNOT1, EEF1B2, PCCB, 
PMP22, POSTN, SRPK1, 
WDR7, GSTM4, UQCRFS1, 
UQCRC1 
Others 
MYL9(7), WDR77(4), DARS(3), 
VIP(3), ATP5J(3), GTF3A(1), 
NR3C2, MLC1(1), GPD1L(1), 
CFD(1), ZNF358(1), FUCA1(1), 
GABRB3(1), SNRPB(1), 
DTWD2(1), CST3(1), FBL(1), 
MARCKSL1(1), SCNN1B(1), 
H11084(1), H40095(1), 
H64807(1) 
ACAA2, ARL6IP, CLNS1A, 
COX6A1, COX8A, FXYD1, 
GYG1, IFITM2, ITPR3, 
KIF5A, MGC22793, MT1M, 
PCNP, PRPSAP1, H73908 
 
3.3.7 Hierarchical clustering analysis of the identified markers  
In Figure 3-3, the 104 colon cancer genes form 2 distinctive clusters. One is 
the upregulated genes in the colon cancer patients, whereas another one is the 
downregulated genes in colon cancer patients.  
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The upregulated genes included 1 successful tumor marker (S100A11), 2 research 
tumor targets (SPARC and MMP9), 1 angiogenesis gene (PECAM1), 2 oncogenes 
(ETS2 and HMGA1) and 2 tumor suppressor genes (PPP2R5C and CDH3). Since 
the activation of oncogenes, angiogenesis genes, tumor targets and tumor markers 
can promote tumorigenesis, it is not surprising that S100A11, SPARC, MMP9, 
PECAM1, ETS2, and HMGA1 are upregulated in colon cancer patients. Although 
CDH3 as a tumor suppressor gene, it was reported to be present at an increased 
level in colon cancer cells (300, 301). Therefore the upregulating of these genes 
which are associated with colon tumorigenesis is actually consistent with the 
experiments.  
 
Other upregulated genes in colon cancer patients are IFITM2, WASF2, 
SERPINE2, H11084, CLNS1A, CKS2, SND1, CD46, MORF4L2, DTWD2, 
ARL6IP, MARCKSL1, CBX3, HNRPA1, MGC22793, CPSF1, SRPK1, H40095, 
WDR77, C15orf15, RPL30, RPS6, PCNP, HSPD1, HSP90AB1, GTF3A, DARS, 
POLD2 , SNRPB, EEF1B2, H73908, ITPR3, POSTN, PPP1R9B and EIF2S2. 
 
The downregulated genes in colon cancer patients include 6 tumor suppressor 
genes (CDX1, CREB5, MXI1, TPM1, CNNM4 and PRKACA), 1 angiogenesis 
genes (CCL14), 1 successful tumor target (HSD11B2), 2 research tumor target 
(CDKN1A and NCOA4 and IL1R2), and 2 tumor marker (MUC2 and KRT8). 
Since the deactivation of tumor suppressor genes promotes tumorigenesis, tumor 
suppressor genes should down-express in cancer patients. It was also reported that 
the decrease of tumor target HSD11B2 mRNA abundance and enzyme activity 
was associated with colorectal cancer (287) and the expression level of tumor 
target DKN1 was tightly controlled by the tumor suppressor protein p53 and could 
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mediate the p53-dependent cell cycle G1 phase arrest in response to a variety of 
stress stimuli (290). Reduction of tumor marker MUC2 expression may be 
associated with the occurrence and progression of colorectal carcinomas (308). 
IL1R2 and CCL2 belong to immune tolerance genes. The cancer patients are 
normally associated with low immune tolerance (338). Therefore the 
downregulating of these genes which are associated with colon tumorigenesis is 
actually consistent with the experiments. 
 
Other downregulated genes in colon cancer patients are COX6A1, CALM2, 
UQCRFS1, PRPSAP1, GSTM4, ATP2A2, ATP5J, GPD1L, WDR7, GABRB3, 
KIF5A, MT1M, ZNF358, TSPAN1, FUCA1, ACAA2, MYL6, UQCRC1, 
COX8A, SCNN1B, H64807, FXYD1, NR3C2, PTPRH, TPM2, CFD, MYL9, 
DES, CSRP1, MYH9, VIP, GSN, SPARCL1, TCF8, MT1G, PMP22, CST3, 
MLC1, GUCA2B, GYG1 and PCCB. 
 
3.3.8 Therapeutic target prediction 
For facilitate the identification of therapeutic targets, a therapeutic target 
system based on SVM classifier was developed (268), as described in Section 
2.2.3 of Chapter 2. SVM classifier separates positive (therapeutic target) and 
negative (non-therapeutic target) training samples in a multi-dimensional space by 
constructing a hyper-plane optimally positioned between the positive and negative 
samples. A testing sample is then projected onto this multi-dimensional space to 
determine its class affiliation based on its relative position to the hyperplane.  
 
The performance of SVM prediction of therapeutic targets was evaluated based on 
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a 5-fold cross validation study of 1,484 therapeutic targets and 6,637 
non-therapeutic targets. The computed prediction accuracies for therapeutic 
targets and non-therapeutic targets were in the range of range 64.1–71.0% and 
85.0–85.8% respectively (268). This suggested the SVM is capable of predicting 
therapeutic targets. 
 
Therapeutic target prediction system was utilized to predict therapeutic targets 
from the identified colon cancer markers. All of the 6 known therapeutic targets 
(NCOA4, SPAC, MMP9, IL1R2, HSD1B2 and CDKN1A) were predicted 
correctly by our therapeutic target system (Table 3-9). 18 markers (PRKACA, 
CDH3, HSP90AB1, PECAM1, SND1, SCNN1B, PCCB, NR3C2, KIF5A, 
HSPD1, GYG1, GPD1L, CNOT1, CFD, CD46, CALM2, ATP2A2 and ACAA2) 
were predicted as therapeutic targets. 
 
Table 3-9 Prediction results from therapeutic target prediction system 
 
Gene Name Gene function therapeutic target prediction result 
NCOA4 oncogene; research tumor target target 
SPARC research tumor target target 
MMP9 research tumor target target 
IL1R2 research therapeutic target; immune tolerance gene target 
HSD11B2 successful research target target 
CDKN1A research tumor target target 
PRKACA tumor suppressor gene target 
CDH3 tumor suppressor gene target 
HSP90AB1 cancer gene target 
PECAM1 angiogenesis gene target 
SND1   target 
SCNN1B   target 
PCCB   target 
NR3C2   target 
KIF5A   target 
HSPD1   target 
GYG1   target 
GPD1L   target 
CNOT1   target 
CFD   target 
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CD46   target 
CALM2   target 
ATP2A2   target 
ACAA2   target 
CDX1 tumor suppressor gene  
TPM1 tumor suppressor gene  
MXI1 tumor suppressor gene  
CREB5 tumor suppressor gene  
CNNM4 tumor suppressor gene  
PPP2R5C tumor suppressor gene  
KRT8 tumor marker  
MUC2 tumor marker  
S100A11 tumor marker  
CCL14 angiogenesis gene, immune tolerance gene  
HMGA1 oncogene  
ETS2 oncogene  
S100P cancer gene  
MYH9 cancer gene  
IFI6 cancer gene, immune tolerance gene  
TPM2    
TCF8    
SRPK1    
MYL6    
MGC22793    
GTF3A    
UQCRC1    
FBL    
CST3    
WDR7    
UQCRFS1    
PTPRH    
GSTM4    
GSN    
POSTN    
ARL6IP    
ATP5J    
C15orf15    
CBX3    
CKS2    
CLNS1A    
COX6A1    
COX8A    
CPSF1    
CSRP1    
DARS    
DES    
DTWD2    
EEF1B2    
EIF2S2    
FUCA1    
FXYD1    
GABRB3    
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GUCA2B    
HNRPA1    
IFITM2    
ITPR3    
MARCKSL1    
MLC1    
MORF4L2    
MT1G    
MT1M    
MYL9    
PCNP    
PMP22    
POLD2    
PPP1R9B    
PRPSAP1    
RPL30    
RPS6    
SERPINE2    
SNRPB    
SPARCL1    
TSPAN1    
VIP    
WASF2    
WDR77    
ZNF358    
 
3.4 Summary 
This chapter described a system for marker discovery. The system was 
designed to overcome the unstable signatures from different combination of 
samples and different classification method. Multiple random sampling method 
and consistency evaluation strategy were incorporated into the normal RFE gene 
selection procedure. The system was tested on colon cancer marker discovery. The 
results show that our selected markers could present both better stability and 
higher predictive performance on different microarray datasets than other 
signatures. 104 genes were selected in twenty groups of colon cancer gene 
signatures, in which the number of genes were in the range of 112 to 157. The 
results from SVM classification system and hierarchical clustering analysis 
suggest that our selected genes could perform stable and well with the variation of 
Chapter 3 Colon cancer marker selection from microarray data 
105 
samples. Our selected genes contain a significantly higher number of 
cancer-related genes and half of the genes selected by other groups. Therefore, our 
signatures tend to more closely reflect the complex nature of cancer known which 
involves collective actions of many genes of different functions. A therapeutic 
target prediction system was utilized to identify the possible therapeutic target 
from the selected markers. 6 known targets and 18 novel targets were identified, 
indicating that our gene selection system may be used to identify the therapeutic 
targets.  
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4 Lung adenocarcinoma survival marker selection 
This chapter provides another case study for our gene selection system – lung 
adenocarcinoma survival marker selection. The predictive ability of these survival 
markers are evaluated by neural network models, SVM models, and unsupervised 
hierarchical clustering analysis from different lung adenocarcinoma datasets. 
Hierarchical clustering analysis and literature search are used to evaluate the 
expression pattern of the identified markers. A therapeutic target prediction 
system is applied to identify the potential therapeutic targets from the identified 
markers. 
  
4.1 Introduction 
The fundamental goals of disease subtype and prognostic prediction, which 
includes the prediction of disease stages, disease recurrence and disease 
survivability, are quite different from the goals of disease diagnosis. Disease 
subtype and prognostic prediction either predict the likelihood of disease 
redeveloping following an apparent resolution of a disease or to predict outcomes 
such as life expectancy, survivability, progression, drug sensitivity after the 
diagnosis of a disease (341). In order to apply proper treatment regime and 
ultimately extend the survival of the patients, the accurate identification of disease 
subtype and prognosis effect is crucial (12). However, the disease subtype 
differentiation and prognostic prediction towards treatment is difficult and 
expensive. Furthermore, the successful rate of prediction is low, and a collective 
expertise of professionals is demanded (29). Taking cancer as an example, they 
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are complex and very heterogeneous. Even for a specific cancer type, such as 
leukemia, a few subclasses with various phenotypes exist (5, 6). By use of 
traditional diagnostic technologies, the different subtypes of a specific disease are 
reluctant to be figured out because they tend to look alike from microscopic 
analysis, and share the same symptoms or markers used in the diagnostic, or 
simply because one or more subclasses of the disease are unknown (12). As a 
result, such similarity leads to misdiagnosis and improper treatment (27). 
Fortunately, recently developed microarray technology provides the opportunity 
of subtype discovery and prognostic prediction based on disease and patients 
molecular details (5, 6, 26-29).  
 
Since disease is a kind of broad class, in order to be specific, lung adenocarcinoma 
was chosen in this study. Our rational is that the study on lung adenocarcinoma 
survival marker discovery and prognosis prediction will provide a platform to 
study other diseases in the same way. 
  
Currently cancer accounts for about 23% of death on human (281). Among 
different sites of cancer origin, lung cancer is the most dangerous one. The death 
rate of lung cancer is 31% for men and 26% for women (282). Lung cancers can 
be classified as non-small cell lung cancer (NSCLC) and small-cell lung cancer 
(SCLC) based on simple pathomorphological criteria. The prognosis for both type 
of lung cancers are poor. 80% of lung cancers are diagnosed as NSCLC (342). For 
advanced NSCLC, average survival time is 6 months for untreated patients, and 9 
months for patients treated with chemotherapy (342). 5-year survival rate is 
60~70% for patients with stage I disease and zero for patients with stage IV 
disease (342). The NSCLC can be further classified as squamous cell carcinoma 
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and adenocarcinoma. The proportional of squamous cell carcinoma is around 
20~25%, and The proportional of adenocarcinoma is 50~60% (342).  
 
The lung cancer patients can be roughly stratified from the morphological 
assessment based on conventional sputum cytology and chest radiography. These 
techniques have so far not demonstrated an impact on decreasing lung-cancer 
mortality (343). In one study, only 41% of cases that independent lung 
pathologists agreed on lung adenocarcinoma subclassification (344). Recently 
some specific indicators, including tumor size, poor differentiation and high 
tumor-proliferative index, have been identified to predict the survival of lung 
cancer patients (345-348), However, these indicators have only limited power in 
survival prediction.  
 
The development of microarray technology makes it possible to find molecular 
markers of lung cancer subtype and outcome prediction systematically (349-352). 
These markers allow new insights in the process of lung carcinogenesis, and they 
may provide new tools for determination of prognosis and identification of 
innovative treatments. However, the molecule marker selection is strongly 
depended on the patient samples, causing the significantly different marker 
signatures in different groups for lung adenocarcinoma prognosis (Table 4-1) (350, 
351) and diminishing their application potential for prognosis (70). Moreover, the 
prognostic power of previous selected survival genes for individual patients was 
seldom reported in their studies (350, 351). Guo et al. provided the prediction 
accuracy for their selected survival genes. However, their selected survival genes 
were only applicable to one dataset, and the predictive power to the independent 
dataset was very limited (349). 
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Table 4-1 Statistics of lung adenocarcinoma survival marker signatures from 
references 
 
Number of genes selected by other N studies 
Reference 
Number of selected 
survival genes in 
signature 4 3 2 1 0 
Lu et al (353) 125 0 0 0 8 116 
Chen et al (354) 16 0 0 0 0 16 
Xu et al (355) 5 0 0 0 2 3 
Beer et al (350) 100 0 0 0 8 92 
Guo et al (349) 37 0 0 0 4 34 
 
In this chapter, we present our proposal to identify important marker genes, which 
can be used to predict the survivability of individual patients with lung 
adenocarcinoma. Employing similar method as colon cancer gene discovery, 
totally 21 genes were selected after 10 times of experiments. Results show that the 
prediction models can accurately predict the clinical outcome for individual 
patients with lung adenocarcinoma by use of independent datasets. The 
differential expression analysis, function prediction, and literature searches of the 
identified marker genes implies that the 21 survival markers should play important 
roles in lung adenocarcinoma progress and may contain novel therapeutic targets. 
 
4.2 Materials and Methods  
4.2.1 Lung adenocarcinoma microarray datasets and data preprocess 
Two independent datasets of clinical samples were used for lung 
adenocarcinoma survival marker gene selection and validation of the effect of our 
selected genes. The original gene expression profiles of patient samples have been 
reported in previous publications (350, 351).  
 
The dataset for survival marker gene selection contained the gene expression 
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profiles from 86 primary lung adenocarcinomas (Beer’s dataset) (350, 356), 
including 67 stage I and 19 stage III tumor, from oligonucleotide arrays seen at the 
University of Michigan Hospital between May 1994 and July 2000. This gene 
expression profile, containing 7129 gene expression levels, was obtained before 
surgery. 62 patients survived (survivable patients) whereas 24 patients died at last 
follow-up (non-survivable patients). The detailed clinical information of samples 
is listed in Appendix Table S3. For preprocessing, those genes with little variation 
(less than 2) were removed, and 6009 genes were used for survival gene selection 
(70, 259).  
 
The robustness of our selected signatures in predicting survivability in lung 
adenocarcinomas was tested using oligonucleotide gene-expression data obtained 
from a completely independent lung adenocarcinoma dataset (Bhattacharjee’s 
dataset) (351, 357). To ensure equivalent testing power and comparability of 
samples, 84 primary lung tumor samples of which at least 40% samples being 
cancer cells were selected (350). In these 84 samples, 41 patients were alive at last 
follow-up (survivable patients), whereas 43 died (non-survivable patients). The 
detailed sample clinical information is listed in Appendix Table S4.  
 
4.2.2 Survival marker selection procedure 
In order to present a statistically meaningful evaluation, signature selection 
was conducted based on multiple random sampling on the Beer’s dataset (350). In 
multiple random sampling, this dataset was randomly divided into a training set 
containing 43 samples (including 12 poor outcome samples and 31 good outcome 
samples) and an associated test set containing the other 43 samples (including the 
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other 12 poor outcome samples and 31 good outcome samples). To reduce 
computational cost, 5,000 training-test sets, each containing a unique combination 
of samples, were generated. These 5,000 training-test sets were randomly placed 
into 10 sampling groups; each containing 500 training-test sets. Every sampling 
group was then used to derive a signature by using the similar way as colon cancer 
marker discovery. Finally, the 10 different signatures derived from these sampling 
groups were compared in order to test the level of stability of selected 
predictor-genes. 
 
4.2.3 Performance evaluation of survival marker signatures 
The predictive capability of survival marker signatures were evaluated by 
using the SVM and PNN classification system on 500 randomly-generated 
training-testing sets generated from the Bhattacharjee’s dataset (351) and the 
Beer’s dataset (350). For each training-testing set, the training data was used to 
construct a classifier model, whereas the testing data was used to evaluate the 
performance of the model. The predictive performance of selected signatures was 
evaluated by the overall accuracies (Q) of the 500 models. Besides the evaluation 
by using supervised classifiers, unsupervised hierarchical clustering analysis was 
also applied to evaluate the performance of signatures. 
 
4.2.3.1 Neural Networks 
Neural networks are another important machine learning method for 
microarray data analysis. This method employs a multilayered approach to 
approximate complex mathematical functions to process data. Probabilistic Neural 
Networks (PNN) is a specific form of neural networks which has 4 layers (Figure 
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4-1). The input layer provides input values to all neurons in the pattern layer and 
has as many neurons as the number of descriptors in the training set. The number 
of pattern neurons is determined by the total number of examples in the training 
set. Each pattern neuron computes a distance measure between the input and the 
training case represented by that neuron. The summation layer has a neuron for 
each class and the neurons sum all the pattern neurons’ output corresponding to 
members of that summation neuron’s class to obtain the estimated probability 
density function for that class. The single neuron in the output layer then estimates 
the class of the unknown vector x by comparing all the probability density 
function from the summation neurons and by choosing the class with the highest 
probability density function. The PNN programme is provided by our group.  
 
Figure 4-1 Architecture of neural networks  
 
 
4.2.3.2 Hierarchical cluster analysis and Kaplan-Meier survival analysis 
Hierarchical cluster analysis was conducted by using the selected survival on 
the 86 samples from Beer et al. (350) and the independent dataset consisting of 84 
samples from Bhattacharjee et al. (351). 
Summation layer 
Input layer 
Pattern layer 
Output layer 
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Kaplan-Meier survival analysis, often referred as survival analysis, was used in 
this study together with hierarchical cluster analysis. This analysis is popularly 
employed in medical research to estimate the percentage of patients living for a 
certain amount of time after surgery. It allows the estimation of survival over time, 
even when patients drop out or are studied for different lengths of time. A typical 
application of Kaplan-Meier analysis involves (1) grouping patients into different 
categories, and (2) comparing the survival curves from those categories by the 
log-rank test to assess the statistical significance of the difference among the 
survival curves for the categories. The Kaplan-Meier analysis was performed by 
using XLSTAT software (358). 
 
4.3 Results and discussion  
4.3.1 System of the lung adenocarcinoma survival marker selection 
 10 sets of survival marker signatures were obtained. PNN and SVM 
classifiers were used to evaluate the survivability prediction system constructed 
from selected signatures. Hierarchical cluster analysis and Kaplan-Meier analysis 
were used for further evaluating survival marker gene signatures, as shown in Fig. 
4-2.  
 
4.3.2 Consistency analysis of the identified markers 
The stability levels of the 10 derived signatures could be estimated from the 
percentage of predictor-genes shared by them. The number or predictor-genes in 
the signatures ranged from 34 to 57 (Table 4-2, Appendices Table S5). A total of 
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21 predictor-genes were shared by all the 10 signatures, as shown in Table 4-2 and 
Table 4-3. The signature we generated had a certain level of stability when 
comparing to the results from 5 previous studies (Table 4-1), which shows that 
5~125 selected predictor-genes in each of the 5 previous studies were seldom 
presented in the other 4 studies. 
 
Figure 4-2 System for lung adenocarcinoma survival marker derivation and 
survivability prediction 
 
 
It is noted that the numbers of selected genes in the lung adenocarcinoma dataset 
(21 genes) is significantly less than the number of genes from the colon cancer 
dataset (104 genes). One possible reason for this difference is that the expression 
profiles of some cancer genes important for differentiating cancer and non-cancer 
patients may not be significantly different in cancer patients of different survival 
groups. As a result, higher number of cancer genes is expected to be selected in 
the signatures of the colon cancer dataset than that of the lung adenocarcinoma 
datasets. 
Microarray data (6009 genes, 86 samples)
Survival marker 
signature 1  
Survival marker 
signature 2 
… Survival marker 
signature 10 
Genes shared by ten signatures 
SVM prediction system 
PNN prediction system 
Hierarchical cluster analysis and Kaplan-Meier analysis
Evaluation on the independent dataset 
from Bhattacharjee et al.  
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Table 4-2 Statistics of the lung adenocarcinoma survival markers by 
class-differentiation systems constructed from 10 different 
sampling-sets, each composed of 500 training-testing sets generated 
by random sampling. 
Number of survival-genes also included in N other signatures derived by 
using different sampling-set Signature 
(method) 
Number of 
selected survival 
genes in signature 
9 8 7 6 5 4 3 2 1 0 
1 51 21 4 1 7 5 3 3 2 1 4 
2 54 21 6 1 6 3 2 5 5 2 3 
3 42 21 6 2 4 3 2 2 2 0 0 
4 34 21 3 2 1 2 2 1 2 0 0 
5 46 21 6 2 7 5 1 2 2 0 0 
6 54 21 6 2 8 5 3 2 2 2 3 
7 57 21 5 1 7 2 1 3 5 2 10
8 50 21 6 2 6 2 1 4 5 2 1 
9 53 21 6 1 5 5 1 4 3 4 3 
10 47 21 6 2 5 4 1 2 3 1 2 
 
 
The optimal SVM parameters for the 10 sample sets were in the range of 41 to 46, 
and the highest average accuracies across the 10 sampling-sets were 
84.1%~88.4% for non-survivable (those died at last follow-up) and 100% for 
survivable patients (those alive at last follow-up) respectively (Table 4-4). The 
accuracies for the 5,000 individual testing-sets ranged from 63.6%~100% for 
non-survivable and 100% for survivable patients respectively. The relatively small 
variations of optimal SVM parameters and prediction accuracies across the 10 
sampling-sets suggest that the performance of the SVM class-differentiation 
systems constructed by using globally optimized parameters and RFE iteration 
steps are fairly stable across different sampling combinations. 
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Table 4-3 Gene information for lung adenocarcinoma survival markers shared by all of 10 signatures.  
Gene 
Name 
Gene 
description 
Chromosome 
Location Type Family 
Function in 
metagenesis 
Gene Ontology: 
Function Gene Ontology: Process 
Pathway (from KEGG, Reactome, 
proteinlounge) References 
VEGF 
vascular 
endothelial 
growth factor 
6p12 Growth Factor
PDGF/VEGF 
Family of 
Growth Factors
Angiogenesis, 
therapeutic 
target for lung 
cancer therapy extracellular matrix 
binding; growth 
factor activity; 
growth factor 
activity; heparin 
binding; protein 
binding; protein 
homodimerization 
activity; vascular 
endothelial growth 
factor receptor 
binding 
angiogenesis; anti-apoptosis; cell 
migration; cell proliferation; 
epithelial cell differentiation; eye 
photoreceptor cell development; 
induction of positive chemotaxis; 
lung development; mesoderm 
development; multicellular 
organismal development; nervous 
system development; nervous 
system development; positive 
regulation of epithelial cell 
proliferation; positive regulation of 
vascular endothelial growth factor 
receptor signaling pathway; 
regulation of progression through 
cell cycle; response to hypoxia; 
signal transduction; vasculogenesis
VEGF Pathway; Inhibition of 
Angiogenesis by TSP1; eNOS Signaling; 
Relaxin Pathway; Phospholipase-C 
Pathway; CRHR Pathway; mTOR 
Pathway; Paxillin Interactions; PAK 
Pathway; Ras Pathway; Cellular 
Apoptosis Pathway; Rap1 Pathway; 
GPCR Pathway; TGF-Beta Pathway; 
MAPK Family Pathway; P2Y Receptor 
Signaling; RhoGDI Pathway ; 
NF-KappaB Family Pathway; FGF 
Pathway; HIF1Alpha Pathway; Rac1 
Pathway; JAK/STAT Pathway; 
Renin-Angiotensin Pathway; 
Mitochondrial Apoptosis; NF-KappaB 
(p50/p65) Pathway; Telomerase 
Components in Cell Signaling; Rho 
Family GTPases 
(359-364) 
 
 
 
BSG basigin 19p13.3   
Tumor marker, 
angiogenesis, 
immunoangiost
asis 
mannose binding; 
signal transducer 
activity; sugar 
binding 
cell surface receptor linked signal 
transduction  (365-369) 
CXCL3 
chemokine 
(C-X-C motif) 
ligand 3 
4q21 Cytokine 
Intercrine 
Alpha 
(Chemokine 
CXC) Family 
Oncogene, 
immune 
tolerance gene, 
angiogenesis, 
organ-specific 
metastases 
chemokine activity 
G-protein coupled receptor protein 
signaling pathway; chemotaxis; 
immune response; inflammatory 
response 
Rho Family GTPases (370-373) 
CHRNA2 
cholinergic 
receptor, 
nicotinic, alpha 
2 (neuronal) 
8p21 
Receptor, 
Transporter, 
Neurotransmitte
r 
Ligand-Gated 
Ionic Channel 
(TC 1.A.9) 
Family; 
autocrine 
growth factors 
therapeutic 
target for lung 
cancer therapy 
acetylcholine 
receptor activity; 
extracellular 
ligand-gated ion 
channel activity; ion 
channel activity; 
nicotinic 
acetylcholine-activate
d cation-selective 
ion transport; signal transduction; 
synaptic transmission  
(364, 
374, 375)  
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channel activity 
FUT3 fucosyltransferase 3 19p13.3   
 
transferase activity, 
transferring glycosyl 
groups 
carbohydrate metabolic process; 
protein amino acid glycosylation  (376-379) 
FXYD3 
FXYD domain 
containing ion 
transport 
regulator 3 
19q13.11-q1
3.12 
ion channel 
activity, 
chloride 
channel activity
 
 chloride channel 
activity; chloride ion 
binding; ion channel 
activity 
chloride transport; ion transport  (380, 381) 
PLD1 phospholipase D1 3q26 
Signal 
Transduction PLD Family 
 hydrolase activity; 
phosphoinositide 
binding; 
phospholipase D 
activity; protein 
binding 
Ras protein signal transduction; cell 
communication; chemotaxis; lipid 
catabolic process; metabolic 
process; phospholipid metabolic 
process 
Ras pathway; Rho Family GTPases; 
RhoA Pathway ;Rac1 Pathway; 
Endothelin-1 Signaling Pathway 
(382, 
383) 
POLD3 
polymerase 
(DNA-directed
), delta 3, 
accessory 
subunit 
11q14   
 DNA binding; delta 
DNA polymerase 
activity; transferase 
activity 
DNA synthesis during DNA repair; 
mismatch repair 
DNA polymerase; Purine metabolism; 
Pyrimidine metabolism; Cell Cycle 
(Mitotic); DNA Repair; DNA 
Replication; Maintenance of Telomeres 
(384) 
PRKACB 
protein kinase, 
cAMP-depend
ent, catalytic, 
beta 
1p36.1 Kinase 
Ser/Thr Family 
of Protein 
Kinases (cAMP 
Subfamily) 
 ATP binding; 
cAMP-dependent 
protein kinase 
activity; magnesium 
ion binding; 
nucleotide binding; 
protein kinase 
activity; protein 
serine/threonine 
kinase activity; 
transferase activity 
G-protein signaling, coupled to 
cAMP nucleotide second 
messenger; protein amino acid 
phosphorylation; signal 
transduction 
Apoptosis; Calcium signaling pathway; 
Gap junction; GnRH signaling pathway; 
Hedgehog signaling pathway; Insulin 
signaling pathway; Long-term 
potentiation; MAPK signaling pathway; 
Olfactory transduction; Taste 
transduction; Wnt signaling pathway; 
PKA pathway(17333334) 
(385) 
CXCR7 
chemokine 
(C-X-C motif) 
receptor 7 
2q37.3   
Immune 
tolerance gene, 
therapeutic 
target for lung 
cancer therapy, 
organ-specific 
metastases 
receptor activity; 
rhodopsin-like 
receptor activity 
G-protein coupled receptor protein 
signaling pathway; 
biological_process; signal 
transduction 
 
(364, 
370, 373, 
386, 387) 
REG1A 
regenerating 
islet-derived 1 
alpha 
2p12   
 
sugar binding positive regulation of cell proliferation  
(388, 
389) 
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RPS3 ribosomal protein S3 
11q13.3-q13.
5 
Structural 
Protein 
S3P Family of 
Ribosomal 
Proteins. 
involved in 
DNA repair 
pathway and 
apoptosis 
pathway, 
interacted with 
metastasis 
suppressor 
nm23 
RNA binding; 
structural constituent 
of ribosome 
translation DNA repair pathway and apoptosis pathway 
(390, 
391) 
SERPINE1 
serpin 
peptidase 
inhibitor, clade 
E (nexin, 
plasminogen 
activator 
inhibitor type 
1), member 1 
7q21.3-q22 Metabolic SERPIN Family 
angiogenesis 
   (392-395) 
SLC2A1 
solute carrier 
family 2 
(facilitated 
glucose 
transporter) 
1p35-p31.3 Transport 
Sugar 
Transporter 
(Subfamily- 
Glucose 
Transporter) 
providing 
energy to 
rapidly dividing 
tumor cells,  
glucose transporter 
activity; protein 
binding; sugar porter 
activity; transporter 
activity 
carbohydrate transport; glucose 
transport  (396) 
SPRR1B 
small 
proline-rich 
protein 1B 
1q21-q22 
structural 
molecule 
activity 
 
 protein binding, 
bridging; structural 
molecule activity 
epidermis development; 
keratinization; keratinocyte 
differentiation; peptide 
cross-linking 
 (397, 398) 
TUBA4A tubulin, alpha 4a 2q35 Structural 
Tubulin 
Superfamily 
angiogenesis 
 
GTP binding; GTPase activity; 
nucleotide binding; protein 
binding; structural molecule 
activity 
 (399-401)  
VDR 
vitamin D 
(1,25- 
dihydroxyvita
min D3) 
receptor 
12q13.11 Transcription Factor 
Nuclear 
Hormone 
Receptor 
Family (NR1 
Subfamily) 
Research tumor 
target 
metal ion binding; 
protein binding; 
sequence-specific 
DNA binding; steroid 
hormone receptor 
activity; transcription 
factor activity; 
vitamin D3 receptor 
activity; zinc ion 
binding 
calcium ion homeostasis; calcium 
ion transport; intestinal absorption; 
multicellular organismal 
development; negative regulation 
of transcription; organ 
morphogenesis; regulation of 
transcription, DNA-dependent; 
signal transduction; skeletal 
development; transcription 
MAPK (402) 
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ADFP 
Adipose 
differentiation-
related protein
9p22.1   
 
    
ANXA8 annexin A8 10q11.2   
 calcium ion binding; 
calcium-dependent 
phospholipid binding 
blood coagulation   
GALNT4 GalNAc transferase 4 12q21.3-q22  
GalNAc-transfe
rase family 
 calcium ion binding; 
manganese ion 
binding; sugar 
binding; transferase 
activity, transferring 
glycosyl groups 
carbohydrate metabolic process 
  
LDHB 
lactate 
dehydrogenase 
B 
12p12.2-p12.
1 Metabolic Ldh Family 
 L-lactate 
dehydrogenase 
activity; 
oxidoreductase 
activity 
anaerobic glycolysis; tricarboxylic 
acid cycle intermediate metabolic 
process 
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Table 4-4 Average survivability prediction accuracy of 500 SVM 
class-differentiation systems on the optimal SVM parameters for 
lung adenocarcinoma prediction. The sigma is the optimal SVM 
parameter which gives the best average class-differentiation accuracy 
over the 500 testing-sets. The accuracies are obtained from 500 
testing-sets. 
Non-survivable 
patients Survivable patients Signature 
(method) 
Optimal 
SVM 
parameter  
Number of 
selected 
survival 
genes in 
signature 
TP FN SE TN FP SP 
Q 
1 45 51 5275 814 86.6% 14908 3 100% 96.1% 
2 44 54 5175 939 84.6% 14886 0 100.% 95.5% 
3 43 42 5173 909 85.1% 14918 0 100% 95.7% 
4 41 34 5347 802 87.0% 14845 6 100% 96.2% 
5 43 46 5340 703 88.4% 14956 1 100% 96.6% 
6 45 54 5230 865 85.8% 14905 0 100% 95.9% 
7 45 57 5139 972 84.1% 14889 0 100% 95.4% 
8 46 50 5201 949 84.6% 14850 0 100% 95.5% 
9 43 53 5313 801 86.9% 14886 0 100% 96.2% 
10 46 47 5333 757 87.6% 14910 0 100% 96.4% 
 
4.3.3 The predictive ability of identified markers 
The predictive capabilities of our selected and 10 previously-derived 
signatures were evaluated by using the SVM and PNN classification system on 
500 randomly-generated training-testing sets generated from the Bhattacharjee’s 
dataset (351) and the Beer’s dataset (350). For each training-test set, the training 
data was used to construct a classifier model, whereas the test data was used to 
evaluate the performance of the model. The predictive performance of selected 
signatures was evaluated by the overall accuracies (Q) of the 500 models.  
 
Table 4-5 gives the prediction accuracies from the SVM prediction system 
constructed by independent samples from Bhattacharjee’s dataset (351) using our 
selected gene signatures and 9 other previous-derived signatures. The accuracies 
for non-survival patients, survival patients and all patients of the our selected 10 
gene signatures over the 500 test sets were in the range of 77.8% to 81.2%, 74.3% 
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to 80.1% and 77.6% to 80.2% correspondingly, while the standard deviations of 
the accuracy of all patients were in the range of 4.7% to 4.9%. The accuracies for 
non-survival patients, survival patients and overall accuracies for all patients of 
the 21 survival genes shared by all of the 10 signatures over the 500 test sets were 
78.9%, 76.8% and 77.9% respectively, while the standard deviation of the 
accuracy of all patients was 4.8%. In contrast, the accuracies for non-survivable 
patients, survival patients and all patients of the 9 previous-derived signatures 
were in the range of 70.1%~77.2%, 56.4% to 78.0% and 66.0% to 77.6% 
respectively, and the standard deviations of the accuracy of all patients were in the 
range of 5.5%~6.9%. These results suggest that the performance of our signatures 
is stabler than those of other signatures by using independent database and by 
applying the SVM models. 
 
Table 4-6 illustrates the predictive performance of the 500 testing sets by using the 
PNN classification system and the 500 randomly generated training-testing dataset 
generated from the independent Bhattacharjee’s dataset (351) using our selected 
genes. The accuracies for non-survivable patients, survival patients and all 
patients of our selected 10 signatures over the 500 test sets were, respectively, in 
the range of 69.3% to 80.2%, 64.5% to 78.0% and 69.1% to 76.6%, while the 
standard deviations of the accuracy of all patients were in the range of 4.2% to 
4.9%. The accuracies for non-survivable patients, survivable patients and all 
patients of the 21 survival genes shared by all the 10 signatures over the 500 test 
sets were 75.2%, 62.6% and 69.2% respectively, while the standard deviation of 
the overall accuracy was 4.4%. The accuracies for non-survivable patients, 
survival patients and patients of the 9 previous-derived signatures were in the 
range of 53.5%~95.6%, 45.7% to 76.8% and 64.0% to 71.7% respectively, while 
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the standard deviations of accuracy of all patients were in the range of 4.7%~6.1%. 
These results recommend that the survival genes we selected have a slightly better 
consistency and stabler predictive performance than those of the signatures 
selected by other studies with the PNN classification system.  
 
Table 4-5 Average survivability prediction accuracy of the 500 SVM 
class-differentiation systems constructed by 84 samples from 
independent Bhattacharjee’s lung adenocarcinoma dataset (351) 
using each of the signatures derived from this study and 9 previous 
studies. The accuracies were obtained from the 500 testing-sets.  
Non-survivable 
patients Survivable patients Signature 
(method) 
Number of 
selected survival 
genes in 
signature TP FN SE TN FP SP 
Q STDEV
1* 51 8495 2369 78.2% 7864 2272 77.6% 77.9% 4.8% 
2* 54 8602 2262 79.2% 7783 2353 76.8% 78.0% 4.7% 
3* 42 8745 2119 80.5% 8014 2122 79.1% 79.8% 4.8% 
4* 34 8452 2412 77.8% 7837 2299 77.3% 77.6% 4.8% 
5* 46 8723 2141 80.3% 8117 2019 80.1% 80.2% 4.9% 
6* 54 8600 2264 79.2% 7731 2405 76.3% 77.8% 4.7% 
7* 57 8802 2062 81.0% 7807 2329 77.0% 79.1% 4.8% 
8* 50 8414 2450 77.4% 7533 2603 74.3% 75.9% 4.8% 
9* 53 8655 2209 79.7% 7992 2144 78.8% 79.3% 4.7% 
10* 47 8823 2041 81.2% 7899 2237 77.9% 79.6% 4.8% 
Genes 
selected by 
all sampling 
sets* 
21 8571 2293 78.9% 7788 2348 76.8% 77.9% 4.8% 
Beer et al 
(350) 100 8287 2577 76.3% 7540 2596 74.4% 75.4% 6.2% 
Beer et al 
(350) 50 7616 3248 70.1% 7407 2729 73.1% 71.5% 6.3% 
Chen et al 
(354) 16 7755 3109 71.4% 7255 2881 71.6% 71.5% 6.6% 
Chen et al 
(354) 5 7684 3180 70.7% 6820 3316 67.3% 69.1% 6.4% 
Guo et al 
(349) 37 8088 2776 74.4% 7443 2693 73.4% 74.0% 6.4% 
Guo et al 
(349) 8 8386 2478 77.2% 7904 2232 78.0% 77.6% 6.6% 
Lu et al (353) 125 8348 2516 76.8% 7588 2548 74.9% 75.9% 5.8% 
Lu et al (353) 64 8237 2627 75.8% 7612 2524 75.1% 75.5% 5.5% 
Xu et al (355) 5 8141 2723 74.9% 5720 4416 56.4% 66.0% 6.9% 
* Data from this study 
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Table 4-6 Average survivability prediction accuracies of the 500 PNN 
class-differentiation systems constructed by 84 samples from 
independent Bhattacharjee’s lung adenocarcinoma dataset (351) 
using each of the signatures derived from this study and 9 previous 
works. 
Non-survivable 
patients Survivable patients 
Signature 
(method) 
Number 
of 
selected 
survival 
genes in 
signature 
TP FN SP TN FP SE 
Q STDEV
1* 51 7769 3156 71.1% 7270 2805 72.2% 71.6% 4.5% 
2* 54 7837 3088 71.7% 7478 2597 74.2% 72.9% 4.9% 
3* 42 8762 2163 80.2% 7333 2742 72.8% 76.6% 4.6% 
4* 34 8656 2269 79.2% 6810 3265 67.6% 73.6% 4.3% 
5* 46 7995 2930 73.2% 7863 2212 78.0% 75.5% 4.6% 
6* 54 8019 2906 73.4% 6502 3573 64.5% 69.1% 4.5% 
7* 57 8177 2748 74.8% 7518 2557 74.6% 74.7% 4.4% 
8* 50 8000 2925 73.2% 7514 2561 74.6% 73.9% 4.2% 
9* 53 7575 3350 69.3% 7140 2935 70.9% 70.1% 4.6% 
10* 47 8379 2546 76.7% 7413 2662 73.6% 75.2% 4.7% 
Genes selected 
by all sampling 
sets* 
21 8217 2708 75.2% 6305 3770 62.6% 69.2% 4.4% 
Beer et al (350) 100 7537 3388 69.0% 7515 2560 74.6% 71.7% 5.5% 
Chen et al (354) 5 10446 479 95.6% 4600 5475 45.7% 71.6% 4.7% 
Guo et al (349) 8 7752 3173 71.0% 7189 2886 71.4% 71.1% 5.2% 
Guo et al (349) 37 7537 3388 69.0% 7284 2791 72.3% 70.6% 5.5% 
Xu et al (355) 5 7884 3041 72.2% 6844 3231 67.9% 70.1% 5.6% 
Beer et al (350) 50 9220 1705 84.4% 5310 4765 52.7% 69.2% 4.9% 
Chen et al (354) 16 6780 4145 62.1% 7734 2341 76.8% 69.1% 5.7% 
Lu et al (353) 125 6874 4051 62.9% 7591 2484 75.3% 68.9% 6.1% 
Lu et al (353) 64 5845 5080 53.5% 7591 2484 75.3% 64.0% 6.1% 
* Data from this study 
 
The predictive accuracies of the 500 SVM survivability prediction systems from 
the original Beer’ dataset (350) are shown in Table 4-7. These 500 training sets 
and 500 test sets were different from those used for survivability gene signatures 
selection. The accuracies for non-survivable patients, survival patients and all 
patients of the 10 survival gene signatures over the 500 test sets were in the range 
of 94.2% to 96.1%, 99.8 to 100% and 98.3% to 98.9% respectively, and the 
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standard deviations of accuracy of all patients were in the range of 3.2~3.7%. The 
accuracies for non-survival patients, survival patients and all patients of the 21 
survival genes shared by all the 10 signatures over the 500 test sets were 90.5%, 
99.5% and 96.9% respectively, and the standard deviation of the accuracy of all 
patients was 4.0%. The performances of our selected genes were both higher and 
stabler than those of the other 9 studies, in which the accuracies for 
non-survivable patients, survival patients and all patients were in the range of 
52.5% to 66.6%, 81.8% to 96.8% and 75.6% to 88.3% respectively, and the 
standard deviations of accuracy of all patients were in the range of 5.8% to 8.0%. 
These results suggest that the survival gene signatures we selected can perform 
better than those selected by other studies by using the SVM classification system. 
Furthermore, our selected genes give stabler predictive performance demonstrated 
by low standard deviation values.  
 
The predictive accuracies of the 500 PNN classification systems for survivability 
prediction from the original Beer’ dataset (350) are shown in Table 4-8. The 
accuracies for non-survivable patients, survival patients and all patients of the 10 
survival gene signatures over the 500 test sets were in the range of 79.6% to 
89.8%, 95.9% to 98.9% and 93.4% to 95.5% respectively, and the standard 
deviations (STDEV) were in the range of 4.3% to 5.2%. The accuracies for 
non-survivable patients, survival patients and all patients of the 21 survival genes 
shared by all the 10 signatures over the 500 test sets were 75.1%, 96.2% and 
90.2% respectively, and the standard deviations of the overall accuracy was 5.7%. 
In contrast, the accuracies for non-survivable patients, survival patients and all 
patients of the 9 gene signatures from other studies over the 500 test sets were in 
the range of 57.2% to 76.1%, 73.5% to 89.7% and 72.1% to 80.6% respectively, 
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and the standard deviation were in the range of 7.5% to 11.0%. This comparison 
indicated that the performance of our selected gene signatures is better and stabler 
than those of other studies using the PNN classification methods for survivability 
prediction. 
 
Table 4-7 Average survivability prediction accuracy of 500 SVM 
class-differentiation systems constructed by 86 samples from Beer’s 
lung adenocarcinoma dataset (350). 
Non-survival patients Survivable patients 
Signature 
(method) 
Number of 
selected survival 
genes in 
signature 
TP FN SE TN FP SP 
Q STDEV
1* 51 5589 342 94.2% 15047 22 99.9% 98.3% 3.4%
2* 54 5671 260 95.6% 15043 26 99.8% 98.6% 3.2%
3* 42 5622 309 94.8% 15061 8 99.9% 98.5% 3.5%
4* 34 5630 301 94.9% 15037 32 99.8% 98.4% 3.3%
5* 46 5679 252 95.8% 15039 30 99.8% 98.7% 3.5%
6* 54 5664 267 95.5% 15054 15 99.9% 98.7% 3.7%
7* 57 5678 253 95.7% 15059 10 99.9% 98.7% 3.4%
8* 50 5694 237 96.0% 15069 0 100% 98.9% 3.3%
9* 53 5702 229 96.1% 15047 22 99.9% 98.8% 3.3%
10* 47 5686 245 95.9% 15052 17 99.9% 98.8% 3.3%
Genes selected 
by all sampling 
sets * 
21 5369 562 90.5% 14987 82 99.5% 96.9% 4.0%
Beer et al (350) 100 3951 1980 66.6% 14589 480 96.8% 88.3% 5.8%
Beer et al (350) 50 3302 2629 55.7% 14134 935 93.8% 83.0% 6.7%
Lu et al (353) 64 3526 2405 59.5% 13658 1411 90.6% 81.8% 6.4%
Lu et al (353) 125 3467 2464 58.5% 13570 1499 90.0% 81.1% 6.2%
Guo et al (349) 37 2760 3171 46.5% 13974 1095 92.7% 79.7% 7.0%
Chen et al 
(354) 16 2925 3006 49.3% 13702 1367 90.9% 79.2% 7.0%
Xu et al (355) 5 3696 2235 62.3% 12432 2637 82.5% 76.8% 7.5%
Chen et al 
(354) 5 3577 2354 60.3% 12325 2744 81.8% 75.7% 8.0%
Guo et al (349) 8 3113 2818 52.5% 12760 2309 84.6% 75.6% 7.3%
* Data from this study 
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Table 4-8 Average survivability prediction accuracies of the 500 PNN 
class-differentiation systems constructed by 86 samples from Beer’s 
lung adenocarcinoma dataset (350). 
Non-survivable patients Survivable patients Signature 
(Method) 
No. of selected 
predictor genes 
in signature TP FN SE TN FP QN 
Q STDEV
 1* 51 5069 862 85.5% 14635 434 97.1% 93.8% 4.8% 
 2* 54 5062 869 85.3% 14726 343 97.7% 94.2% 4.6% 
 3* 42 4939 992 83.3% 14715 354 97.7% 93.6% 4.7% 
 4* 34 4719 1212 79.6% 14904 165 98.9% 93.4% 5.2% 
 5* 46 5210 721 87.8% 14798 271 98.2% 95.3% 4.5% 
 6* 54 5326 605 89.8% 14730 339 97.8% 95.5% 4.3% 
 7* 57 5214 717 87.9% 14533 536 96.4% 94.0% 4.9% 
 8* 50 5089 842 85.8% 14707 362 97.6% 94.3% 4.5% 
 9* 53 5319 612 89.7% 14450 619 95.9% 94.1% 4.4% 
 10* 47 5100 831 86.0% 14571 498 96.7% 93.7% 4.8% 
Genes selected 
by all sampling 
sets* 
21 4454 1477 75.1% 14495 574 96.2% 90.2% 5.7% 
Beer et al (350) 50 3393 2538 57.2% 13523 1546 89.7% 80.6% 7.5% 
Beer et al (350) 100 4183 1748 70.5% 12648 2421 83.9% 80.1% 9.0% 
Lu et al (353) 64 4515 1416 76.1% 11700 3369 77.6% 77.2% 10.0%
Xu et al (355) 5 4205 1726 70.9% 11960 3109 79.4% 77.0% 7.5% 
Chen et al (354) 5 3601 2330 60.7% 11985 3084 79.5% 74.2% 7.9% 
Guo et al (349) 8 3743 2188 63.1% 11768 3301 78.1% 73.9% 8.2% 
Chen et al (354) 16 3569 2362 60.2% 11936 3133 79.2% 73.8% 7.8% 
Lu et al (353) 125 4310 1621 72.7% 11078 3991 73.5% 73.3% 12.5%
Guo et al (349) 37 3903 2028 65.8% 11232 3837 74.5% 72.1% 11.0%
* Data from this study 
 
4.3.4 Patient survival analysis using survival markers 
Hierarchical cluster analysis can cluster the samples according to their 
expression profiles across the gene we selected. The comparison of the survival 
curves from these clusters can be used to assess the statistical significance of the 
survivability difference among the clusters.  
 
By using 21 identified markers, hierarchical cluster analysis grouped 86 lung 
adenocarcinoma patients in the Beer’s dataset (350) into three clusters (Figure 
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4-3). Kaplan-Meier survival analysis showed that the survival time after therapy 
was significantly different in the three patient clusters (P<0.0001, log-rank test, 
Figure 4-4). Cluster 1 was the poor prognosis group. The average survival time of 
patients in this cluster was 50.6 months. In this cluster, the numbers of survivable 
patients (SP) and non-survivable patients (NSP) were 12 and 14 respectively 
(Table 4-9). The survival percentage, which defined by SP/(SP+NSP), were 46%. 
Cluster 2 was the good prognosis groups with average survival time of 82.2 
months. The SP, NSP and survival percentage were 26, 1 and 96% respectively. 
Cluster 3 was the moderate prognosis group with average survival time of 74.8 
months. The SP, NSP and survival percentage were 22, 9 and 72% respectively. 
By using the similar way, Guo et al (349) clustered these samples (350) into three 
clusters by using 37 genes and the survival percentages were 69%, 72% and 75% 
for poor, moderate and good prognosis clusters, respectively (Table 4-9). The 
survival percentage for three clusters generated by 100 genes in Beer et al (350) 
are 43%, 57% and 88% for poor, moderate and good prognosis clusters, 
respectively (Table 4-9). These results indicate that the 21 genes selected by using 
our method can be classified into better clinically meaningful groups for further 
prognosis than the genes selected by other group. 
 
Hierarchical clustering of the 21 genes on the independent validation dataset - 
Bhattacharjee’s dataset (351) showed the similar results (Figure 4-5). Three 
clusters had significant difference by using Kaplan-Meier analysis with P<0.001 
from log-rank test (Figure 4-6). The average survival time for cluster 1, which was 
poor prognosis group, was 35.7 months. The average survival time for cluster 2, 
which was moderate prognosis group, was 32.0 months. The average survival time 
for cluster 3, which was good prognosis group, was 78.3 months. The survival 
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percentages of the three clusters were 30%, 43 % and 73% for poor, moderate and 
good prognosis clusters, as shown in Table 4-10. By using the similar strategies, 
Guo et al (349) clustered the sample into three clusters. However, the survivability 
percentages among the clusters were 45%, 46% and 51% for three clusters by 
using the Kaplan-Meier analysis, showing little statistically different among the 
clusters (Table 4-9). The survival percentage of three clusters formed by 21 genes 
we selected were more spread out than those formed by the genes selected by 
other researchers, further suggesting that 21 genes we selected have robust 
behavior for prognosis prediction.  
 
Table 4-9 Comparison of the survival rate in clusters with other groups, by 
using different signatures and Beer’s microarray dataset (350). 
Poor prognosis cluster Moderate prognosis 
cluster 
Good prognosis 
cluster 
Study Gene 
number 
in 
signatures 
SP1 NSP2 Survival 
rate3 
SP NSP Survival 
rate 
SP NSP Survival 
rate 
This 
study 21 12 14 46% 22 9 72% 26 1 96% 
Guo’s 
group 
(349) 
37 25 11 69% 15 6 71% 20 7 74% 
Beer’s 
group 
(350) 4 
100 25 19 43% 23 19 57% 37 5 88% 
1 SP: the number of survivable patients 
2 NSP: the number of non-survivable patients 
3 Survival rate= SP/(SP+NSP)  
4 The cluster analysis was done on 128 lung cancer samples
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Figure 4-3 Hierarchical clustering analysis of the 21 lung adenocarcinoma 
survival markers from Beer’s microarray dataset (350). The tumor samples were 
aggregated into three clusters. Substantially elevated (red) and decreased (green) 
expression of the genes is observed in individual tumors. 
 
 
Patient cluster 1  
(Poor prognpsis) 
Patient cluster 2 
(Good prognosis) 
Patient cluster 3  
(Moderate prognosis) 
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Figure 4-4 Kaplan-Meier survival analysis of the three clusters of patients from 
Figure 4-3. Average survival time of patients in cluster 1 is 50.6 
months; average survival time of patients in cluster 2 is 82.2 months; 
average survival time of patients in cluster 3 is 74.8 months 
(P<0.0001, log-rank test). 
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 Figure 4-5 Hierarchical clustering analysis of the 21 lung adenocarcinoma 
markers from Bhattacharjee’s microarray dataset (351). The tumor samples were 
aggregated into three clusters. This 21-gene signature are shared by 10 survival 
genes sets of lung adenocarcinoma derived by using datasets from Beer et al (350) 
and by using multiple random sampling method. 
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Figure 4-6 Kaplan-Meier survival analysis of the three clusters of patients from 
Figure 4-5. Average survival time of patients in cluster 1 is 35.7 
months; average survival time of patients in cluster 2 is 32.0 months; 
average survival time of patients in cluster 3 is 78.3 months (P<0.001, 
log-rank test). 
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Table 4-10 Comparison of the survival rate in clusters with other groups, by 
using different signatures and Bhattacharjee’s microarray dataset 
(351). 
Poor prognosis cluster Moderate prognosis cluster Good prognosis cluster 
Study 
Gene 
number in 
signatures SP NSP Survival rate SP NSP 
Survival 
rate SP NSP 
Survival 
rate 
This 
study 21 10 23 30% 9 12 43% 22 8 73% 
Guo’s 
group 
(349) 
37 9 11 45% 11 13 46% 20 19 51% 
 
4.3.5 Hierarchical clustering analysis of the survival markers  
In the hierarchical analysis for 86 lung adenocarcinoma patients in the Beer’s 
dataset (350), 21 survival genes were formed into two clusters (Figure 4-7). Genes 
in gene cluster 1 are correlated with a poor prognosis of lung adenocarcinoma, 
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whereas genes in cluster 2 are correlated with a moderate prognosis of lung 
adenocarcinoma. Figure 4-3 shows that higher expression of the genes in cluster 1 
is associated with poor prognosis in patients in lung adenocarcinoma, and higher 
expression of the genes in cluster 2 is associated with moderate prognosis in 
patients in lung adenocarcinoma. On the other hand, the lower expression of all 
these 21 genes in both cluster 1 and 2 is associated with good prognosis. The 11 
poor-prognosis genes in cluster 1 are CXCR7, POLD3, ADFP, VEGF, SLC2A1, 
RPS3, LDHB, PLD1, SPRR1B, VDR, and TUBA4A, of which four genes, VEGF, 
CXCR7, TUBA4A and VDR, are therapeutic tumor targets. The 10 
moderate-prognosis genes in cluster 2 consist of PRKACB, CXCL3, REG1A, 
FUT3, GALNT4, FXYD3, CHRNA2, ANXA8, SERPINE1 and BSG. CHRNA2 is 
a molecular target for lung cancer therapy. The target information was obtained 
from the latest version of therapeutic target database (270, 271), 
 
Figure 4-7 Hierarchical clustering analysis of the 21 lung adenocarcinoma 
survival markers from Beer’s microarray dataset (350) 
 
Most of the selected genes were experimentally proved that high expression of 
these genes was related to adverse survivability of patients. High level of serum 
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VEGF (vascular endothelial growth factor) in the NSCLC may directly predict 
worse survival (403, 404), and acts as a crucial parameter in lung cancer, 
especially associated with NSCLC (403, 404). The expression of VDR (Vitamin D 
receptor) was observed in lung adenocarcinoma (405). Increased SLC2A1 (solute 
carrier family 2) expression in tumors was identified as an adverse prognostic 
factor and a predictive prognosis marker (406). Elevated PLD1 (phospholipase D1) 
activity could promote tumor progress and show high invasive potential (383, 
407-409). Up-regulated expression of FXYD3 (FXYD domain containing ion 
transport regulator 3) in cancer indicated that FXYD3 might contribute to the 
proliferative activity of malignancy (380). In vivo experiments demonstrated that 
BSG (basigin; CD147) overexpression stimulated tumor angiogenesis and growth 
(367). Higher expression of FUT3 (fucosyltransferase 3) was often observed in 
high grade and poor prognosis tumors (410). The expression level of SERPINE1 
(plasminogen activator inhibitor-1) in tissue was significantly and positively 
correlated with tumor severity and tumor size (411), and high level of SERPINE1 
could indicate an aggressive phonotype of carcinomas (412, 413), serving as an 
indicator of poor prognosis in adenocarcinomas of the lung (414). REG1A 
(regenerating islet-derived 1 alpha) expression was reported to be closely related 
to the carcinoma invasiveness of neoplasm (415), and to be an independent 
predictor of overall cancer patient survival as well (416). The over-expression of 
SPRR1B (small proline-rich protein 1B (cornifin) ) for prolonged periods might 
disrupt normal progression of mitosis (397). Therefore, the expression of most of 
our selected survival marker genes has been validated as either directly or closely 
related to cancer metastasis and prognosis in the literatures. 
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4.3.6 Therapeutic target prediction of survival markers 
4.3.6.1 The prediction results 
Therapeutic target prediction system (268), which was developed by Han et al, 
can be applied to predict the function of the survival markers. The detailed 
information and performance evaluation of this system were introduced in Chapter 
2 (Section 2.2.3) and Chapter 3 (Section 3.3.8). Table 4-11 shows the prediction 
results. All of the five known therapeutic targets (VEGF, CXCR7, CHRNA2, 
TUBA4A and VDR) were predicted correctly. 7 markers (SERPINE1, PLD1, 
RPS3, BSG, ANXA8, LDHB and SLC2A1) were predicted as novel therapeutic 
targets.  
 
4.3.6.2 The function of the known targets  
The five known targets play important roles for lung cancer survivability from 
the literature searches. It was reported that VEGF induction might promote 
angiogenesis in lung adenocarcinoma (417), and genetic variations in VEGF 
might predict both carcinoma risk and tumor aggressiveness (418). CXCR7 
(chemokine receptor 7) (364, 370, 386, 387) and CHRNA2 (cholinergic receptor, 
nicotinic, alpha 2) (364, 374, 375) are molecular targets for lung cancer therapy. 
CXCR7 (chemokine (C-X-C motif) receptor 7) has properties that affect a 
spectrum of biological and pathological processes, including cell growth/survival 
and adhesion, as well as promotion of tumor growth (386). TUBA4A (Tubulin 
4A), as a successful anticancer target (419), can moderate drug resistance in lung 
carcinoma (400). VDR (Vitamin D receptor) polymorphisms may be associated 
with improved survival among SCC patients of early-stage NSCLC (420).  
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Table 4- 11Prediction result from therapeutic target prediction system 
Gene name Gene function Prediction status 
VEGF therapeutic target for lung cancer therapy, angiogenesis gene target 
CXCR7 therapeutic target for lung cancer therapy, immune tolerance gene target 
CHRNA2 therapeutic target for lung cancer therapy target 
TUBA4A successful tumor target, angiogenesis gene target 
VDR research tumor target, cancer gene target 
SERPINE1 angiogenesis gene target 
PLD1 cancer gene target 
RPS3 cancer gene target 
BSG tumor marker, angiogenesis (stimulate angiogenesis genes), immunoangiostasis target 
ANXA8   target 
LDHB   target 
SLC2A1   target 
SPRR1B cancer gene   
CXCL3 oncogene, immune tolerance gene, angiogenesis gene   
PRKACB     
ADFP     
FUT3     
FXYD3     
GALNT4     
POLD3     
REG1A     
 
4.3.6.3 The function of the predicted novel targets  
Literatures also indicated the important roles of the 4 of the 7 novel targets 
(SERPINE1, PLD1, RPS3 and BSG) in lung adenocarcinoma progression. 
Currentky there is no biological evidence that the other 3 novel targets (ANXA8, 
LDHB and SLC2A1) involve in lung cancer progress .  
 
SERPINE (plasminogen activator inhibitor-1), a component of 
plasminogen/plasmin system, is an important player in tumor growth, invasion 
and metastasis, through the regulation of cellular proteolysis, adhesion, 
proliferation, migration, and processes closely related to the pathogenesis of lung 
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injury and neoplasia (421-423). Therefore, SERPINE have previously been 
suggested as prognostic markers in NSCLC (414, 423). 
 
PLD1 (Phospholipase D1), which is recognized as a receptor-regulated signaling 
enzyme that can modulate many cellular functions, plays an important role in 
signal transduction (424). Endogenous PLD1 is a critical factor in the organization 
of the actin-based cytoskeleton, with regard to cell adhesion and migration (382) 
and a critical downstream mediator of H-Ras-induced tumor formation. PLD1 is 
critical in the oncogenic ability of Ras (425). Elevated PLD activity generates 
survival signals allowing cells to overcome default apoptosis programs (383) and 
contributes to the cell's high invasive potential in a protein 
phosphorylation-independent manner (409). 
 
RPS3 (ribosomal protein S3), a component of the 40S ribosomal subunit of 
eukaryotes, plays a role as a base damage endonuclease. It induces apoptosis 
whose signal is executed through the activation of caspase-8 followed by 
caspase-3 activation, and increases the proapoptotic potential of cytokines(390). It 
was suggested that DNA repair pathway and apoptosis pathway might cross-talk 
via RPS3 (390). RPS3 inhibits tumor invasion via blocking the ERK pathway and 
MMP-9 secretion. The interaction of RPS3 and nm23-H1, a metastasis suppressor, 
may be critical in this inhibition (391).  
 
BSG (Basigin) mediates tumor-stroma interactions and directly contributes to 
tumor invasion, metastasis, tumor angiogenesis and growth by stimulating 
extracellular matrix remodeling around tumor cell clusters, stroma, and blood 
vessels (366) and by stimulating VEGF and MMP expression (367).  
Chapter 4 Lung adenocarcinoma survival marker selection  
138 
 
The literature searching indicated that our gene selection method could identify 
therapeutic targets. The therapeutic target prediction system can be incorporated 
into this system to predict the novel therapeutic targets.  
 
4.3.6.4 The function of other survival markers  
The other identified survival markers may also involve in cancer progress. 
FUT3 plays an important role in organ-specific metastasis (426). FXYD3 plays an 
important role in cellular growth of carcinomas (380). PRKACB (protein kinase, 
cAMP-dependent) plays different roles in proliferation and differentiation and 
could be potential markers for cancer progression (385). SPRR1B is likely 
coupled to signals responsible for withdrawal from the proliferative state (397). 
The analysis showed that the function of the identified survival markers might 
have direct impact on cancer development in the literatures.  
 
4.4 Summary 
In this chapter, the comprehensive gene selection system was further 
evaluated on the selection of survival marker for lung adenocarcinoma. By way of 
multiple random sampling, 21 genes were selected by all of ten sets of lung 
adenocarcinoma survival marker signatures, in which 34 to 53 genes were selected. 
These 21 markers were then used to develop PNN and SVM prediction models to 
predict prognosis for lung adenocarcinoma patients from different datasets. The 
survivability analysis by hierarchical clustering analysis and Kaplan-Meier 
survival analysis further suggested that the derived signatures from our system 
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could provide better performance when comparing with other signatures. Most of 
the selected genes have been experimentally proved that high expression of the 
genes is relevant to adverse survivability of patients. 12 markers, including 5 
known targets and 7 novel targets, were successfully predicted as therapeutic 
targets by using a therapeutic target prediction system.  
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5 The development of bioinformatics tools for disease 
targeting antibody prediction 
An important application for gene selection from microarray data is to 
discover potential disease targets which can be used for therapeutic molecule 
design and achieve the goal of treatment and prevention of disease. Antibody, as a 
very effective therapeutic molecule, was chosen in this chapter as an example of 
therapeutic molecular. A computational tool for therapeutic antibody prediction 
was developed in this chapter. First, we developed an immunoinformatics 
database - antibody-antigen information resource (AAIR) (Section 5.2). This 
database provides information about the known antibody and its corresponding 
antigen together with the targeted disease and the diagnosis and therapeutic 
indications (Section 5.3). Then, a statistical analysis of this database is presented 
(Section 5.4), which helps to explain the trends of antibody therapeutic 
development. Finally, a preliminary SVM prediction model is built for therapeutic 
antibody design (Section 5.5). Such information may provide useful hints about 
the current trends for the exploration of the antibodies and for disease treatment.  
  
5.1 Introduction 
Targeted therapy is a type of treatment which is based on the idea that 
therapeutic molecules will attack their specific molecular targets involved in 
pathogenesis and disease progress without damaging other tissue (155, 156). 
Currently, antibodies, as a frequently used form of therapeutic molecule, can 
specifically act on the disease-causing targets (antigens) (15) on many diseases 
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such as cancer (16), heart disease (160) and rheumatic diseases (161).  
 
The discovery of potential target genes is greatly facilitated by microarray 
technology (30), which was also shown in Chapters 3 and 4. Microarray can be 
used to discover the upregulated genes in disease status or bad prognosis. Those 
upregulated genes with important biological clues give a strong indication to act 
as potential targets for therapeutic molecular design, including antibody design 
(427).  
 
The research and application of therapeutic antibodies grow very fast, and 
antibody is the second largest class of drugs (167). This chapter covers the usage 
of antibody as an example for therapeutic molecular design. As a well-established 
drug class, the successful rate of antibody therapeutics is 18−29% from the first 
use in humans to regulatory approval (162), much higher than 11% of successful 
rate for small-molecule drugs (159).  
 
However, the development of antibody has not been an easy task because the 
behavior of antibodies seems to vary, even though they have similar structures 
(177). The explosive growth in biotechnology combined with major advances in 
informatics technology has the potential to radically transform immunology (196). 
Publicly accessible resources, which include the rapidly increasing number of 
databases of immunoinformatics and computational tools, can be used for 
antibody design.  
 
All therapeutic applications of antibodies are based on their ability to recognize 
specific target molecules – antigens. Much effort has been done to understand the 
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antibody-antigen interaction for generation and optimization of antibodies to 
improve their potential in the prevention and treatment of disease. The rapid 
advances in informatics technology and computational technology may be helpful 
to understand the antibody-antigen interaction (428, 429). Since the interaction 
between targets (antigens) and their corresponding therapeutic molecules 
(antibodies) are very important for targeted therapy, in this chapter we constructed 
a bioinformatics database emphasizing on the sequence-recognition of antibody 
and antigens and their disease indication. A computational tool can be developed 
based on the information from the database. 
 
5.2 The development of antibody information database 
5.2.1 The objective of the AAIR development 
Molecular-level information about antibody-antigen (Ab-Ag) recognition is 
critically important because it can help to understand the mechanism of immune 
responses, to discover new vaccines, antibody-based drugs and diagnostic tools 
(167). A number of immunological databases have been developed (KABAT (197), 
IMGT (200), IEDB (205), FIMM (202), MMDB (203), JenPep (204), SACS (209), 
BCIPEP (214), VBASE2 (215), TumorAntigen database (216), AntiJen (220), 
HaptenDB (206), Epitome (207) and CED (221) etc). These databases provide 
valuable information about the antibodies and antigens, such as sequences (IMGT, 
KABAT, FIMM, BCIPEP), structures (IMGT, IEDB, MMDB, SACS), epitope 
information (IEDB, FIMM, Epitome, CED), binding information (IEDB, JenPep, 
AntiJen, Epitome) and disease implication (IMGT, FIMM). However, it tends to 
be difficult to extract the information of targeted diseases, the therapeutic 
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indications and sequence-level recognition data (i.e. which antibody sequence 
recognizes which antigen sequence or sequences) from these databases. Although 
other database such as the epitome database (207) contains sequence-specific 
information about antibody and antigen interactions, it only covers a limited 
number of antigen-antibody pairs obtained from protein Databank (194). As a 
result, there is a need to develop a database capable of providing both easily 
accessible information and more comprehensive coverage of sequence-specific 
Ab-Ag recognition to complement existing databases. 
 
5.2.2 The collection of related information 
Three classes of information should be included: The first class is antigen 
information that includes antigen name sequences, function and source organism. 
The second is antibody information that contains antibody isotype, source 
organism, molecular and structural type of antibody. The third is disease and 
therapeutic information that describes disease class, targeted disease, diagnosis 
and therapeutic indication. Figure 5-1 shows the detailed information included in 
AAIR.  
 
The entries of the database were obtained by a comprehensive search of published 
literatures via Medline (277). Specifically, in order to collect the data for AAIR 
development, keywords such as “antibody”, “antibodies”, and “immunoglobulin” 
were used to search those literatures containing both the antibody sequence and 
the corresponding antigen or antigens. Meanwhile, the sequence of the 
corresponding antigen or antigens were obtained either from the respective 
literatures (if they are described in that literature) or from the protein sequence
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Figure 5-1 Structure of AAIR  
(http://bidd.nus.edu.sg/group/antibody/antibody.asp) 
 
 
database Swiss-Prot based on the name and host species of the antigen or antigens. 
Other information such as disease and therapeutic indications was retrieved by 
using keywords either as a combination of “disease” and the name of antibody (if 
available) or as a combination of “disease”, “antibody” and antigen name.  
 
5.2.3 The construction of AAIR database  
AAIR is a relational database, which represents the antibody-antigen 
interaction database in the form of two-dimension tables. The two-dimensional 
tables include antibody-antigen pair ID table (Table 5-1), antibody-antigen pair 
AAIR 
Antibody 
information 
Antigen 
information 
Disease information 
Diagnosis and therapeutic 
indication 
z Name 
z Function 
z Source organism 
z Epitope 
information (if 
available) 
z Protein sequence 
z Nucleotide 
sequence 
z Chromosome 
position 
z Link to NCBI  
z References 
z Name 
z Isotype 
z Structural type 
z Molecule type 
z Source organism and strain 
z Production method 
z Identification method 
z Affinity constant of Ab-Ag 
pair (if available) 
z Protein sequence 
z Nucleotide sequence 
z Chromosome position 
z Link to NCBI 
z References 
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main information table (Table 5-2), antibody-antigen pair data type table (Table 
5-3), antibody or antigen information table (Table 5-4), antibody or antigen data 
type table (Table 5-5), and reference information table (Table 5-6). In these tables, 
antibody-antigen pair ID serves as primary key; antibody-antigen pair data type 
ID, antibody or antigen ID, antibody or antigen Data type ID and reference ID are 
considered as foreign keys. 
Table 5-1 Antibody-antigen pair ID table 
Antibody-antigen pair ID The antigen name of this pair 
AAIR0001 HEL 
AAIR0002 AahII 
  
 
Table 5-2 Antibody-antigen pair main information table 
Antibody-antigen 
pair ID 
Antibody-antigen 
pair data type ID 
Antibody-antigen pair 
data content 
AAIR0001 101 AA5523  
AAIR0001 102 AA5524  
AAIR0001 103 AA1396 
AAIR0001 104 6806606 
AAIR0001 106 Food Allergy 
   
 
Table 5-3 Antibody-antigen pair data type table 
Antibody-antigen pair 
data type ID 
Data type 
101 Antibody heavy chain ID 
102 Antibody light chain ID 
103 Antigen ID 
104 Reference 
105 Disease indication 
  
 
Table 5-4 Protein information table 
Antibody or 
antigen ID 
Antibody or antigen 
Data type ID 
Data content 
AA5523 101 AAA39270 
AA5523 102 Mus musculus (house mouse) 
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Table 5-5 Protein data type table 
Antibody or antigen Data type ID Data content 
101 Locus 
102 Source Organism 
  
 
Table 5-6 Reference information table 
Reference ID Reference 
6806606 Kobayashi T, Fujio H et al, A monoclonal antibody specific for 
a distinct region of hen egg-white lysozyme. Mol Immunol. 
1982 Apr;19(4):619-30 
  
 
5.2.4 The interface of the AAIR database  
Basically AAIR web interface comprise four layers, and the top layer is the 
main graphical user interface with a querying tool for finding specific entries. The 
searching results followed by some specific matching rules will be listed in the 
second layer. By clicking into each pair entry, the browser can access the detailed 
information for this interacted pairs, which is displayed in the third layer. More 
information about antibody and antigen is given in the fourth layer.  
 
The AAIR database can be found at the website 
http://bidd.nus.edu.sg/group/antibody/antibody.asp. Entries of this database are 
searchable by several methods. These methods include the search of antigen 
information (names or source organisms), antibody information (isotype, source 
organism, molecular type or structure type), disease and therapeutic information 
(disease classes, disease names, or diagnosis and therapeutic indications). The 
disease classes are defined by the international classification of diseases from 
World Health Organization (430). The diseases names and diagnosis and 
therapeutic indications are derived from the related terms described in the relevant 
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publications. Full list of antigen names, antibody information, disease names, 
disease classes, and diagnosis and therapeutic indications are provided on the web 
page for facilitating the search of particular entries.  
  
Moreover, case-insensitive keyword-based text search and wildcards are also 
supported. In a query, one can specify full name or part of the name in a text field. 
For instance, wild characters of '*' and '?' are allowed in the text field. In this case, 
'?' represents any single character, and '*' represents a string of characters of any 
length. As an example, input of ‘phosphatase’ in the field of antigen name enables 
the search of all entries containing the antigen name of ‘phosphatase’ such as heat 
stable alkaline phosphatase, acid phosphatase, anti-placental alkaline phosphatase 
antibody, small guanosine triphosphatase (GTPase) Rab6 etc. As another example, 
input of ‘heat*phosphatase’ enables the finding of all phosphatases whose names 
start with ‘heat’.  
 
The outcome of a typical search result is illustrated in Figure 5-2. In this interface, 
all entries that satisfy search criteria are listed along with AAIR antibody-antigen 
pair entry ID, antibody name (extracted from the original publications), antigen 
name, targeted disease and diagnosis/therapeutic indication. More detailed 
information of an antibody-antigen pair entry can be obtained by clicking the 
corresponding pair ID. The result is displayed in an interface shown in Figure 5-3, 
from which one may find the three classes of information. The first class is 
antibody information which includes antibody sequence, isotype, structure and 
biochemical type, source organism/strain, production and identification method, 
and affinity constant with relevant antigen. The second is antibody-targeted 
antigen information which consists of antigen name, function, source organism 
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and epitope position or sequence. The third is disease and therapeutic information 
of the retrieved antibody which includes targeted disease, and diagnosis and 
therapeutic indications. For completeness, the relevant references are provided in 
the interface. 
 
Further information about each antibody or antigen entry can be retrieved from an 
interface by clicking the corresponding entry ID, as illustrated in Figure 5-4. From 
this interface, one can locate antibody or antigen name, entry ID, source organism 
and strain/isolate, protein sequence and NCBI Entrez protein (277) ID, related 
DNA sequences and Entrez nucleotide (277) ID. Antibody entry provides 
additional information such as tissue type, development stage, cell line, cell type, 
clone, the express system, cell line/strain and host plasmid/vector, while antigen 
entry provides functional information. Similarly, related references and links to 
Entrez protein and nucleotide are provided in the interface.  
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Figure 5-2 The interface displaying a research result on AAIR. All entries that 
satisfy the specified search criteria are listed along with the Ab-Ag 
pair ID, antibody name, antigen name, targeted disease type and 
diagnosis and therapeutic indications in this database. 
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Figure 5-3 Interface displaying the detailed information of an antibody-antigen 
pair in the AAIR  
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Figure 5-4 Interface displaying the detailed information of an antibody entry in 
AAIR.  
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5.3 Statistic analysis of disease targeting antibody information 
database 
The disease targeting antibody information database currently contains 2,777 
antibody-antigen pairs covering 159 disease conditions, 2,035 heavy chain 
sequences (535 IgG (232 IgG1, 37 IgG2a, 14 IgG2b, 6 IgG3 and 4 IgG4), 52 IgM 
and 23 IgE), and 1,701 light chain sequences (693 kappa and 113 lambda), 619 
distinct antigen sequences (584 proteins and 35 other type of molecules), 254 
antigen epitope sequences and 157 binding affinity constants for Ab-Ag pairs, 
from various viruses, bacteria, tumor types, and autoimmune responses. With the 
rapid advances in genomics (431), proteomics (431, 432), immunology (433) and 
biotechnology (434), new entries about disease targeted antibody can be 
incorporated or the corresponding database can be cross-linked to AAIR database 
to provide more comprehensive information about the disease targeted antibody, 
corresponding antigen, and related disease and therapeutic information. It is 
expected that a significantly higher number of entries of naturally occurring 
antibodies can be included in this and other databases as the relevant information 
are being made available from the vast number of medical studies and therapeutic 
explorations.  
 
5.3.1 Distribution pattern of antibody-antigen pairs 
5.3.1.1 Distribution pattern of antibody-antigen pairs with respective disease 
classes 
Ab-Ag recognition has been widely explored for disease treatment (167, 
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435-437) . Table 5-7 lists the distribution pattern of Ab-Ag pairs involved in 
disease classes. The Ab-Ag pairs involved in infectious and parasites diseases, 
immunity disorders, and neoplasms contain 1123, 587, and 398 pairs, respectively. 
They constitute the group which has the largest number of Ab-Ag pairs. Other 
disease types composed of a substantial number of Ab-Ag pairs (indicated by the 
numerical number in brackets) are skin and subcutaneous tissue disease (143), 
circulatory system disease (119), musculoskeletal system and connective tissue 
diseases (108), blood and blood-forming organs diseases (92), nervous system and 
sense organs diseases (87), injury and poisoning (67), endocrine disorders (52), 
congenital anomalies (47), and digestive system diseases (45).  
 
Table 5-7 Distribution pattern of antibody-antigen pairs involved in different 
disease classes 
Disease Class Number of Ab-Ag pairs
Percentage in the 
AAIR database 
Infectious and parasitic diseases 1123 40.4% 
Immunity disorders 587 21.1% 
Neoplasms 398 14.3% 
Skin and subcutaneous tissue diseases 143 5.1% 
Circulatory system diseases 119 4.3% 
Musculoskeletal system and connective 
tissue diseases 108 3.9% 
Blood and blood-forming organs diseases 92 3.3% 
Nervous system and sense organs diseases 87 3.1% 
Injury and poisoning 67 2.4% 
Endocrine disorders 52 1.9% 
Congenital anomalies 47 1.7% 
Digestive system diseases 45 1.6% 
Inflammation 27 1.0% 
Respiratory system diseases 21 0.8% 
Nutritional and metabolic diseases 17 0.6% 
Genitourinary system diseases 13 0.5% 
Mental disorders 6 0.2% 
 
The distribution pattern of Ab-Ag involved in disease types are listed in Table 5-8. 
Antibodies targeting cancer, influenza, HIV infection, allergy, rabies and hepatitis, 
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which contain 398, 220, 167, 158, 150, and 116 antibodies respectively, constitute 
the group with the largest number of antibodies.  
 
Table 5-8 Distribution pattern of antibody-antigen pairs involved in different 
disease types (only those disease types with more than 25 antibodies 
are listed here) 
 
Disease Type Numbers of Ab-Ag pairs
Percentage in the 
AAIR database 
Cancer 398 14.4% 
Influenza 220 8.0% 
HIV Infection 167 6.1% 
Allergy 158 5.7% 
Rabies 150 5.4% 
Hepatitis 116 4.2% 
Lupus 88 3.2% 
Organ Transplantation 78 2.8% 
Cytomegalovirus 
Infection 58 2.1% 
Prion Disease 55 2.0% 
Rheumatoid Arthritis 55 2.0% 
Sjogren's Syndrome 47 1.7% 
Botulinum Intoxication 42 1.5% 
Graves' Disease 42 1.5% 
Staphylococcal Infection 42 1.5% 
Multiple Sclerosis 41 1.5% 
Rotavirus Infection 37 1.3% 
Anthrax Infection 36 1.3% 
Thyroid Disease 35 1.3% 
Thyroiditis 32 1.2% 
Vitiligo 32 1.2% 
Injury 31 1.1% 
Heart Block 28 1.0% 
Thrombocytopenia 28 1.0% 
Alzheimer's Disease 26 0.9% 
Rheumatic Heart 
Disease 26 0.9% 
Rheumatic Disease 26 0.9% 
Myocarditis 25 0.9% 
   
The most common and earliest application of antibodies is the detection and 
treatment of viral, bacterial and other types of infection (166). Our database 
includes 1123 entries related to infectious and parasites diseases, such as influenza, 
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rabies, hepatitis, HIV infection, prion disease, staphylococcal infection, rotavirus 
infection and anthrax infection. For examples, 80 antibodies targeted on HIV 
glycoprotein gp120, 31 antibodies targeted on HIV glycoprotein gp41, 147 
antibodies on rabies virus glycoprotein, and 36 antibodies on cytomegalovirus 
glycoprotein B are included in AAIR database.  
 
Cancer treatment is another crucially important application for antibody (438). In 
the development of our database, one of the major focuses is to collect as much as 
possible numbers of cancer-related antibody and its corresponding antigen. AAIR 
database includes 398 Ab-Ag pairs involved in breast cancer, colon cancer, 
non-Hodgkin’s lymphoma, leukemia and other cancers. The most common cancer 
targets are epidermal growth factor receptor (EGFR), ERBB2 (also known as 
HER2/neu, associated with lung and breast cancer), CD52 on lymphocytes, CD20 
on B cells (a marker for non-Hodgkin’s lymphoma (NHL)) and vascular 
endothelial growth factor (VEGF). In our database we include 5, 15, 5, 6, 5 
antibody-antigen pairs for EGFR, ERBB2, CD52, CD20 and VEGF respectively. 
These cancer targets are the most popular antigens of the FDA approved 
anticancer antibodies, for example, Erbitux (Cetuximab) and Vectibix 
(Panitumumab) which target EGFR for Metastatic colorectal cancer treatment and 
head and neck cancer treatment, herceptin (Trastuzumab) which targets ERBB2 
for metastatic breast cancer treatment (167), campath (Alemtuzumab) which 
targets CD52 for B-cell chronic lymphocytic leukemia treatment, bexxar 
(Tositumomab), rituxan (Rituximab) and zevalin (Ibritumomab tiuxetan) which 
target CD20 for non-Hodgkin’s lymphoma treatment (166, 167), and Avastin 
(Bevacizumab) and Lucentis (Ranibizumab) which target VEGF so as to inhibit 
angiogenesis for the treatment of breast cancer and colorectal cancer.  
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Our database also includes a substantially number of antibodies targeted on 
cytokines and cytokine receptors which are associated with inflammation and 
autoimmunity for the treatment of inflammatory diseases such as rheumatoid 
arthritis and nephritis (166) and transplant rejection. These cytokines and cytokine 
receptors include tumor-necrosis factor-alpha (TNFalpha), complement proteins, 
interleukins (IL), and interleukin receptors. There are 16 antibodies targeted for 
TNFalpha, 6 antibodies for complement proteins, 11 antibodies for interleukin 2 
and 6 antibodies for interleukin 2 receptor in AAIR database. These targets are the 
most popular antigens of the FDA approved antibodies for the treatment of 
inflammatory diseases and transplant rejection. TNFalpha was targeted by Humira 
(Adalimumab) and Remicade (Infliximab) in the treatment of Inflammatory 
diseases (mostly auto-immune disorders), interleukin 2 receptor was targeted by 
Simulect (Basiliximab) and Zenapax(Daclizumab) in the treatment of transplant 
rejection, complement protein C5 was targeted by Soliris (Eculizumab) in the 
treatment of Inflammatory diseases such as paroxysmal nocturnal hemoglobinuria.  
 
5.3.1.2 Distribution pattern of antibody-antigen pairs with respective Pfam of 
antigen  
We also investigated the distribution pattern of protein families of antigens in 
the database. Pfam, a comprehensive database of protein families, which contains 
over 8957 protein families in the current release (version 21.0) (272), was 
employed herein. It has been widely used for protein function prediction (236) and 
protein structure prediction (439). The family that Pfam provides is the domain 
family, and was widely used in protein function prediction (236) and protein 
structure prediction (439). The disease related antibody can be classified recording 
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to the Pfam of corresponding antigen. Table 5-9 shows the distribution pattern of 
Ab-Ag pairs with respect to the Pfam of corresponding antigen. Most of the 
antigens belong to PF01500 (Keratin B2 protein), PF02440 (Adenovirus E3 
region protein CR1) and PF00509 (Hemagglutinin).  
 
Table 5-9 Distribution pattern of antigen in different Pfam (only those Pfams 
with more than 50 antigens are listed here) 
Pfam Description 
Number of 
antigens in AAIR 
database 
PF01500 Keratin B2 protein 124 
PF02440 Adenovirus E3 region protein CR1 92 
PF00509 Hemagglutinin 89 
PF01464 Transglycosylase SLT domain 81 
PF01686 Adenovirus penton base protein 80 
PF00516 Envelope glycoprotein GP120 80 
PF00517 Envelope Polyprotein GP41 75 
PF07654 Immunoglobulin C1-set domain 75 
PF08791 Viral envelope protein 72 
PF00062 C-type lysozyme/alpha-lactalbumin family 72 
PF06737 Transglycosylase-like domain 72 
PF08205 CD80-like C2-set immunoglobulin domain 72 
PF08475 Viral capsid protein 91 N-terminal 69 
PF03236 Domain of unknown function DUF263 69 
PF04110 Ubiquitin-like autophagy protein Apg12 69 
PF00431 CUB domain 69 
PF02525 Flavodoxin-like fold 68 
PF04839 Plastid and cyanobacterial ribosomal protein (PSRP-3 / Ycf65) 67 
PF03056 Env gp36 protein (HERV/MMTV type) 63 
PF03151 Triose-phosphate Transporter family 60 
PF03217 Bacterial surface layer protein 57 
PF07690 Major Facilitator Superfamily 56 
PF07951 Clostridium neurotoxin, C-terminal receptor binding 56 
PF03595 C4-dicarboxylate transporter/malic acid transport protein 55 
PF05316 Mitochondrial ribosomal protein (VAR1) 55 
PF03938 Outer membrane protein (OmpH-like) 54 
PF02489 Herpesvirus glycoprotein H 52 
PF03600 Citrate transporter 50 
PF07554 Uncharacterised Sugar-binding Domain 50 
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5.3.2 Statistical analysis of sequence specificity of antibody-antigen 
recognition 
While there are many instances of antibodies interacting with multiple 
antigens and antigens interacting with multiple antibodies, antibodies typically 
recognize their target antigen selectively. This indicates that each antibody binds 
specifically to a particular antigen sequence, which is a key feature for therapeutic 
applications of antibodies (167). Furthermore, it is uncommon for antibodies to 
bind the corresponding antigen from different species. Therefore, the level of 
sequence selectivity can be analyzed from the sequence data of AAIR. As an 
example, the level of selectivity of antigen recognition can be characterized by the 
extent of sequence variation of the antigens recognizable by antibodies with 
different sequence variations, which can be measured by the sequence variations 
of VH-VL of the antibodies. As a result, this method can be used to address the 
questions such as whether antibodies differing by a few amino acids are able to 
selectively recognize antigens differing by both lower (close homologues) and 
higher number of amino acids (remote homologues). 
 
A statistical picture about sequence selectivity of antigen recognition in the known 
Ab-Ag pairs was obtained by the following study: First, all antibody pairs 
generated from antibodies of the known Ab-Ag pairs were grouped into classes 
that differ by one, two, …, and n number of amino acids of VH-VL of the 
corresponding antibodies. The sequence variation among the corresponding 
antigen pairs for the antibody pairs in each antibody group was then analyzed to 
determine to what extent the VH-VL of antibodies that differ by one to n number 
of amino acids were able to selectively recognize antigens that differ by one to m 
number of amino acids. 
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Table 5-10 summarizes the distribution of antigen pairs differing by one to 2815 
amino acids selectively recognized by antibodies in which VH-VL differ by one to 
208 amino acids. It can be found that a substantial number of antibodies, in which 
VH-VL differ by a few amino acids, are capable of specifically recognizing 
antigens that differ by both a few amino acids and up to 208 amino acids. One 
example of such antigen pairs is horse cytochrome C and mouse cytochrome C, 
which can be recognized by antibody E8 and CA4-1 respectively. The sequences 
of the VH-VL in the two antibodies differ by 1 amino acid only, compared to the 
difference of 93 amino acids between horse cytochrome C and mouse cytochrome 
C. Another example of such antigen pairs is Der p I allergen and Human Heat 
Shock Protein 70. The sequence variation of these two antigens is 228 amino acids, 
compared to the difference of 2 amino acids between the VH-VL of their 
corresponding antibodies. It can be inferred that antibodies in which the VH-VL 
showing small variations are able to selectively recognize antigens of both close 
and remote homologues that differ by both lower and higher number of amino 
acids.  
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Table 5-10 Distribution of antigens of different sequence variations that can be selectively recognized by antibodies in which the VH-VL differ 
by one to 208 amino acids 
Number of corresponding antigen pairs with different sequence variation 
Sequence variation 
between antibodies 
(VH-VL) 
Number of 
antibody pairs 
with this 
sequence 
variation 
variation 
by 1 
amino 
acid 
variation 
by 2~5 
amino 
acids 
variation 
by 6~10 
amino 
acids 
variation 
by 11~20 
amino 
acids 
variation 
by 21~50 
amino 
acids 
variatio
n by 
51~100 
amino 
acids 
variation 
by 
101~150 
amino 
acids 
variation 
by 151~200 
amino 
acids 
variation 
by 
201~250 
amino 
acids 
variation 
by >250 
amino 
acids 
1 amino acid 385 120 60 0 1 0 2 195 7 0 0 
2~5 amino acids 422 135 31 11 8 1 7 218 4 0 7 
6~10 amino acids 73 5 0 0 2 3 0 43 3 0 17 
11~20 amino acids 499 61 5 15 0 11 2 369 2 0 34 
21~50 amino acids 486 8 2 9 13 50 62 93 60 40 149 
51~100 amino acids 9728 44 38 126 266 348 1798 1956 1135 914 3103 
101~150 amino acids 367506 2946 1175 3730 5658 11998 49914 78513 61655 27948 123969
151~200 amino acids 1175133 7442 5993 19033 18591 40122 148014 259527 199895 95245 381271
>201 amino acids 80842 346 238 1175 1374 2757 9193 13481 14861 9160 28257 
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5.4 Prediction performance of disease targeting antibody 
prediction system  
5.4.1 Overview of the prediction system 
The antibody-antigen sequence-recognition information in the AAIR database 
is very important to understand the mechanism of antibody-antigen interaction and 
helpful for vaccine design and antibody design. Therefore, we developed some 
prototype prediction systems based on the sequence information of antibodies and 
antigens which either makes use of all data, or is restricted to a certain disease or 
Pfam. It was expected that this prototype system can be further extended for 
antibody design and vaccine design. 
 
5.4.2 Prediction performance  
5.4.2.1 Prediction performance of machine learning model for prediction 
antibody-antigen pairs involved in certain diseases.  
Figure 5-11 give the performance of SVM prediction of Ab-Ag pairs for some 
datasets generated from AAIR using the 5-fold cross validation method described 
above. The four datasets in Figure 5-11 contain Ab-Ag pairs involved in four 
disease types, which are cancer, influenza, HIV infection, and allergy. The 
corresponding non-Ab-Ag pairs in each dataset contain two parts. For those 
antibodies and antigens in Ab-Ag pairs, random pairing of antibodies with 
antigens of other antibodies forms one part. Another part is selected as a 
representative Ab-Ag pairs which are not involved in this disease types.  
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The prediction accuracies for antibody-antigen and non-antibody-antigen pairs 
involved in cancer, influenza, HIV infection, and allergy were in the range of 
96.9% to 97.7%, 95.5% to 97.9%, 94.1% to 96.7%, and 92.6% to 95.4% 
respectively, suggesting that SVM is potentially useful for predicting 
antibody-antigen pairs.  
 
Table 5-11 Performance evaluation of SVM prediction system of 
antibody-antigen pairs involved in cancer, influenza, HIV infection 
and allergy by using five-fold cross validation. 
Training data Test data 
Prediction accuracy 
for Ab-Ag pairs 
Prediction accuracy for 
non-Ab-Ag pairs 
Disease 
type in 
which 
Ab-Ag 
pairs 
involved 
Cross 
validation Ab-Ag 
pair 
non-Ab
-Ag 
pair TP FN SE (%) TN FP SP (%) 
PPV 
(%) 
NPV 
(%) Q (%)
1 264 5296 52 15 77.6 1307 17 98.7  75.4 98.9 97.7
2 265 5296 46 20 69.7 1301 23 98.3  66.7 98.5 96.9
3 265 5296 49 17 74.2 1309 15 98.9  76.6 98.7 97.7
4 265 5296 52 14 78.8 1297 27 98.0  65.8 98.9 97.1
Cancer 
5 265 5296 48 18 72.7 1299 25 98.1  65.8 98.6 96.9
Average      74.6   98.4  70.0 98.7 97.3
Standard deviation     ±3.3   ±0.3  ±4.9 ±0.2 ±0.4
1 92 1856 15 9 62.5 457 7 98.5 68.2 98.1 96.7
2 93 1856 15 8 65.2 455 9 98.1 62.5 98.3 96.5
3 93 1856 18 5 78.3 456 8 98.3 69.2 98.9 97.3
4 93 1856 18 5 78.3 447 17 96.3 51.4 98.9 95.5
Influenza 
5 93 1856 17 6 73.9 460 4 99.1 81.0 98.7 97.9
Average      71.6   98.1 66.5 98.6 96.8
Standard deviation     ±6.6   ±0.9 ±9.6 ±0.3 ±0.8
1 115 2209 14 15 48.3 538 14 97.5  50.0 97.3 95.0
2 115 2209 18 11 62.1 538 14 97.5 56.3 98.0 95.7
3 115 2209 18 11 62.1 540 12 97.8 60.0 98.0 96.0
4 115 2209 15 14 51.7 532 20 96.4 42.9 97.4 94.1
HIV 
infection 
5 116 2208 15 13 53.6 547 6 98.9 71.4 97.7 96.7
Average      55.5   97.6 56.1 97.7 95.5
Standard deviation     ±5.6   ±0.8 ±9.6 ±0.3 ±0.9
1 105 1035 17 10 63.0 255 3 98.8  85.0 96.2 95.4
2 105 1035 18 9 66.7 252 6 97.7  75.0 96.6 94.7
3 106 1034 13 13 50.0 251 8 96.9  61.9 95.1 92.6
4 106 1034 16 10 61.5 248 11 95.8  59.3 96.1 92.6
Allergy 
5 106 1034 16 10 61.5 248 11 95.8  59.3 96.1 92.6
Average      60.5   97.0  68.1 96.0 93.6
Standard deviation     ±5.6   ±1.2  ±10.3  ±0.5 ±1.2
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5.4.2.2 Prediction performance of machine learning model for prediction 
antibody-antigen pairs with respect to Pfam of antigen  
The four datasets in Figure 5-11 contains Ab-Ag pairs of antigens that belong 
to the Pfam (440) protein family PF01500 (Keratin B2 protein), PF02440 
(Adenovirus E3 region protein CR1), PF00509 (Hemagglutinin), and PF01464 
(Transglycosylase SLT domain). The generation of corresponding non-Ab-Ag is 
similar as previous description in generating non-Ab-Ag pairs for disease types. 
The computed prediction accuracies for antibody-antigen and 
non-antibody-antigen pairs of which antigens belong to PF01500, PF02440, 
PF00509, and PF01464 were in the range of 96.3% to 97.1%, 96.6% to 98.2%, 
95.2% to 98.9%, and 93.5% to 95.3% respectively.  
 
5.4.2.3 Prediction performance of machine learning model for prediction 
antibody-antigen pairs 
Table 5-13 shows the performances of SVM prediction of antibody-antigen 
pairs which have certain therapeutic applications based on a 5-fold cross 
validation study. The antibody-antigen pairs were chosen if they have certain 
diagnosis or therapeutic application. The non-antibody-antigen pairs were 
generated by random pairing of antibodies with antigens of other antibodies.  
 
The computed prediction accuracies for antibody-antigen pairs and 
non-antibody-antigen pairs were in the range of 61.6% to 65.4% and 99.9% to 
100%. The positive predictive values were in the range of 94.1% to 98.1%. The 
overall accuracy for all data was in 99.5%. Therefore, our SVM prediction system 
appears to show reasonably good capability for prediction the antibody-antigen 
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interaction based on the data in the AAIR database.  
 
Table 5-12 Performance evaluation of SVM prediction system of 
antibody-antigen pairs for antigens from four different protein 
domain families, Keratin high sulfur B2 protein, Adenovirus E3 
region protein CR1, Hemagglutinin and Transglycosylase SLT 
domain by using five-fold cross validation. 
Training data Test data 
Prediction 
accuracy for  
Ab-Ag pairs 
Prediction 
accuracy for 
non-Ab-Ag pairs 
Pfam in 
which 
antigens 
belong to 
 
Cross 
validation Ab-Ag pair 
 
non-Ab
-Ag 
pair 
 TP FN SE (%)
 
TN FP SP (%) 
 
PPV 
(%) 
 
NPV 
(%) 
 
Q 
(%) 
1 99 992 20 5 80.0  243 5 98.0  80.0  98.0 96.3 
2 99 992 20 5 80.0  244 4 98.4  83.3  98.0 96.7 
3 99 992 24 1 96.0  241 7 97.2  77.4  99.6 97.1 
4 99 992 16 9 64.0  247 1 99.6  94.1  96.5 96.3 
Keratin, high 
sulfur B2 
protein 
(PF01500) 
5 100 992 19 5 79.2  245 3 98.8  86.4  98.0 97.1 
Average   79.8    98.4  84.2  98.0 96.7 
Standard deviation  ±10.1    ±0.8  ±5.8  ±1.0 ±0.3 
1 73 1472 17 2 89.5  360 8 97.8  68.0  99.4 97.4 
2 73 1472 10 9 52.6  364 4 98.9  71.4  97.6 96.6 
3 74 1472 12 6 66.7  361 7 98.1  63.2  98.4 96.6 
4 74 1472 10 8 55.6  363 5 98.6  66.7  97.8 96.6 
Adenovirus 
E3 region 
protein CR1 
(PF02440) 
5 74 1472 17 1 94.4  362 6 98.4  73.9  99.7 98.2 
Average   71.8    98.4  68.6  98.6 97.1 
Standard deviation  ±17.2    ±0.4  ±3.7  ±0.9 ±0.6 
1 71 679 14 4 77.8  168 2 98.8  87.5  97.7 96.8 
2 71 679 14 4 77.8  165 5 97.1  73.7  97.6 95.2 
3 71 679 15 3 83.3  167 3 98.2  83.3  98.2 96.8 
4 71 680 16 2 88.9  169 0 100.0 100.0  98.8 98.9 
Hemagglutinin 
(PF00509) 
5 72 679 15 2 88.2  169 1 99.4  93.8  98.8 98.4 
Average   83.2    98.7  87.7  98.2 97.2 
Standard deviation   ±4.8    ±1.0  ±9.0  ±0.5 ±1.3 
1 64 1296 13 4 76.5  307 17 94.8  43.3  98.7 93.8 
2 65 1296 13 3 81.3  311 13 96.0  50.0  99.0 95.3 
3 65 1296 12 4 75.0  306 18 94.4  40.0  98.7 93.5 
4 65 1296 11 5 68.8  310 14 95.7  44.0  98.4 94.4 
Transglycosyl
ase SLT 
domain 
(PF01464) 
5 65 1296 10 6 62.5  311 13 96.0  43.5  98.1 94.4 
Average    72.8    95.4  44.2  98.6 94.3 
Standard deviation   ±6.5    ±0.6  ±3.2  ±0.3 ±0.6 
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Table 5-13 Performance evaluation of SVM prediction system of 
antibody-antigen pairs 
training data Test data 
Prediction accuracy for 
Ab-Ag pairs 
Prediction accuracy for 
non-Ab-Ag pairs 
Cross 
validation Ab-Ag pair non-Ab-Ag pair 
TP FN SE (%) TN FP SP (%) 
 
PPV 
(%) 
 
NPV 
(%) 
 
Q (%)
1 1376 110176 217 128 62.9 27539 5 100.0 97.7 99.5 99.5 
2 1377 110176 225 119 65.4 27530 14 99.9 94.1 99.6 99.5 
3 1377 110176 221 123 64.2 27538 6 100.0 97.4 99.6 99.5 
4 1377 110176 223 121 64.8 27535 9 100.0 96.1 99.6 99.5 
5 1377 110176 212 132 61.6 27540 4 100.0 98.1 99.5 99.5 
Average       63.8     100.0     99.5 
Standard 
deviation     ±1.5   ±0.0     ±0.0 
 
Based on the sequence information of antibodies and antigens which either makes 
use of all data, or is restricted to a certain disease or is restrict to a certain Pfam, 
the SVM prediction results suggest that SVM is potentially useful for predicting 
Ab-Ag pairs, which give insight for developing systems for predicting antibody 
from antigen sequence or antigen sequence from antibody sequence in our future 
study. The prediction accuracies for non-Ab-Ag pairs are better than that of Ab-Ag 
pairs in all of these datasets. This probably results from the more diverse set of 
non-Ab-Ag pairs compared to that of Ab-Ag pairs which enables SVM to better 
recognize non-Ab-Ag pairs.  
 
5.5 Conclusion 
The AAIR database is intended to provide comprehensive information about 
Ab-Ag pair sequence, function, diagnosis and therapeutic indications, and other 
information from a single source. Through a few illustrative case studies, data 
from the database are proved to be highly effective in facilitating immunological 
research and development tasks such as the development of antibody discovery 
tools and the analysis of selective antigen recognition. Preliminary results of the 
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machine learning models suggest that the information in AAIR is useful to 
characterize pair-wise antibody-antigen interactions. Further investigations are 
being made to collect more Ab-Ag data via improved searching algorithms and 
from more recently published papers. Rapid advances in the technologies for 
identifying Ab-Ag recognitions will enable the generation of more comprehensive 
and useful molecular level data that can be incorporated into our database. 
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6 Conclusion and future works 
In drug discovery, disease targets and therapeutic molecules are two important 
molecules. This work developed a computational system to discover potential 
disease targets from microarray data, and implement a bioinformatics tool for 
therapeutic molecular discovery. 
 
In this study, a robust computational system for gene signature derivation from 
microarray data was developed. A popular and accurate machine learning method, 
support vector machines, was applied to classify the samples. Recursive feature 
selection incorporating with multiple random sampling method and gene 
consistency evaluation strategies was used in gene selection procedure. This 
system was used to select colon cancer markers and lung adenocarcinoma 
survivability markers. For both cases, the markers were consistent with the 
variation of the samples, and present good predictive performances. 104 colon 
cancer markers were shared by all of the 20 signatures which were selected from 
different combination of samples. By applying a therapeutic target prediction 
system, all of the 6 known therapeutic targets were predicted correctly and 18 
markers were predicted as potential therapeutic targets. 21 lung adenocarcinoma 
survivability markers were shared by all of the 10 signatures. All of the 5 know 
therapeutic targets were predicted correctly by therapeutic target prediction system. 
In addition, 7 markers were identified as potential therapeutic targets. 
 
The results from the two demonstrative examples – colon cancer gene selection 
and lung adenocarcinoma survival gene selection suggest that, our system can 
derive stable and good predictive marker signatures. Since the cost for microarray 
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experiments is very high, the sample size is much smaller than what is required 
for a satisfactory diagnosis and prognosis of a certain disease such as cancer. In 
such situations, our system is particular useful to get real important markers for 
disease diagnosis, patient survival prediction and therapeutic target discovery. The 
use of consensus scoring for multiple random sampling and evaluation of 
gene-ranking consistency seem to have impressive capability in avoiding 
erroneous elimination of predictor-genes due to such noise as measurement 
variability and biological differences. Further improvement in measurement 
quality, annotation accuracy and coverage, and signature-selection will enable the 
derivation of more accurate signatures for facilitating biomarker and target 
discovery. The currently available platforms for microarray data are different. 
Therefore if we could synchronize the platform and provide more samples, we 
could further improve the accuracy of our system and reduce the computational 
time. The gene ontology information also could be integrated into the system and 
the selected genes would be given a biological meaning directly.  
 
Another aspect of this work was to develop a bioinformatics tools for disease 
targeting antibody prediction. An antibody-antigen interaction database (AAIR) 
was developed. The information from the AAIR database was used to develop a 
prediction system for antibody design and vaccine design. The accuracy of the 
system is in the range of 92.6% to 99.5% from the five-fold cross validation. The 
information of this database was also used to analyze the recognition variation 
between antibody and antigen. It was shown that small variation of antibodies can 
recognize both close homologues and remote homologues.  
 
With the development of immunology and biotechnology, it is expected that a 
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significant higher number of entries of antibodies can be incorporated in this 
database. Structural information of antibody and antigen may include in this 
database and develop a prediction system not only based on sequence information 
but also on the structural information in order to get a better performance of the 
system. A more comprehensive database system could make it possible to screen 
the genome to find out the possible antibody-antigen pairs for the purpose of 
antibody design or vaccine design. 
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APPENDICES 
Table S1 The information of colon microarray data collected from Standford 
Microarray Database (SMD) (284) 
ExptID in SMD Tissue Description in SMD Tissue type 
33061 CACO-2 Colon cancer cell line 
48604 COLO205 Colon cancer cell line 
48603 COLO320 Colon cancer cell line 
48602 COLO741 Colon cancer cell line 
33055 DLD-1 Colon cancer cell line 
48599 GP2D Colon cancer cell line 
48607 GP5D Colon cancer cell line 
48608 HCA7 Colon cancer cell line 
60328 HCT 116 Colon cancer cell line 
33052 HCT116 Colon cancer cell line 
60329 HCT116+Ch2 Colon cancer cell line 
60327 HCT116+Ch3 Colon cancer cell line 
33058 HCT15 Colon cancer cell line 
30367 HT-29 Colon cancer cell line 
48606 LIM1215 Colon cancer cell line 
48605 LIM2412 Colon cancer cell line 
30370 LOVO Colon cancer cell line 
33050 LS-174T Colon cancer cell line 
33048 LS-180 Colon cancer cell line 
48600 LS411 Colon cancer cell line 
33062 NCI-H508 Colon cancer cell line 
33060 NCI-H747 Colon cancer cell line 
30369 RKO Colon cancer cell line 
33059 SK-CO-1 Colon cancer cell line 
48609 SNUC2B Colon cancer cell line 
33057 SW-1116 Colon cancer cell line 
33051 SW-403 Colon cancer cell line 
33053 SW-480 Colon cancer cell line 
30371 SW-837 Colon cancer cell line 
48597 SW1417 Colon cancer cell line 
30297 SW48 Colon cancer cell line 
33056 SW620 Colon cancer cell line 
48598 SW948 Colon cancer cell line 
48601 T84 Colon cancer cell line 
32614 Colon 2075 Normal colon tissue 
20950 Colon, ascending 0222 Normal colon tissue 
32615 Colon, sigmoid 0361 Normal colon tissue 
16373 colon,autopsy Normal colon tissue 
56125 6.01.04 colonic omentum Normal colon tissue 
56109 7.16.04 colonic omentum Normal colon tissue 
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56123 8.30.04 colonic omentum Normal colon tissue 
56121 6.01.04 pericolonic/mesenteric Normal colon tissue 
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Table S2 List of 20 derived colon cancer gene signatures selected by SVM class-differentiation systems 
Gene rank in each signature (Number of selected gene in each signaure) 
Gene Name 
(EST number) 
Number 
of 
signatures 
which 
included 
this gene
1 
(155) 
2 
(135) 
3 
(156)
4 
(146)
5 
(116)
6 
(112)
7 
(119)
8 
(127)
9 
(133)
10 
(156) 
11 
(139)
12 
(115)
13 
(144)
14 
(157)
15 
(149)
16 
(136)
17 
(136)
18 
(127)
19 
(146) 
20 
(122) 
DES (M63391) 20 1 1 3 3 1 3 1 3 1 1 3 3 1 1 3 1 3 3 1 1 
GUCA2B (Z50753) 20 2 3 1 1 2 1 3 1 2 2 1 1 3 2 1 2 1 1 3 2 
MYH9 (R87126) 20 3 2 2 2 3 2 2 2 3 3 2 2 2 3 2 3 2 2 2 3 
WDR77 (H08393) 20 4 4 5 4 4 5 5 4 4 5 5 5 4 5 5 5 4 5 5 5 
CSRP1 (M76378) 20 5 5 4 5 5 4 4 5 5 4 4 4 5 4 4 4 5 4 4 4 
VIP (M36634) 20 6 6 6 6 6 6 6 6 7 7 6 6 6 6 6 6 6 6 6 6 
MYL9 (J02854) 20 7 7 7 7 7 7 8 7 8 8 7 7 7 7 7 7 7 7 7 8 
NR3C2 (R44301) 20 8 11 9 8 8 8 7 8 9 9 8 11 11 8 9 8 10 9 9 9 
MYL6 (H20709) 20 9 8 12 9 10 9 14 10 10 10 9 8 9 9 11 9 8 16 10 13 
GTF3A (R36977) 20 10 9 11 10 11 10 10 11 11 11 10 9 10 10 10 10 9 11 11 11 
HNRPA1 (X12671) 20 11 13 10 12 12 12 12 9 12 12 12 12 12 11 12 11 11 12 12 10 
CDH3 (X63629) 20 12 10 8 11 9 11 11 12 6 6 11 10 8 12 8 14 12 8 8 12 
CFD (H43887) 20 13 21 14 17 16 21 21 22 19 15 20 21 21 13 20 21 19 22 20 18 
MT1G (T71025) 20 14 17 16 19 19 14 9 14 22 17 22 17 14 18 25 12 21 10 13 7 
GSN (H06524) 20 15 14 13 14 14 13 15 15 14 13 14 16 15 23 14 15 14 13 14 14 
H40095 20 16 20 17 18 21 20 19 20 18 18 21 20 20 16 19 19 18 19 19 19 
H64807 20 17 16 18 16 17 17 18 16 16 16 17 15 16 17 18 16 15 14 17 15 
TPM2 (T92451) 20 18 15 19 15 23 18 17 18 15 21 16 14 17 14 16 17 16 18 16 16 
SNRPB (R84411) 20 19 43 21 20 37 19 16 19 17 42 19 45 19 15 28 18 17 64 44 17 
MXI1 (L07648) 20 20 12 20 13 13 15 13 13 13 19 13 13 13 19 13 13 13 15 15 20 
DARS (J05032) 20 21 22 15 21 20 16 20 17 21 20 15 18 18 22 15 22 20 17 18 21 
SERPINE2 (T51261) 20 22 19 24 23 18 23 22 21 23 24 25 23 23 20 22 20 22 21 25 25 
MXI1 (H49870) 20 23 18 28 25 22 28 24 27 25 22 26 19 26 24 21 26 23 20 26 26 
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HMGA1 (X14958) 20 24 26 22 29 28 31 28 31 24 23 32 26 32 27 34 29 24 28 29 28 
S100P (T47377) 20 25 24 23 22 15 22 23 23 20 14 18 22 22 21 17 23 25 23 21 22 
FUCA1 (M80815) 20 26 31 25 30 38 29 27 33 29 34 43 32 34 29 32 28 34 32 36 27 
HSD11B2 (U14631) 20 27 33 27 26 33 30 25 34 30 36 30 35 27 25 29 32 37 33 38 24 
CKS2 (X54942) 20 28 23 26 24 24 26 26 24 28 26 23 24 25 26 26 25 27 24 22 23 
CDKN1A (R46753) 20 29 27 30 33 27 32 30 38 26 25 28 28 33 28 36 37 26 29 30 32 
C15orf15 (T62947) 20 30 28 29 32 26 27 31 26 27 28 24 30 30 30 24 27 28 27 32 33 
TPM1 (X12369) 20 31 25 31 28 29 25 29 35 31 29 27 29 28 39 27 35 29 30 31 29 
SPARCL1 (X86693) 20 33 36 33 31 36 36 36 28 36 32 34 37 29 33 31 30 32 37 27 35 
EIF2S2 (R54097) 20 34 34 45 44 31 37 32 36 38 30 33 33 31 38 46 31 38 38 34 30 
TSPAN1 (H64489) 20 35 29 40 34 30 33 35 25 37 27 35 25 36 31 35 24 30 26 28 34 
SND1 (U22055) 20 36 35 34 38 34 38 34 29 35 33 31 36 48 34 30 33 33 36 33 36 
PCNP (T95018) 20 37 38 35 37 44 39 33 42 34 39 87 31 35 37 42 34 35 39 35 31 
SRPK1 (U09564) 20 38 32 36 40 32 35 52 61 39 35 39 34 38 46 38 40 39 34 37 49 
UQCRC1 (R55310) 20 39 41 37 41 41 43 46 43 41 40 40 41 45 41 43 41 41 40 42 46 
CST3 (T51534) 20 40 44 41 42 43 40 40 40 43 44 46 43 40 44 40 45 44 43 46 40 
S100A11 (T51571) 20 41 39 32 35 25 41 38 30 32 37 41 39 42 35 23 38 42 25 23 37 
EEF1B2 (X60489) 20 42 37 38 36 39 34 37 32 33 38 36 38 37 32 33 36 36 35 39 38 
ATP5J (R88740) 20 43 45 43 47 45 42 42 46 44 43 48 47 43 42 45 43 43 45 45 42 
CLNS1A (U17899) 20 44 30 39 46 40 24 50 41 42 31 37 27 39 43 39 44 31 31 47 39 
GYG1 (U31525) 20 45 59 52 51 53 60 60 53 52 55 55 61 51 51 57 58 55 56 52 56 
SRPK1 (R62549) 20 47 42 53 54 42 50 45 39 48 50 49 46 57 45 48 49 49 48 53 45 
PPP2R5C (T51493) 20 48 57 47 49 49 46 44 49 51 52 51 51 49 60 47 54 56 41 62 53 
H11084 20 49 58 51 61 54 48 39 51 50 48 53 44 52 50 37 50 57 42 64 55 
MARCKSL1 
(X70326) 20 50 46 44 52 48 47 41 47 45 45 47 42 53 40 44 42 45 44 57 41 
PRKACA (X07767) 20 51 52 55 50 56 57 47 60 59 56 57 54 46 57 56 57 47 57 56 52 
TCF8 (U19969) 20 52 51 57 60 59 62 54 58 58 51 61 49 56 52 54 55 58 62 40 48 
SPARC (J03040) 20 53 49 56 53 50 54 53 57 53 53 56 50 55 53 55 56 54 51 58 50 
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HSPD1 (M22382) 20 54 50 49 43 63 52 49 44 65 61 42 59 44 56 51 62 62 61 59 44 
GABRB3 (M82919) 20 55 48 50 39 46 44 48 45 47 47 29 48 47 47 50 53 48 46 43 47 
PPP1R9B (T86444) 20 57 56 60 55 55 49 51 52 49 49 52 53 54 54 49 51 50 50 60 54 
IFI6 (X02492) 20 58 40 61 58 35 59 55 37 40 41 38 40 62 36 58 39 40 55 55 66 
CREB5 (R33481) 20 59 54 67 70 60 56 56 59 75 85 58 55 60 63 65 48 84 58 68 60 
ZNF358 (H81558) 20 60 55 64 57 51 55 57 56 54 54 59 52 61 61 63 52 53 54 50 61 
MLC1 (D25217) 20 61 60 42 72 52 61 64 62 61 62 44 94 70 49 62 64 52 59 61 62 
HSP90AB1 (T51023) 20 62 72 59 71 77 76 66 76 73 73 72 66 73 67 76 79 74 67 41 75 
CNNM4 (R67343) 20 63 53 63 56 62 53 59 54 56 58 65 58 59 62 41 47 60 52 51 57 
ARL6IP (D31885) 20 64 91 62 59 82 58 71 71 67 66 69 100 69 83 61 91 51 74 54 80 
MUC2 (M94132) 20 66 68 74 75 69 73 70 87 85 80 70 68 75 69 64 67 72 71 77 78 
NCOA4 (X77548) 20 67 67 75 76 67 75 69 75 72 67 73 69 74 68 77 77 73 73 71 76 
RPS6 (T57619) 20 68 62 65 62 81 63 58 66 63 68 64 57 65 72 53 59 63 87 69 59 
KRT8 (T54303) 20 69 61 66 68 71 64 61 64 62 60 63 60 71 58 52 65 61 63 65 63 
H73908 20 70 64 69 69 61 65 62 63 60 63 62 62 66 59 60 61 66 60 70 70 
MT1M (R06601) 20 71 65 79 79 58 69 90 68 57 57 67 85 64 55 87 68 96 53 87 65 
MMP9 (T41204) 20 72 71 81 91 74 79 87 82 80 83 99 72 80 74 82 73 67 68 73 73 
POLD2 (U21090) 20 73 69 90 87 72 82 80 83 86 79 81 73 88 76 71 87 77 77 80 81 
GPD1L (D42047) 20 74 80 80 84 102 112 88 125 93 84 89 89 102 99 78 72 83 99 72 122 
ETS2 (J04102) 20 75 78 73 65 110 67 72 67 66 77 68 76 68 119 70 69 65 92 86 69 
SCNN1B (X87159) 20 76 63 71 66 57 68 65 65 64 64 78 56 63 65 68 63 75 47 67 58 
WDR7 (T64012) 20 77 66 83 74 75 74 68 74 69 65 71 70 76 75 73 75 68 72 81 74 
COX6A1 (H48072) 20 78 92 86 80 78 81 78 77 70 69 76 88 84 80 89 93 85 85 91 86 
CD46 (R33367) 20 79 93 92 89 100 78 77 86 81 94 75 84 79 82 86 95 87 84 90 90 
PECAM1 (L34657) 20 80 74 82 77 70 71 75 73 76 72 77 65 83 70 72 71 71 69 79 79 
RPL30 (T58861) 20 81 85 72 67 66 66 63 55 55 59 54 64 58 64 66 70 59 65 66 64 
UQCRFS1 (L32977) 20 82 87 70 64 65 70 73 72 68 71 79 92 67 87 69 81 70 78 82 82 
ACAA2 (D16294) 20 84 89 85 98 84 87 79 91 83 78 84 83 93 86 80 80 82 79 88 87 
WASF2 (H81068) 20 85 77 84 90 86 77 74 69 78 76 74 75 92 84 79 76 90 80 89 93 
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MGC22793 
(H87135) 20 86 84 77 82 85 86 82 100 90 89 85 90 86 85 84 84 79 75 75 88 
PMP22 (T94350) 20 87 90 93 86 87 105 89 107 99 98 90 93 94 92 85 86 103 106 99 83 
TPM1 (Z24727) 20 88 75 95 78 89 90 76 92 77 93 100 80 81 91 83 96 91 95 94 68 
POSTN (D13665) 20 89 82 106 108 95 94 94 99 89 92 97 82 107 90 103 113 88 98 110 109 
PTPRH (D15049) 20 90 76 88 81 79 85 81 80 74 88 83 78 85 78 75 92 78 81 84 71 
PRPSAP1(T65380) 20 91 95 104 120 90 98 110 98 97 86 109 79 99 93 110 100 92 91 85 118 
CDX1 (U15212) 20 92 81 91 93 91 84 83 85 84 82 86 81 89 88 81 82 81 82 93 98 
CCL14 (Z49269) 20 93 123 78 114 76 80 95 105 122 87 104 101 77 104 97 107 117 89 74 85 
COX8A (T51250) 20 94 104 103 88 107 93 104 110 109 75 103 74 117 114 121 99 101 94 95 101 
KIF5A (U06698) 20 95 73 121 96 80 83 111 111 71 70 80 71 91 73 74 101 76 76 109 114 
DTWD2 (R98842) 20 96 96 87 103 114 99 85 81 103 108 95 108 106 98 98 85 95 90 104 94 
CBX3 (U26312) 20 97 79 99 92 73 88 93 84 82 81 82 102 82 77 99 102 80 83 105 96 
FXYD1 (T67077) 20 99 135 76 105 103 92 112 90 87 97 105 77 87 100 100 109 93 105 98 103 
IFITM2 (X57351) 20 100 110 94 85 93 95 107 114 101 119 94 104 78 96 92 110 110 108 112 67 
CPSF1 (U37012) 20 101 112 101 106 111 107 108 115 114 112 107 106 110 107 95 105 104 109 106 106 
CNOT1 (T64885) 20 103 88 98 97 83 89 92 88 92 90 96 87 96 81 93 90 86 93 96 95 
MORF4L2(D14812) 20 108 99 89 95 99 97 86 79 88 102 93 95 98 79 88 94 97 86 107 99 
GSTM4 (M96233) 20 109 70 108 102 101 108 96 106 110 74 92 67 100 71 91 89 102 70 103 77 
ATP2A2 (M23115) 20 110 106 109 116 115 111 97 113 118 109 123 112 143 126 125 121 114 124 145 121 
FBL (X56597) 20 111 101 112 99 104 100 99 89 94 118 117 86 103 106 105 74 89 107 92 91 
CALM2 (D45887) 20 112 109 107 118 105 101 101 95 113 95 106 96 97 95 108 97 99 96 100 105 
PCCB (X73424) 20 116 100 116 110 108 106 98 94 105 99 98 97 109 111 104 103 108 100 117 110 
ITPR3 (H25136) 20 119 113 114 113 113 104 109 109 108 107 102 107 111 103 101 106 105 103 121 112 
IL1R2 (H78386) 20 130 94 110 117 96 91 84 78 98 115 88 91 95 94 90 83 136 88 97 89 
HSP90AA1(X15183) 19 83 86 96 100 94 103  102 91 91 101 99 116 89 96 78 69 115 83 72 
SFRS9 (U30825) 19 107 116 113 101 112 96 116 103 115 106 91  104 108 109 111 111 110 101 107 
THBS2 (L12350) 19 125 102 119 111 116  119 101 119 105 131 109 115 133 106 88 109 101 111 104 
CALM2 (M19311) 18 113 111 120 125 92  102 108 95 100 125 105 130 101 135 104 116 114 119  
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PCK1 (L05144) 18 115 105 123 104   105 112 131 123 121 111 113 117 117 112 127 112 115 108 
ALDH1A1 (M31994) 17 56 47 46 45 47 45  48 46 46 45  50 48  46 46 49 49 51 
H05803 17 65  68 73 64 72 113 70 107  66 98 72 66 67 66 98 66 78  
HDGF (D16431) 17 102 103 97 83 88  103 97 102 103 113  105 113 114 98 106  108 100 
MAPK3 (M84490) 17 117 120 126 139   118 126 112 117 116 115 136 132 119 122 122 120 139  
NXPH3 (H40699) 17 123 114 125 138 97   119 106 116 110 114 129 130 133 129 121 127 138  
ZNRF1 (H11460) 16 131 126 124 145    118 125 131 130 113 128 118 118 128 120 126 137  
CANX (L10284) 16 134 98 128 94    104 96 120 108  112 121 94 117 100 117 114 117 
MYH9 (T57882) 16 141 122 134 126 106  115 116  142 112  132 127 113 123 130 116  111 
MSTP9 (T51539) 15 98 83 140 63   67 93  96  63 121 110 59 60 64  76 102 
CD46 (T83368) 15 105 107 111 109   106  124 104 115  108 105 140 114 107  136 97 
FGFR2 (T94993) 15 122 119 133 123   117   110 137 103 144 140 112 108 129 125 116  
CCDC106 (T47424) 15 126 97 150 112  102  122 120 101 126  131 102 136 116  102 120  
CD44 (M59040) 14 137  132 122  110   132 124 135  127 124 131 127  113 129 120 
PRPS1 (D00860) 14 138 118 145 129     117 130 122  142 125 132 120 128 123 131  
AVPI1 (R60883) 14 145 125 138 143    124  122 128  135 122 123 124 118 122 135  
ATP5A1 (T74556) 13 106 115 127 141   114   149 127  138 151 120  123  113 116 
FAS (M67454) 13 118 108 148  98  100 120 100 111 124   112  115 115  118  
IARS (U04953) 13 120 132 139 128     129 128 129  119 129 124 133 119  122  
PFN1 (T61661) 13 149 129  140   91 121  133  110 137 120 107 130  121 140  
PSMC2 (H72965) 12 121 133 131 121    117  129 120   138 129 134   127 119 
ITGA7 (X74295) 12 128  122 135     123 137 134  125 123 130 126 126  128  
ZNF3 (X07290) 12 132 127 146 130     126 140 138  122 131 148    124 115 
PTPRO (Z48541) 11 127  129 127    123  121 118  118 154 122  132   113 
DPT (R48303) 11 129  100 115     111 125   120 139 111  113 104 123  
RIMS2 (R75843) 11 151 124 130      127 135 133  140 116 145  133  134  
T47383 10 46  48 48  51 43 50   50  41      48 43 
AMPD3 (M84721) 9 124  117 146 109   127 133  111  114 149       
SULT1E1 (H67764) 9 135 117        151 114  133  115 118 112  132  
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MXD1 (L06895) 9 142  135 133      127    128 137 132 131 118   
T47342 9 144  136      121 114    115 138 119  119 133  
IGFBP3 (M35878) 8 104  105 107     104    90  102  94  130  
CYP2A7 (K03192) 8 155 128 155       147 139   141 141 136     
IMPDH2 (R42501) 8  130 142 132      126   139 136  131   142  
DNAJA1 (L08069) 7 136        128 153 119   156  125 125    
CEACAM1(X16354) 7  134  136     130    101 109     144 92 
RPS19 (T52185) 6 32  54 27       60  24      24  
PLP2 (L09604) 6 133  141        132  123 134 127      
PTPRD (L38929) 6 139   144      145 136   157 126      
TNIP1 (D30755) 6 143  143      116 113   134  116      
RNASE3 (M28128) 6   102  68   96      97    97  84 
POLD4 (R44418) 5 114  115 119              111 102  
COL1A1 (T51558) 5 146  152       144    137   134    
EIF1 (T61599) 5  131 137 134      143         126  
GCN5L2 (R52081) 5   154       156    146 146    146  
MUC1 (X52228) 4 147     109    138   126        
RBMY2BP(U36621) 4 148  156       148     149      
ACTA2 (T60155) 4 150             135 144    141  
SLC2A4 (M91463) 4  121 147 131      132           
KCNH2 (X86779) 4   149       134    142 134      
HIVEP2 (R39209) 4   153       155    145   135    
CDK4 (T86749) 3 140   137          147       
GYPC (X12496) 3 153         154   141        
COX5B (T71049) 3 154              147 135     
NPM1 (M26697) 3          141    150 143      
TUBB (T56604) 3    142         124      125  
C1R (T53889) 3          136    144   124    
NME1 (T86473) 2 152             155       
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GTF2A2 (R01221) 2          150    153       
ITGB1 (H65425) 2          146    148       
CD55 (M31516) 2   58                63  
ATP6V1E1(X76228) 1               139      
FTL (H87344) 1                   143  
PI3 (Z18538) 1          152           
WEE1 (X62048) 1   118                  
H61410 1              152       
FLNA (R78934) 1               142      
SELENBP1(T59162) 1   151                  
AURKB (R97912) 1   144                  
AP3B2 (U37673) 1    124                 
ANXA13 (Z11502) 1         79            
PPIB (T59878) 1               128      
NPTN (R61359) 1              143       
SEMG2 (M81651) 1          139           
 
 
Appendices  
203 
Table S3 The clinical information of 86 lung adenocarcinoma samples from Beer et al (350) 
Sample 
ID 
cluster 
ID1 
Age Sex 
Tumor 
stage. 
either 1 
or 3 
T 
(tumor 
size)
N 
(nodal 
status)
Survival 
times 
(month)2 
Patient's 
survival 
status 
classification 
(tumor 
histological 
type)3 
Tumor 
differentiation
p53 nuclear 
accumulation 
status 
12/13th codon 
K-ras mutation 
status 
Smoking 4 
AD2 Cluster 1 65.6 F 1 1 0 91.8 alive BD Poor + - 48 
AD5 Cluster 1 62 F 1 2 0 108.2 alive BA Well - + positive 
L01 Cluster 1 76.7 M 1 2 0 47 alive BD/CC Poor - - 100 
L06 Cluster 1 57.9 F 1 1 0 91.9 alive BD Poor - + NA 
L26 Cluster 1 61.4 M 1 2 0 17.7 alive BD Poor - + 90 
L33 Cluster 1 53.5 F 3 4 0 29.4 alive BD Moderate - - 23 
L43 Cluster 1 50.6 F 1 2 0 78.5 alive BD Moderate - - 57 
L56 Cluster 1 60.2 M 1 1 0 61.8 alive BD/CC Moderate + - 90 
L62 Cluster 1 52.3 F 3 3 2 52.4 alive BD Moderate - - none 
L83 Cluster 1 62 F 1 2 0 30.6 alive BA/mucinous Well - - none 
L91 Cluster 1 63.7 M 3 2 2 6.1 alive BD/mucinous Poor - - 30 
L92 Cluster 1 55.4 M 3 4 0 8.5 alive BD Poor - - 50 
AD10 Cluster 1 65 M 1 1 0 84.1 death BD Moderate - NA 60 
L04 Cluster 1 51.7 M 1 2 0 45.8 death BD Poor - - 50 
L13 Cluster 1 67.1 M 1 1 0 79.5 death BD Moderate + + 25 
L19 Cluster 1 56.5 M 3 3 2 9.6 death BD Moderate - + 40 
L34 Cluster 1 77.2 M 3 1 2 14.9 death BD Moderate + - 45 
L36 Cluster 1 69.7 M 3 1 2 7.2 death BD/PA Moderate - + 25 
L37 Cluster 1 64.4 M 3 1 2 2.6 death BD Poor - + 84 
L41 Cluster 1 73.1 F 1 2 0 8.4 death BD/CC Poor - + 26 
L54 Cluster 1 45.8 F 3 3 1 4 death BD Poor + + 75 
 
1These clusters are obtained from hierarchical cluster analysis of the 86 samples and 21 survival marker genes share by 10 signatures 
2This is patient's survival time from operation date to death or last follow up as of May 2001 
3BD: bronchial derived; BA: bronchial alveolar; CC: clear cell; PA: papillary; Note that some tumors contained a mixture of two histological types 
4Patient smoking history in packs per year 
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L40 Cluster 1 54.9 F 3 1 2 20.1 death BD Moderate - - 7.5 
L80 Cluster 1 68.2 F 1 2 0 10.1 death BD/mucinous Moderate + + 50 
L61 Cluster 1 63.1 F 1 2 0 20.6 death BD Moderate - - 30 
L95 Cluster 1 72 F 3 2 2 5.4 death BD Poor - + 50 
L96 Cluster 1 64 F 3 3 1 21.2 death BD Moderate - + 50 
AD7 Cluster 2 56 M 1 1 0 68.1 alive BD Moderate + - 80 
L02 Cluster 2 63.2 M 1 1 0 39.1 alive BD Poor - - 27 
L09 Cluster 2 48.2 F 1 1 0 98.7 alive BD Moderate - + none 
L101 Cluster 2 46.3 F 1 1 0 40 alive B/A/mucinous Well - - NA 
L103 Cluster 2 84.6 F 1 1 0 30.8 alive B/A Well - - none 
L104 Cluster 2 68.5 F 1 1 0 24.4 alive B/A Well - - 5 
L105 Cluster 2 74.2 F 1 1 0 28.3 alive B/A with PA Well - + 75 
L108 Cluster 2 61 F 1 1 0 19.5 alive B/A Well - + 100 
L111 Cluster 2 54.9 F 1 1 0 1.5 alive B/A Well - + 40 
L12 Cluster 2 44.6 F 1 1 0 85.2 alive BD Moderate - - 15 
L18 Cluster 2 82.5 F 1 1 0 48.2 alive BD Well - - none 
L23 Cluster 2 62.2 M 3 2 2 15.1 alive BD/PA Moderate - + 20 
L25 Cluster 2 62.6 F 1 2 0 14.5 alive BD Well - + 50 
L27 Cluster 2 70 M 1 1 0 21.1 alive BD Poor + - 60 
L38 Cluster 2 78.5 F 3 4 2 10 alive BD Poor + + 2 
L42 Cluster 2 76 F 1 1 0 63.4 alive BD Well - - 40 
L46 Cluster 2 60.4 M 1 2 0 82.4 alive BD Poor - + 160 
L47 Cluster 2 60 M 1 2 0 60.5 alive BD Moderate - + 27 
L48 Cluster 2 42.8 M 1 1 0 77.8 alive BD Moderate - - 60 
L52 Cluster 2 67.3 M 1 1 0 65.4 alive BA Well - - 30 
L57 Cluster 2 73.6 F 1 2 0 54.8 alive BD/PA Moderate - + 50 
L65 Cluster 2 59.6 M 1 1 0 52.9 alive BD Moderate - - 60 
L78 Cluster 2 75.6 F 1 1 0 36.5 alive BD Moderate - + 108 
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L82 Cluster 2 69.2 F 1 1 0 34.1 alive BA/BD Well - - 40 
L85 Cluster 2 60.2 M 1 1 0 26.8 alive BD/mucinous Moderate - + 60 
L97 Cluster 2 63.6 F 1 1 0 4.9 alive B/A Well - + 34 
L50 Cluster 2 72.1 M 1 1 0 19 death BD/PA Moderate + + 100 
AD3 Cluster 3 59.5 F 1 2 0 93.7 alive BD Moderate - - positive 
AD8 Cluster 3 75 M 1 2 0 34.2 alive BD Moderate - - 14 
L05 Cluster 3 54.6 F 1 1 0 110.6 alive BD/CC Moderate - - 29 
L08 Cluster 3 59.9 F 1 1 0 107.9 alive BD Moderate - + 80 
L102 Cluster 3 74.6 F 1 1 0 40 alive BD Moderate - - 50 
L106 Cluster 3 82.8 F 1 1 0 25.3 alive B/A Well - - none 
L107 Cluster 3 59.4 F 1 1 0 13 alive BD well/mod. - + none 
L17 Cluster 3 40.9 F 1 2 0 83.7 alive BD/PA Moderate - + 15 
L22 Cluster 3 65.6 M 1 1 0 12.5 alive BD Moderate + - 90 
L30 Cluster 3 51.8 F 1 1 0 20.2 alive BD Moderate + - 20 
L31 Cluster 3 62.1 F 1 1 0 25.2 alive BA/mucinous Well - - 20 
L49 Cluster 3 65.8 F 1 1 0 70.7 alive BD Moderate - + 20 
L59 Cluster 3 71.5 F 3 2 2 54.6 alive BD/PA Moderate - + 25 
L64 Cluster 3 65.4 M 1 2 0 48.1 alive BD Moderate + - 12 
L76 Cluster 3 46.2 M 1 1 0 87.7 alive BD Poor - + 50 
L81 Cluster 3 58.4 M 1 1 0 36 alive BA Well - - 90 
L84 Cluster 3 66.8 F 1 2 0 32.2 alive BD Poor - - 15 
L86 Cluster 3 62.7 F 1 1 0 10.1 alive B/A Well - - 45 
L87 Cluster 3 66.3 M 1 1 0 10.4 alive BD Moderate + - 18 
L88 Cluster 3 52.9 F 1 1 0 8.3 alive BD Poor + + 60 
L89 Cluster 3 58.8 M 3 2 2 12.2 alive BD Moderate NA + 48 
L99 Cluster 3 73.8 M 1 2 0 4.5 alive B/A/mucinous Well - + 55 
L100 Cluster 3 72.9 F 1 1 0 43.8 censored B/A Well - - 2.5 
L24 Cluster 3 84.5 F 1 1 0 1.6 censored BD Poor - - 75 
AD6 Cluster 3 66.2 M 1 2 0 34.6 death BA Well - + NA 
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L11 Cluster 3 68.2 F 1 2 0 34.7 death BA Well - + none 
L20 Cluster 3 79.8 M 1 2 0 19.9 death BA Well - - 30 
L35 Cluster 3 64.4 M 3 2 2 28.2 death BD Moderate + + 4 
L45 Cluster 3 74.9 F 1 1 0 29.6 death BD Poor - + 30 
L53 Cluster 3 58.5 F 3 2 2 16.6 death BD/PA Moderate - - none 
L79 Cluster 3 49 F 1 2 0 8.7 death BD Poor - - 60 
L90 Cluster 3 63.8 F 1 1 0 5.8 death BD/PA Moderate - - 100 
L94 Cluster 3 72 M 3 3 2 2.4 death BD/mucinous Moderate - - 50 
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Table S4 The clinical information of 84 lung adenocarcinoma samples from Bhattacharjee et al (351) 
Sample 
ID 
Cluster 
ID1 Age Sex 
Stage:AJCC 
TNM 
Stage 
Summary 
Survival 
time 
(month)2
Patient's 
status* 
Clinical Path (type 
diameter features) 3 Path II
4 Site of elapse/ metastasis Smoking5
AD111 Cluster 3 76 F T1NxMx IA 72.4 1 ad 2.0 m-p   40 
AD115 Cluster 2 70 F T2N1M0 IIB 21.9 3 ad 6.5 m adm/adw lung, LN 75 
AD118 Cluster 3 69 M T1N0Mx IA 49.6 3 ad 2.5 m adm lung, LN 25 
AD120 Cluster 3 68 M T2N0Mx IB 38.9 3 ad 8.0 m adm bone 54 
AD122 Cluster 1 73 F T2N1Mx IIB 33.9 3 ad 5.0 m adm lung 0 
AD123 Cluster 1 60 M T3N0Mx IIB 74 1 ad 5.0 m adm,pap  126 
AD127 Cluster 3 65 F T1N2Mx IIIA 8.2 3 ad 1.8 p adp LN 69 
AD130 Cluster 1 75 M T2N1Mx IIB 7.1 d ad 15.0 BAC BAC  100 
AD136 Cluster 1 66 F T2N0Mx IB 31.4 1 ad 4.0 m adm  100 
AD159 Cluster 1 71 M T2N1Mx IIB 19.7 d ad 5.5 m-p adw,acinar  80 
AD162 Cluster 3 75 F T2N0Mx IB 41.7 1 ad 3.5 m admod,acinar  60 
AD164 Cluster 1 68 M T3N0Mx IIB 15 3 ad 4.5 p adpoor, acinar LN 80 
AD167 Cluster 2 77 M T2N0Mx IB 41.7 1 ad 2.5 w w/BAC adw,acinar/adm bac  0 
AD169 Cluster 1 47 F T2N0Mx IB 20 3 ad 2.5 m 
adw/pap or 
BAC,mucinous 
w/pap 
bone, myocardium 21.6 
AD170 Cluster 3 61 F T1N0M0 IA 78.4 1 ad 2.5 w w/pap BAC & pap,well  60 
AD173 Cluster 1 57 F T2N1Mx IIB 22.3 d ad 5.0 m-p admod,acinar  27 
AD179 Cluster 2 85 M T2N0Mx IB 24.3 3 ad 5.6 m w/BAC adw//adw,acinar lung, bone 24.75 
AD187 Cluster 1 69 M T1N0Mx IA 86.3 3 ad 1.8 p adp lung 120 
1These clusters are obtained from hierarchical cluster analysis of the 84 samples and 21 survival marker genes we selected.  
2Patient status at last followup or death (1= alive; 2=alive with recurrence; 3= dead with recurrence; 4= dead without evidence of recurrence; d= dead, disease status 
unknown) 
3,4diameter (cm) subtype (BAC = bronchioloalveolar carcinoma). type (ad = adenocarcinoma ) differentiation (p, m-p, m, m-w, w) /w= with 
5Smoking: patient smoking history (self-reported) in pack/year 
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AD183 Cluster 2 75 F T1N0Mx IA 42.2 2 ad 2.0 m BAC adw//adw,acinar  22.5 
AD188 Cluster 1 74 F T2NxMx IB 21.6 d ad 2.7  BAC adw,acinar  116 
AD201 Cluster 1 46 M T1N2 IIIA 12.3 3 ad 1.5 m  lung, bone 90 
AD203 Cluster 3 60 F T1N0Mx IA 106.1 1 ad 2.2 m-p   0 
AD207 Cluster 3 64 F T2 IB 66.8 4 ad 3.5 w BAC ad m  0 
AD212 Cluster 3 55 F T2N0M0 IB 59 1 ad 3.0 m-p   54 
AD213 Cluster 2 69 M T1Nx IA 48.8 d ad 2.5 m   111 
AD225 Cluster 1 88 M T2NxMx IB 2.6 4 ad 3.5 m   72 
AD226 Cluster 1 56 F T1N0Mx IA 60.5 1 ad 2.0 m   18 
AD228 Cluster 1 60 F T2N0 IB 41.2 3 ad 3.0 m  brain 75 
AD230 Cluster 3 56 M T1N0 IA 56.7 1 ad 2.5 p adp  60 
AD232 Cluster 3 73 M T1Nx IA 56.3 a ad 2.4 w BAC adm (BAC cluster)  25 
AD236 Cluster 1 53 F T2N0Mx IB 14.2 3 ad 5.5 m-p  lung, brain 40 
AD239 Cluster 3 60 M T2N0M0 IB 58.5 1 ad 2.9 m w/BAC BAC  40 
AD240 Cluster 1 77 F T1N0M0 IA 43.5 1 ad 2.0 m-w   5 
AD243 Cluster 2 64 F T1N0M0 IA 50.1 1 ad 1.5 w w/BAC 
adw 
resemblance to 
BAC 
 30 
AD247 Cluster 3 49 M T1N0 IA 71.1 1 ad 2.0 m   32 
AD249 Cluster 1 67 M T1Nx IA 31 4 ad 1.2 m   45 
AD250 Cluster 3 61 F T1Nx IA 91 2 ad 2.0 w w/BAC adm lung 10 
AD252 Cluster 2 66 F T1N0 IA 16.5 3 ad 1.4  LN, CSF, brain 50 
AD255 Cluster 3 79 M T2N0 IB 44.8 1 ad 3.5 m   50 
AD258 Cluster 1 67 M T2Nx IB 12.3 3 ad 4.5 p  bone 54 
AD259 Cluster 2 58 M T3N0 IIB 20.5 d ad 5.0   45 
AD260 Cluster 1 61 M T2Nx IB 21 d ad 3.0 m adm some BACpattern  50 
AD261 Cluster 2 66 F T1N0 IA 57.6 1 ad 2.7 w w/BAC   75 
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AD262 Cluster 2 63 F T4N1Mx IIIB 16.6 4 ad 2.0 m-p   10 
AD266 Cluster 2 65 F T1N0 IA 41.9 3 ad 2.5 w w/BAC adm lung, bone, liver 0 
AD267 Cluster 3 61 M T2N0M0 IB 56 1 ad 2.8 m-p   120 
AD268 Cluster 3 50 F T2N0M0 IB 50.1 1 ad 3.5 p   10 
AD276 Cluster 2 68 M T2N2 IIIA 4.5 3 ad 2.1 m-p  pleura, brain 140 
AD277 Cluster 3 72 F T1Nx IA 8.2 3 ad 3.0 m  liver, ?bone 27 
AD283 Cluster 3 78 M T1N0 IA 47.2 3 ad 2.5 m w/pap  lung, LN, bone, groin 20 
AD287 Cluster 3 36 F T4Nx IIIB 7.4 d ad 4.0 p adp  10 
AD296 Cluster 1 63 M T1N1 IIA 9.3 3 ad 2.4 m-p w/pap  liver 88 
AD299 Cluster 1 78 F T1N0M0 IA 37.9 3 ad 2.2 m-p  lung 50 
AD301 Cluster 1 59 F T2N0M0 IB 7.8 3 ad 4.0 p  brain 40 
AD302 Cluster 3 65 F T2N3Mx IIIB 57.8 3 ad 3.7 w BAC adm w/BAC lung 0 
AD304 Cluster 2 71 F T2N0 IB 8.2 3 ad 5.0 p  lung, liver, spleen 35 
AD308 Cluster 3 62 M T2N0 IB 79 2 ad 4.0 m  brain 66 
AD309 Cluster 1 77 F T2N0 IB 37.6 3 ad 3.4 w adw lung 0 
AD311 Cluster 1 63 F T2N0 IB 50.5 1 ad 5.0 m ok 50%  13 
AD313 Cluster 1 74 F T1N0 IA 25.3 3 ad 1.5 m-p adp LN 90 
AD317 Cluster 3 41 F T2Nx IB 99.1 1 ad 3.5 m pap   7 
AD318 Cluster 1 54 M T2N0M0 IB 83 1 ad 4.0 muc adm  100 
AD323 Cluster 1 56 F T2N1 IIB 6.8 d ad 4.0 p   39 
AD327 Cluster 1 50 F T2N0 IB 81.9 1 ad 6.5 m   27 
AD330 Cluster 3 50 F T1N1 IIA 7.3 3 ad 2.4 m  brain 40 
AD331 Cluster 3 59 M T1N0M0 IA 52.9 1 ad 2.0 m   45 
AD332 Cluster 1 52 M TxN0 I 6 3 ad m  pleura, liver, colon, ?adrenal, ?pancreas 75 
AD335 Cluster 2 40 F T3N0 IIB 46.9 1 ad 4.5 m   20 
AD336 Cluster 3 71 M T2N0Mx IB 21.1 4 ad 1.7 m   0 
AD338 Cluster 3 55 F T2NxMx IB 75.4 1 ad 5.0 w BAC (1) ad w/BAC or ( 2)BAC  15 
AD346 Cluster 2 65 F T1N0 IA 17.3 1 ad 2.5 m   50 
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AD347 Cluster 1 65 F T2N0Mx IB 0.5 1 ad 3.5 m BAC adm  20 
AD351 Cluster 2 43 F T2N1 IIA 24.3 3 ad 5.5 m  lung, LN 0 
AD353 Cluster 3 69 M T2N0Mx IB 13.7 1 ad 3.5 m BAC adw w/bac  30 
AD356 Cluster 2 72 M T2N0 IB 49.2 1 ad 4.0 w BAC   50 
AD361 Cluster 1 54 F T2N IB 6.4 4 ad 4.5 p   0 
AD362 Cluster 3 56 M T2N0 IB 71.5 d ad 6.5 BAC BAC muc  40 
AD366 Cluster 2 71 M T2N2 IIIA 9.4 3 ad 6.2 m-p w/pap  lung 23 
AD367 Cluster 1 55 F T2N0 IB 76.1 2 ad 6.5 m-p  brain 25 
AD368 Cluster 3 33 F T2N0 IB 62.6 1 ad 6.0 m-p w/muc   32 
AD374 Cluster 1 51 M T2N0 IB 8.8 3 ad 11.0 p  lung, pleura, pericardium, diaphragm 100 
AD375 Cluster 2 47 F T2N0 IB 23.4 d ad 7.2 p adm  13 
AD379 Cluster 2 65 M T2N1 IIB 35.4 2 ad 5.5 w/clear  lung, adrenal, brain 80 
AD382 Cluster 2 51 F T2N2Mx IIIA 30.1 3 ad 5.0 p  brain 31 
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Table S5 List of 10 derived lung adenocarcinoma prognosis marker gene 
signatures selected by SVM class-differentiation systems 
Gene rank in each signature (Number of selected gene in each signaure) 
Gene Name 
(EST number) 
Number of 
signatures 
which 
included 
this gene 
1 
(51)
2 
(54)
3 
(42)
4 
(34)
5 
(46)
6 
(54)
7 
(57)
8 
(50) 
9 
(53) 
10 
(47) 
ADFP(X97324) 10 1 46 35 28 19 22 15 18 3 13 
CXCL3(X53800) 10 2 37 24 7 23 3 14 4 6 19 
PLD1(U38545) 10 5 7 2 31 41 17 8 9 11 3 
SLC2A1(K03195) 10 6 3 12 3 3 8 13 12 2 11 
SPRR1B 
(M19888) 10 7 10 29 11 10 7 9 10 5 12 
GALNT4 
(Y08564) 10 8 23 25 27 11 32 25 14 1 28 
LDHB(X13794) 10 10 11 1 1 15 16 11 8 15 1 
FXYD3(U28249) 10 11 6 7 29 14 52 18 42 22 5 
REG1A(J05412) 10 13 8 9 23 9 15 16 45 14 6 
CHRNA2 
(U62431) 10 14 24 26 30 8 46 28 40 27 27 
SERPINE1 
(J03764) 10 18 30 16 22 12 2 1 31 4 15 
FUT3(U27326) 10 19 14 19 21 2 28 10 15 30 21 
PRKACB 
(M34181) 10 20 5 5 15 6 1 3 1 33 4 
TUBA4A(X06956) 10 21 1 14 25 13 53 49 29 26 14 
VEGF(M27281) 10 22 33 8 26 30 14 26 19 23 32 
RPS3(X55715) 10 25 2 10 2 5 39 55 13 17 36 
ANXA8(X16662) 10 28 32 18 12 21 20 4 22 18 26 
VDR(J03258) 10 32 39 33 6 4 30 2 11 16 37 
CXCR7(U67784) 10 33 47 30 24 43 41 37 27 39 29 
POLD3(D26018) 10 35 25 15 18 1 11 50 2 31 8 
BSG(X64364) 10 36 38 39 17 33 48 27 3 20 33 
CYP24(L13286) 9 23 13 34 20 22 23  41 19 25 
HLA-G 
(HG273-HT273) 9 30 27 11  25 19 34 32 24 31 
WNT10B 
(U81787) 9 39 35 28  39 36 29 25 38 41 
GARS(U09510) 9 41 26 31  31 26 19 46 44 20 
SPRR2A(M21302) 9  21 13 34 40 21 21 34 47 18 
NULL 
(HG2175-HT2245) 9  49 37 5 44 34 56 35 53 16 
CD58(Y00636) 8 16 12 3 14 17 6  44  34 
KRT14(J00124) 8   20 9 34 25 12 23 12 22 
E48(X82693) 7 9 15   20 33 22 5 48  
FADD(X84709) 7 12  6  35 51 17  8 9 
STX1A(L37792) 7 15 18 22  46 5  6  24 
ENO2(X51956) 7 24 4   32 38 32  45 47 
SPRR2A(L05188) 7 29 41   7 45 44 48 28  
FEZ2(U69140) 7 38  23   42 30 26 9 17 
KRT18(X12876) 7 43 42 41  26 44 6 43   
ALDH2(X05409) 7  19  10 45 4 20 21  23 
UCN(U43177) 6 4  36 13 18 9    10 
SCYB5(L37036) 6 31 16  33 42 31   29  
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AIP-1(U23435) 6 37  42  28 18   32 7 
NULL(U92014) 6 42 17   27  39  36 42 
NULL(L43579) 6 47 54    35 5 24 37  
CEBPA(U34070) 6   17  24 12  47 25 30 
KIAA0138 
(D50928) 5 34 29  19  37    2 
TFF1(X52003) 5 40 34   37 24   43  
KRT19(Y00503) 5 49   4  40 54 20   
RPS26(X69654) 4 17 28    49   21  
S100A2(Y07755) 4 26 51     40  34  
GS3686 
(AB000115) 4 46 36      49 41  
EMP1(Y07909) 4  9   38 27  38   
HPCAL1(D16227) 4  43  8   33 36   
LCN2(S75256) 4   38    41 37  44 
PEX7(U88871) 4   4  29    40 43 
EFNB2(U81262) 3 44       30  40 
ALDH8(U37519) 3 45 52      17   
EPS8(U12535) 3  20    50   51  
NDRG1(D87953) 3  22     48   46 
CSTB(U46692) 3  40     45  10  
PSPH(Y10275) 3  44 27    23    
CYBA(M21186) 3      29 7 7   
CNN3(S80562) 3       57 39 49  
VIPR1(X77777) 3   40     50  35 
NULL(U49020) 2 51       16   
ALDH7(U10868) 2  45    10     
AXL 
(HG162-HT3165) 2  53       35  
TYRO3(U02566) 2   32  36      
P2RX5(U49395) 2    32 16      
GRO1(X54489) 2        28 42  
ERBB3(M34309) 2       51  7  
BM-002(Z70222) 2    16  13     
LAMB3(U17760) 2   21       39 
INHA(X04445) 2       38  46  
TAX1BP2 
(U25801) 1 3          
IGHM(V00563) 1 27          
SPRR2A(X53065) 1 48          
NP(K02574) 1 50          
P63(X69910) 1  31         
AP3B1(U91931) 1  48         
C6(X72177) 1  50         
HFL1(M65292) 1          38 
PRKCN 
(HG2707-HT2803) 1       24    
SHB(X75342) 1         13  
EIF5A(S72024) 1        33   
FCGR3B(J04162) 1       47    
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GRIN1 
(HG4188-HT4458) 1      47     
SLC2A3(M20681) 1          45 
CA9(X66839) 1       42    
FLJ20746 
(U61836) 1      43     
PPBP(M54995) 1       52    
TUBA4A 
(HG2259-HT2348) 1      54     
EMS1(M98343) 1       53    
IGF2(M17863) 1       36    
CHAT 
(HG4051-HT4321) 1       31    
LAMC2(U31201) 1         50  
BMP2(M22489) 1       43    
KIAA0111 
(D21853) 1         52  
TNFAIP6 
(M31165) 1       35    
NULL 
(HG415-HT415) 1       46    
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